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Benzo[a]pyrene (BaP), an environmental pollutant, and ellipticine, an anticancer drug, are 
carcinogens that exert genotoxic effects after metabolic activation by cytochrome P450 
enzymes. In the present study two mouse models, the Hepatic Reductase Null (HRN) and 
Hepatic Cytochrome b5/P450 Reductase Null (HBRN) and the cancer cell lines Hepa-1c1c7 
and HepG2 have been used to study the role of P450-mediated metabolism and disposition of 
BaP and ellipticine. In HRN mice cytochrome P450 oxidoreductase (POR), the electron donor 
to P450 enzymes, is deleted specifically in hepatocytes. In HBRN mice the microsomal 
haemoprotein cytochrome b5 (Cyb5), which can also act as an electron donor from cytochrome 
b5 reductase to P450 enzymes, is also deleted in the liver. HRN and HBRN mice were treated 
once with BaP or ellipticine for 24 hours. DNA adduct levels were measured by 32P-
postlabelling analysis. Mice treated with ellipticine had significantly fewer DNA-adducts in 
the livers on HRN and HBRN mice compared to WT, with no significant difference between 
HRN and HBRN. In the mice treated with BaP, however, there were significantly higher levels 
of DNA adducts in the livers of HRN mice than wild-type (WT) mice while no significant 
difference in adduct formation was observed in liver between HBRN and WT mice. Hepatic 
microsomal fractions were also incubated with BaP/ellipticine and DNA in the presence of 
NAD(P)H in vitro which showed as electron donors were lost, adduct formation decreased. 
This correlated with incubations carried out with BaP or ellipticine which measured formation 
of metabolites which decreased as electron donors were lost. The results from the incubations 
also correlated with measured enzyme activity. In order to model the paradoxical phenomenon 
seen in the HRN mice, Hepa-1c1c7 and HepG2 cells that do not express POR were exposed to 
BaP. In the Hepa-1c1c7 cells, despite the absence of POR expression, both formation of 
metabolites, DNA damage (comet assay) and adduct formation was increased compared to WT 
cells. The HepG2 cell line showed decreased levels of DNA damage (comet assay) in the 
absence of POR compared to WT cells. Whilst formation of metabolite and adduct formation 
was reduced compared to WT HepG2 cells 24 hours after treatment with BaP, metabolite and 
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XME   Xenobiotic-metabolising enzyme 
P450   Cytochrome P450 
AKR   Aldo-keto reductase 
mEH   Microsomal epoxide hydrolase 
PTGS   Prostaglandin H synthase 
GST   Glutathione S-transferase 
POR   NADPH:cytochrome P450 oxidoreductase 
Cyb5R   NADH:cytochrome b5 reductase 
Cyb5   Cytochrome b5 
AHR   Aryl hydrocarbon receptor 
PXR   Pregnane X receptor 
CAR   Constitutive androstane receptor 
TCDD   2,3,7,8-tetrachlorodibenzo-p-dioxin 
PAH   Polycyclic aromatic hydrocarbon 
 
 
BaP   Benzo[a]pyrene 
HAA   Heterocyclic aromatic amine 
PhIP   2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
4-ABP   4-Aminobiphenyl 
AaC   2-Amino-alpha-carboline 
NNK   Nicotine-derived nitrosamine ketone 
SSB   Single strand break 
DSB   Double strand break 
CRISPR  Clustered Regularly Interspaced Short Palindromic Repeats 
CAS9   CRISPR associated protein 9 
ES   Embryonic Stem Cells 
WT   Wild-type 
HRN   Hepatic Reductase Null 
HBRN   Hepatic Cytochrome b5/P450 Reductase Null 
SD   Standard deviation  
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1.1 Xenobiotic metabolism 
Humans are constantly exposed, unavoidably, to a myriad of environmental chemical 
substances. Xenobiotics, any exogenous chemical, can be natural or synthetic and 
include dietary toxins, pollutants and drugs. They are able to enter the body through a 
variety of routes, predominantly the digestive system although this route may be 
bypassed by absorption via the lungs and skin. Cell membranes are able to prevent the 
entry and exit of many xenobiotics but are, however, susceptible to lipophilic 
molecules that are able to diffuse through into the organism. Living organisms have 
therefore evolved enzyme systems to detoxify these xenobiotics to prevent 
accumulation of harmful toxins. These enzymes are termed biotransforming enzymes 
and play a key role in the process of xenobiotic metabolism.  Although the gut is 
capable of metabolising many xenobiotics, the main site of biotransformation is the 
liver with many xenobiotic-metabolising enzymes (XMEs) residing in the 
hepatocytes. The primary function of these enzymes is to convert a lipophilic 
xenobiotic to a more hydrophilic metabolite, promoting a decline in its reabsorption 
by kidney tubules allowing it to be easily cleared by the kidneys into the aqueous urine 
where it can be eliminated from the body (Croom, 2012).  
The stages of biotransformation are traditionally described as phases I, II and III. Phase 
I reactions are thought to prepare the xenobiotic for the conjugative reactions of phase 
II metabolism by making them more reactive. Although predominantly oxidative, 
phase I reactions also include hydroxylation and reduction. These reactions are 
catalysed by XMEs such as cytochrome P450 (P450), aldo-keto reductases (AKRs), 
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microsomal epoxide hydrolase (mEH), prostaglandin H synthase (PTGS), 
NAD(P)H:quinone oxidoreducatse (NQO1), NAD(P)-dependent alcohol 
dehydrogenases (ADHs) and microsomal flavin-containing monooxygenases (FMOs). 
Phase II metabolism conjugates small molecules in the form of polar endogenous 
sugars, salts or amino acids, to functional groups resulting from phase I metabolism 
in order to further increase the polarity of the molecule, making it more hydrophilic 
for excretion. Although phase II metabolism often proceeds a phase I reaction 
conjugation can also occur directly without preparation by oxidative processes 
(Croom, 2012). Phase II XMEs include sulfotransferases (SULTs), N,O-
acetyltransferases (NATs), methyltransferases such as catechol-O-methyltransferase 
(COMT), glutathione S-transferases (GSTs) and uridine diphosphate 
glucuronosyltransferases (UGTs) (Rendic and Guengerich, 2012). Phase III 
metabolism has been defined more recently and describes the system of efflux pumps 
that exclude water soluble products from the cell to the interstitial fluid, blood and 
finally the kidneys. The hydrophilic metabolites resulting from the metabolism 
process are shuttled through cellular lipid bilayer membranes, facilitated by 
transporter proteins of the ATP-binding cassette (ABC) or solute carrier (SLC) 
families (Omiecinski et al., 2011). It is noteworthy that whilst separating the stages of 
biotransformation into phases is convenient, this system has been argued against due 
to grouping mechanistically unrelated reactions together and dividing related ones, 
and can be misleading due to phase I and II metabolism not always occurring 
sequentially (Josephy et al., 2005). 
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1.2 Cytochrome P450s 
P450 enzymes belong to a ubiquitous superfamily of haemoproteins which all have 
similar core structures and modes of operation and play a central role in the 
metabolism of a wide variety of substrates (Guengerich, 2008). There are 57 putatively 
functional human P450s and of these only about a dozen enzymes are responsible for 
the biotransformation of most foreign substances (Zanger and Schwab, 2013). P450s 
are generally classified using a systematic nomenclature scheme with current 
guidelines suggesting that members of new CYP families share at least 40% and 
members of subfamilies share 55% amino acid identity. Each P450 enzyme is 
designated the abbreviation CYP to denote the superfamily (Cytochrome P450), 
followed by a number for the gene family, a capital letter showing the subfamily and 
a final numeral assigning the individual gene (Sim and Ingelman-Sundberg, 2010). 
Mammalian P450s play a multitude of roles within the body, with a set of P450s (e.g. 
families 5, 8, 11, 17, 19, 21, 24, 26 and 27) responsible for the synthesis of important 
steroids and eicosanoids from ω-3 and ω-6 polyunsaturated fatty acids such as 
arachidonic acid or eicosapentaenoic acid (Nebert and Karp, 2008) as well as the 
catabolism of natural products. Out of the remaining mammalian P450s a small set 
(i.e. CYP1A2, 2C9, 2C19, 2D6 and 3A4) accounts for most of the metabolism of drugs 
(Guengerich, 2001). P450s play a major role in phase I metabolism with 70-80% of 
all phase I XMEs comprising P450 enzymes (Evans and Relling, 1999). This makes 
them the focus of pharmacological and toxicological research as oxidation reactions 
catalysed by P450s can result in poor drug bioavailability, leading to acute and chronic 
toxicities with adverse drug interactions and subsequently cancer susceptibility 
(Guengerich, 2001). P450 enzymes make up part of a mixed-function oxidase system, 
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along with other enzymes including NADPH:cytochrome P450 oxidoreductase (POR) 
(Riddick et al., 2013), NADH:cytochrome b5 reductase (Cyb5R) and the haemoprotein 
cytochrome b5 (Cyb5) (Porter, 2002), bound to the membrane of the endoplasmic 
reticulum (ER). The most common reaction catalysed by P450 enzymes are mono-
oxygenase reactions that require two electrons and involve the insertion of one oxygen 
atom into the substrate, whilst reducing the other oxygen atom to water: 
R-H +O2 + NADPH + H
+ → R-OH + H2O + NADP
+ 
1.2.1 Catalytic cycle 
Despite the vast array of CYP family members, their activity is reliant on the P450 
catalytic cycle. Although the cycle is a complex process with many steps, there are 
five main features of the process: (i) substrate binding, (ii) oxygen binding, (iii) 
oxygen splitting, (iv) insertion of oxygen into substrate and (v) release of product. A 
simplified diagram of the catalytic cycle for P450 enzymes is shown in Figure 1.1. 
The iron is usually, but not always, in the ferric form (Fe3+-RH) at the start of the 
cycle. (i) The first step in the cycle is the P450 substrate binding that must be oriented 
in such a way that it is in proximity to the heme iron, on the side opposite to the axial 
thiolate of the cysteine (Cys) residue in the active site of the enzyme. Substrate binding 
brings about a conformational change of the active site, often displacing a water 
molecule from the distal axial coordination position of the heme iron from low-spin 
to high-spin (Guengerich, 2001, Meunier et al., 2004, Poulos et al., 1987). (ii) The first 
of two electrons is then received from the REDOX partners, reducing the iron (Fe2+-
RH) (Sligar et al., 1979). Molecular oxygen sourced from the lungs binds to the 
iron/substrate complex at the ferrous heme centre at the distal axial coordination 
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position, initially giving a dioxygen adduct (Fe-O2). (iii) The second electron is 
transferred from REDOX partners reducing the Fe-O2 adduct resulting in a short-lived 
peroxo state. The peroxo group reacts with two protons from the surrounding solvent, 
breaking the O-O bond. The process is so rapid it has not yet been detected 
experimentally, therefore the most likely pathway has been proposed whereby the 
oxygen atom with two spare electrons forms water with two hydrogen atoms leaving 
a single oxygen atom bound to the iron of the enzyme (Coleman, 2010). A highly 
reactive intermediate, referred to as P450 compound I, is also formed (Rittle and 
Green, 2010).  
This P450 protein-bound porphyrin complex with the iron-coordinated active oxygen 
atom is the proposed intermediate species which hydroxylates inert carbon-hydrogen 
bonds of substrates (Jung, 2011). (iv) The oxygen atom ligated to the iron is transferred 
to the substrate forming a hydroxyl group. The hydroxyl group and the P450 
Figure 1.1: Basic reaction cycle of the P450 monoxygenase system. See text for details 
Adapted from Guengerich 2008. 
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compound I react, yielding an alcohol (Fe2+ and ROH). (v) The metabolite is released 
from the active site of the enzyme which returns to its initial state with a water 
molecule returning to occupy the distal coordination of the iron nucleus. An alternative 
pathway for the P450 mono-oxygenation reaction is via the ‘peroxide shunt’ (path ‘S’ 
in Figure 1.1). This enables oxidation of the ferric-substrate complex with oxygen 
donors such as peroxides (Guengerich, 2008, Guengerich, 2001). A hypothetical 
peroxide ‘XOOH’ is shown in Figure 1.1. Whilst it is possible to simplify this process, 
and has proven useful in rationalising most oxidation reactions, the cycle is dynamic 
with steps not necessarily proceeding in a linear order. Substrate binding and release 
can occur at other steps along the cycle (Guengerich, 2008).  
1.2.2 P450 oxidoreductase (POR) 
P450 REDOX partners are essential to the P450 catalytic cycle, donating the electrons 
needed for the oxidative reactions to be catalysed. POR is an NADPH reductase that, 
although a separate entity from P450s, is indispensable to them. POR is found in most 
tissues but particularly in the liver, and systemic deletion of POR results in embryonic 
lethality, demonstrating its necessity to life (Shen et al., 2002, Otto et al., 2003). The 
reductase is a membrane anchored diflavin protein complex with its catalytic site at 
the surface of the endoplasmic reticulum, binding the electron carrier flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) in distinct globular domains 
connected by a flexible hinge region (Murataliev et al., 2004, Wang et al., 1997). FAD 
has evolved to discriminate strongly in favour of NADPH over NADH, fuelling 
reductive reactions. Electrons are transferred from NADPH through FAD producing 
NADP+. FAD transports two electrons as FADH2 that are passed on to FMN, forming 
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FMNH2 which in turn passes the electrons to the iron atom in the prosthetic haem 
group of P450s (Figure 1.2) (Laursen et al., 2011).   
 
Figure 1.2: Transfer of electrons from the electron donor proteins POR and Cyb5 to the P450 enzyme 
in the presence of the enzymatic cofactor NADPH and NADH, respectively.  
1.2.3 Cytochrome b5 (Cyb5) 
For many years it was widely believed that POR was the sole electron donor to P450 
enzymes. However, microsomal Cyb5 in conjunction with Cyb5R can also be 
important electron donors in the P450 catalytic cycle (Finn et al., 2008). Cyb5 is an 
electron transport haemoprotein that is ubiquitous in nature and strongly resembles the 
active site of P450s due to them being built around a central F-9 haem group. Cyb5 is 
anchored by a helix which is deeply embedded in the membrane of the smooth 
endoplasmic reticulum (SER) with its haem structure standing clear of the SER 
membrane in the cytosol (Sergeev et al., 2014).  Unlike POR, Cyb5 does not possess 
enzymatic activity and is dependent on the enzymatic cofactor NADH in conjunction 
with Cyb5R. The transfer of two electrons during the catalytic cycle are essential and 
the rate of transfer of the second electron is considered a rate-limiting step in the P450 
reaction (Guengerich and Johnson, 1997). Cyb5 can modulate P450 activity in three 
ways: (i) by direct transfer of both electrons via Cyb5R in a pathway independent of 













second, and rate limiting, electron from either POR or Cyb5R (Figure 1.2) 
(Hildebrandt and Estabrook, 1971); or (iii) by acting as an allosteric modifier of the 
enzyme in a non-catalytic role that can enhance reactions for many, but not all, P450 
enzymes (Yamazaki et al., 2002). Cyb5 is both substrate and enzyme specific, and has 
been shown to both stimulate and inhibit P450 reactions. The P450-mediated 
metabolism of methoxyflurane, 7-ethoxycoumarin and p-nitroanisole demonstrates an 
absolute requirement for Cyb5 (Canova-Davis et al., 1985, Sugiyama et al., 1980, 
Sugiyama et al., 1982, Yamazaki et al., 1996b). The P450-mediated metabolism of 
benzphetamine, a central nerve system stimulant, however, is NADPH-supported and 
the presence of Cyb5 inhibits the reaction (Morgan and Coon, 1984). Therefore, it is 
difficult to predict the contribution of Cyb5 to xenobiotic metabolism.  
1.2.4 Induction of cytochrome P450 
Not all XMEs are constitutively expressed; very often their expression will be induced 
by the presence of a xenobiotic. The process of enzyme induction has three main 
requirements (i) the cell must detect the presence of particular persistent lipophilic 
xenobiotics and correctly sense their concentration, (ii) the process of detection is 
translated into an increase in the capability of the appropriate metabolic systems to 
allow the xenobiotic to be cleared as efficiently as possible and (iii) the detection and 
action system needs to be reversible to allow it to be sensitive to further changes in 
xenobiotic concentration. The inducible P450s make up a large percentage of the 
P450s in the human liver and in most cases, induction of P450s occurs by a process 
involving de novo RNA and protein synthesis that has been demonstrated in studies 
using transcription and translation inhibitors (Daujat et al., 1991). The main inducible 
P450s, CYP1A1/1A2, CYP2C8/9 and CYP3A4, have a similar induction mechanism, 
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where ligand activation of key receptor transcription factors including the aryl 
hydrocarbon receptor (AHR), pregnane X receptor (PXR) and the constitutive 
androstane receptor (CAR) leads to increased transcription (Figure 1.3). The 
induction of P450s is highly conserved and is found not only in humans but also in 
many other species including rodents (Tompkins and Wallace, 2007). Another 
mechanism of P450 induction involves compounds that either stabilise translation or 
inhibit the protein degradation pathway, e.g. ethanol and CYP2E1 (Woodcroft and 
Novak, 1998). 
The AHR receptor complex is located in the cytoplasm of most cells and consists of 
four components: (i) the AHR, (ii) heat shock protein (Hsp90), (iii) co-chaperone p23 
and (iv) an immunophilin called XAP2 (Figure 1.3a) (Kewley et al., 2004). The 
ligand, e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), binds to the AHR complex 
which then migrates towards the nucleus (Mimura and Fujii-Kuriyama, 2003). The 
AHR/ligand complex then breaks away from the Hsp90, p23 and XAP2 and enters the 
nucleus alone where it heterodimerises with the nuclear protein aryl hydrocarbon 
nuclear receptor translocator (ARNT) and this new complex binds to specific DNA 
sequences, termed xenobiotic responsive elements (XRE), upstream of the 
CYP1A1/1A2 and 1B1 genes (Tsuji et al., 2014). 
Like the AHR, CAR is also found in the cytoplasm complexed with Hsp90 and p23 
(Figure 1.3b). The CAR retention protein (CCRP) is also part of the complex. As the 
name suggests, CAR is constitutively expressed so does not necessarily require a 
ligand to induce its activity, but the presence of inducers, e.g. phenobarbital (PB), will 
hasten the rate of enzyme induction (Kretschmer and Baldwin, 2005). Upon binding 
of the ligand, cytoplasmic CAR dissociates from the Hsp90, p23 and CCRP and enters 
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the nucleus alone where it first forms a heterodimer with the retinoid X receptor (RXR) 
followed by association with the co-activator SRC-1 to form a complex. The 
CAR/RXR/SRC-1 complex binds to DNA at the phenobarbitone-responsive enhancer 
module (PBREM) in the CYP2B gene and to the Everted repeat 6 (ER6) element of 
the CYP3A4 and CYP2C9 genes.  
This triggers transcriptional activation leading to an induction of the particular P450s 
(Timsit and Negishi, 2007). Alongside CAR, PXR is also heavily involved in CYP3A 
regulation. PXR is considered highly promiscuous as it has a wide range of substrate 
structures and, as with AHR, PXR lies dormant in the absence of any ligands. PXR is 
sequestered in the cytosol, like CAR and AHR, by Hsp90 or CCRP (Figure 1.3c). 
Upon binding of a ligand to the receptor, PXR dissociates from Hsp90 or CCRP and 
translocates to the nucleus where a heterodimer is formed with RXR (Squires et al., 
2004). Binding occurs at the CYP3A gene in two separate areas, an ER6 in the 
proximal promoter of the gene and at the same time the PXR complex binds to a 
second area called the xenobiotic responsive element (XREM). Both the proximal 
promoter and the XREM must be bound by the PXR complex before induction can 
proceed (Chen et al., 2012). 
1.3 Chemical carcinogenesis 
Associations between cancer and occupational exposures can be dated back to the 16th 
century when Paracelsus proposed that exposure to natural ores such as arsenic 
sulphide may have been causing the ‘wasting disease of miners’ in 1567; making 
Paracelsus the first to consider a chemical compound as an occupational carcinogen. 




Figure 1.3: Mechanisms of P450 induction. (a) AHR-mediated control of CYP1A1/2 and 1B1, (b) 
CAR-mediated control of CYP2B6/2C9 and CYP3A4, (c) PXR-mediated control of CYP3A4. See text 







occupational fields was published by Bernadini Ramazzini in 1700. In 1761 John Hill 
traced cancerous alterations in the nasal mucosa to long term exposure to tobacco 
snuff. A few years later in 1775 Percival Pott attributed the onset of scrotal cancer in 
chimney sweeps to repetitive local contamination by soot. The occurrence of scrotal 
cancer in workers was also linked to arsenic fumes in the copper-smelting works of 
Cornwall and Wales in 1822 by John Ayrton Paris. By the end of the 19th century it 
was evident that the occupational exposure to certain chemicals or mixtures of 
chemicals resulted in carcinogenic effects (Luch, 2005). The field of chemical 
carcinogenesis came to the fore in the twentieth century when malignant epithelial 
tumours were experimentally produced for the first time when coal tar was applied to 
the ears of rabbits; marking the transition into the modern era of experimental cancer 
research (Yamagiwa and Ichikawa, 1915). Identifying the compounds responsible for 
carcinogenesis was difficult due to the complex nature of the mixtures, however Sir 
Ernest Kennaway and his colleagues at the Royal Cancer Hospital in London 
demonstrated that single polycyclic aromatic hydrocarbons (PAHs) such as 
dibenz[a,h]anthracene were tumourigenic in mouse skin (Kennaway and Hieger, 
1930, Cook et al., 1937). During this time benzo[a]pyrene (BaP) was isolated and 
found to be the highly carcinogenic compound from coal tar pitch (Cook et al., 1933). 
By the 1940s chemical carcinogens were shown to be able to bind covalently to 
cellular macromolecules such as proteins (Miller and Miller, 1947) and following the 
discovery of the structure of DNA by Watson and Crick in 1953 it was later 
demonstrated that the carcinogenicity of compounds such as PAHs correlated with the 
extent of their binding to DNA in mouse skin, but not to RNA or protein (Brookes and 
Lawley, 1964). Over the course of the latter half of the 20th century, epidemiological 
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and experimental evidence continued to both compliment and support each other, ever 
strengthening the link between environmental agents and cancer (Wogan et al., 2004). 
1.3.1 Environmental Carcinogens 
Around 200 different chemical compounds and mixtures are known or suspected to be 
environmental carcinogens. Some known human carcinogens are shown in Table 1.1. 
Environmental carcinogens can be divided into 4 categories: organics, inorganics, 
fibres and particulates and hormones. The largest category of these is the organics 
(Gooderham and Carmichael, 2007). The International Agency for Research on 
Cancer (IARC) (http://monographs.iarc.fr/) has developed the classification of 
carcinogens by evaluation of their carcinogenicity:  
Group 1  Carcinogenic to humans (108 agents) 
Group 2A Probably carcinogenic to humans (64 agents) 
Group 2B Possibly carcinogenic to humans (272 agents) 
Group 3  Not classifiable as to its carcinogenicity to humans (508 agents) 
Group 4  Probably not carcinogenic to humans (1 agent)  
One of the most widely studied groups of carcinogens is the PAHs. They are 
ubiquitous in the environment as a result of their formation by the incomplete 
combustion of organic matter (IARC, 2010b, Baird et al., 2005). BaP is the most 
commonly studied and measured of the PAHs (Arlt et al., 2015b, Krais et al., 2016, 
Labib et al., 2016, Labib et al., 2012, Siddens et al., 2012, Wohak et al., 2016) and it  
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Table 1.1: Examples of human chemical carcinogens, their sources of exposure and the target organs. 
Adapted from Luch 2005. 
 
  
Compounds Main sources/uses Target organ 
Aminoazo dyes   
o-Aminoazotoluene 






Colour polishes; waxes  Lung. liver 
Aromatic amines/amides   
2-Naphthylamine Dyes; antioxidant  Bladder 
Aromatic hydrocarbons   
Benzo[a]pyrene 





Flame retardants; hydraulic 
fluids 
Liver, skin 
Metals (and compounds)   
Arsenic 
Natural ores; alloys; 
pharmaceutical agent 
Skin, liver, lung 
Cadmium 




Natural carcinogens   
Aflatoxin B1 
Mycotoxin (found in 
contaminated food) 
Liver 
Asbestos Thermal insulation; gaskets  Lung 
N-nitroso compounds   
N-Nitrosodimethylamine 
Polymers; batteries; 






Research tool; cigarette 
smoke 
Lung, liver 
Olefins   





Paraffins/ethers   
1,2-Dichloroethane 




Mustard gas (sulphur mustard) Chemical warfare; research Lung 
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is classified by the IARC as a Group 1 human carcinogen. The unavoidable exposure 
of the human race to PAHs makes a substantial contribution to the overall burden of 
cancer in humans (Baird et al., 2005, IARC, 2010a, Phillips and Venitt, 2012). A major 
source of exposure to BaP is tobacco smoke (Alexandrov et al., 2016). However for 
non-smokers the principal sources can be the diet (Phillips, 1999) and from exposure 
to air pollution (IARC, 2016). Nitro-PAHs are also widespread environmental 
contaminants found in grilled food, river sediments, on the surface of ambient air 
particulate matter and in extracts from diesel and petrol engine emissions (Tokiwa et 
al., 1986, INCHEM, 2003, Möller, 1994, Purohit and Basu, 2000). Nitro-PAHs have 
been detected in the lungs of non-smokers with lung cancer leading to increased 
interest in assessing their potential risk to humans (Tokiwa et al., 1993). Heterocyclic 
aromatic amines (HAAs) are another class of environmental carcinogens formed from 
heated products which contain sources of nitrogenous compounds, mainly heated 
foods of animal origin (Skog et al., 1998). They have also been detected in rain water 
and cigarette smoke condensate as well as in particles from diesel exhaust fumes 
(Kataoka, 1997, Liu et al., 2013, Zhang et al., 2011). Originally developed as 
pesticides, 2-aminofluorene (AF) and N-acetyl-2-aminofluorene (AAF) are among the 
most well-studied of the aromatic amines (Kriek, 1992). Their use as pesticides was, 
however, ceased due to the discovery that they were animal carcinogens (Clayson, 
1981). They have since served as a foundation of knowledge for the development of 
human biomarkers towards aromatic amines as well as HAAs (Turesky and Le 
Marchand, 2011). Not all environmental carcinogens are derived from anthropogenic 
activity; aristolochic acid I (8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-
carboxylic acid, AAI) is a major component of the natural plant extract aristolochic 
acid (AA) (Stiborova et al., 2013b, Stiborova et al., 2014b, Arlt et al., 2002). AA and 
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herbal remedies containing AA have been classed as Group I human carcinogens by 
IARC (IARC, 2012) as they have been shown to be the cause of Chinese herb 
nephropathy , now referred to as aristolochic acid nephropathy (AAN), and associated 
malignancies (Vanherweghem et al., 1993, Debelle et al., 2008). AAN is a rapidly 
progressive renal fibrosis with a high risk of developing upper urothelial tract 
carcinoma leading to bladder urothelial carcinoma (Gokmen et al., 2013, Nortier et 
al., 2000). Aflatoxins are a family of mycotoxins produced by Aspergillus fungi found 
on agricultural crops. Of the four main aflatoxins, aflatoxin B1 (AFB1) is the most 
commonly occurring and the most toxic. Chronic exposure causes liver cancer and 
individuals with hepatitis B are at a much greater risk (Kew, 2013). Aspergillus spp. 
are abundant in warm, humid regions of the world with many people in sub-Saharan 
Africa, Latin America and Asia at risk of exposure (IARC, 2015, McMillan et al., 
2018).  
1.3.2  Metabolic activation 
Some highly reactive carcinogens are considered ‘direct carcinogens’ that are reactive 
and electrophilic enough to bind covalently to cellular proteins and DNA, e.g. 
alkylating agents such as mustard gas or ethylene oxide. These compounds, however, 
are only a small proportion of known human carcinogens. The great majority of 
carcinogens are nucleophilic or chemically inert, e.g. PAHs, aromatic and heterocyclic 
amines, aminoazo dyes and N-nitrosamines, and are termed procarcinogens (Luch, 
2005). Procarcinogens go through the detoxication process, as with all xenobiotics, 
however they are often activated by XMEs (Table 1.2) producing reactive metabolites 









Organ Carcinogenic substrates 
CYP1A1 Many, particularly after 
induction 
 Polycyclic aromatic hydrocarbons 
 Heterocyclic amines 
 Aromatic amines 
 Nitroarenes 
 Aristolochic acid I 
 Ellipticine 
CYP1A2 Liver 
 Aromatic amines 
 Heterocyclic amines 
 Polycyclic aromatic hydrocarbons 
 Aristolochic acid I 
 Estragole 
 Aflatoxin B1 
CYP1B1 Extrahepatic organs 
 Polycyclic aromatic hydrocarbons 
 Nitroarenes 




 Aflatoxin B1 
CYP2E1 Liver, GI tract 
 1,3-butadiene 




CYP3A4 Liver, small intestine 
 Aflatoxin B1 







Figure 1.4: Contribution of (a) human XMEs and (b) the individual cytochrome P450s to carcinogen 
activation according to Rendic and Guengerich 2012. (AKR – aldoketoreductases, NAT – N-
acetyltransferases, FMO – flavin monooxygenases, SULT – sulfotransferases, COX – 
cyclooxygenases) 
macromolecules such as proteins and nucleic acids. Cytochrome P450s play an 
important role in the bioactivation of many carcinogens with 
CYP1A1/1A2/1B1/2A6/2E1 and 3A4 being implicated in ~80% of carcinogen 
bioactivation reactions (Rendic and Guengerich, 2012) (Figure 1.4). 
CYP1A1/1A2/1B1 play a major role in the bioactivation of PAHs (Baird et al., 2005), 
aromatic amines (Besaratinia and Tommasi, 2013) and HAAs (Turesky and Le 
Marchand, 2011). BaP is considered a procarcinogen as it is chemically inert and 
requires activation via P450-dependent monooxygenases, with CYP1A1 and CYP1B1 
playing major roles in the bioactivation pathway, before exerting its genotoxic effects 
(Hamouchene et al., 2011, Shimada and Fujii-Kuriyama, 2004, Stiborova et al., 2017). 
The two enzymes catalyse the initial oxidation of BaP to form BaP-7,8-epoxide, which 
is then converted to BaP-7,8-dihydrodiol by epoxide hydrolase. BaP-7,8-dihydrodiol 
then undergoes further bioactivation by CYP1A1 and CYP1B1 to form the ultimately 
reactive species, BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) (Baird et al., 2005, Luch 
and Baird, 2005) (Figure 1.5). BPDE is able to react with DNA, preferentially at 
guanine residues, to form primarily the pre-mutagenic adduct 10-(deoxyguanosin-N2-
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yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-BaP (dG-N2-BPDE) (Arlt et al., 2008, Kucab 
et al., 2015, Long et al., 2017, Long et al., 2000). 4-Aminobiphenyl (4-ABP) is an 
aromatic amine that is metabolised primarily in the liver to N-hydroxy-4-ABP, the 
precursor to 4-ABP-derived DNA adduct formation (Figure 1.6a) (Yoshihara and 
Tatsumi, 1995). The primary step in the activation pathway is N-hydroxylation 
catalysed by CYP1A2, (Yoshihara and Tatsumi, 1995, Turesky et al., 1991, Butler et 
al., 1989a, Butler et al., 1989b, Hammons et al., 1991, Landi et al., 1996). Metabolic 
activation of N-hydroxy-4-ABP is by esterification mediated by phase II enzymes such 
sulfotransferases (SULTs) or N-acetyltransferases (NATs) (Probst-Hensch et al., 
2000, Turesky et al., 1991). PhIP is one of the most abundantly formed carcinogenic 
HAAs in cooked meat and it is also present in tobacco smoke (Gooderham et al., 
2002). Evidence primarily from in vitro studies has demonstrated  
 
Figure 1.5: P450-mediated bioactivation pathway of BaP producing reactive metabolites that bind to 
DNA resulting in the dG-N2-BPDE adduct. 
 
that P450 enzymes are the most important enzymes involved in the initial oxidation of 
PhIP to form the intermediate N-OH-PhIP with CYP1A2 as the predominant P450 
enzyme in the activation of PhIP followed by CYP1A1 and 1B1 (Edwards et al., 1994, 
Shimada et al., 1996) (Figure 1.6b). 2-Amino-alpha-carboline (AaC) is another 
carcinogenic heterocyclic amine present in cooked meat and tobacco smoke. The first 
step of AaC metabolism has been demonstrated in rodent and human liver microsomes 
to be the N-oxidation by P450s to form 2-hydroxy-amino-9H-pyrido[2,3-b]indole 
mEH CYP1A1 +DNA
dG-N2-BPDE





(HO-NH-AaC) that then undergoes conjugation by SULTs or NATs (Figure 1.6c) 
(Niwa et al., 1982, Raza et al., 1996, King et al., 2000). Nicotine-derived nitrosamine 
ketone (NNK), a nitrosamine, is one of the most potent carcinogens present in tobacco 
smoke. Carcinogenesis occurs with P450-mediated α-hydroxylation producing 
reactive metabolites that form pyridyloxobutyl (POB)- and methyl-DNA adducts such 
as O6-methylguanine (O6-mG) (Hecht, 1998, Jalas et al., 2003, Lao et al., 2006) 
(Figure 1.6d). In some cases a bioactivation pathway is not mediated by a single P450 
or P450 subfamily but can be more complex and involve other XMEs. An example of 
this is ellipticine (5,11-dimethyl-6H-pyrido[4,5-b]carbazole), a cytotoxic alkaloid 
isolated from the Apocynaceae family of plants.  
 








Activation of ellipticine is catalysed by P450 enzymes and peroxidases, which 
generate reactive intermediates capable of damaging DNA by forming covalent 
adducts (Stiborová et al., 2001, Arlt et al., 2003, Stiborova et al., 2003a, Stiborova et 
al., 2003b, Stiborova et al., 2007, Stiborová et al., 2007, Stiborova et al., 2008, Kizek 
et al., 2012, Stiborova et al., 2012a, Stiborová et al., 2012). As shown in Figure 1.7, 
ellipticine is oxidised by P450 enzymes and peroxidases to form five metabolites, 
including the reactive metabolites 12-hydroxy- and 13-hydroxy-ellipticine which 
dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind to DNA (Aimová 
et al., 2008, Stiborova et al., 2015, Stiborova et al., 2014a, Stiborova and Frei, 2014, 
Stiborová et al., 2011, Stiborova et al., 2004, Tmejova et al., 2014). The N2-oxide is 
also considered an active ellipticine metabolite as it converts to 12-hydroxy-ellipticine 
by the Polonowski rearrangement (Stiborova et al., 2004, Kotrbova et al., 2006). 7-
Hydroxy-ellipticine and 9-hydroxy-ellipticine are considered detoxication metabolites 
(Stiborova et al., 2011, Stiborova et al., 2012a, Stiborová et al., 2012).  
1.3.3 Induction of DNA damage  
Many carcinogens, whether bioactivated procarcinogens or direct-acting carcinogens, 
are DNA reactive. Covalent binding of the carcinogen to DNA results in the formation 
of DNA adducts that are generally formed at purine or pyrimidine bases, with guanine 
being the most commonly modified base. It is possible for carcinogens to bind to 
phosphate groups in the nucleic acid but this mechanism is far less common (Phillips, 
2007). The resulting DNA adduct can be stable and persist or unstable depending on 
position of modification within the DNA base. An unstable DNA adduct can lead to 
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the destabilisation of the sugar-base bond which results in the loss of the adducted 
base (depurination or depyrimidation) (Phillips and Arlt, 2008). DNA adducts can also 
 
Figure 1.7: P450- and peroxidase-mediated bioactivation pathway of ellipticine. 
 
arise from endogenous processes, including chronic inflammation, oxidative stress 
and normal metabolism. The most common oxidation lesion in DNA is 8-oxo-2’-
deoxyguanosine (8-oxo-dG) which can be formed either through free radical attack on 


























induced carcinogenesis (Liguori et al., 2018). Experimental studies have shown a 
linear relationship between dose, tumour outcome and DNA adduct levels; however 
this is not always the case at higher doses and several studies have found that whilst 
tumours do not arise in the absence of DNA adducts, DNA adducts can be formed 
without necessarily giving rise to tumour formation (Poirier, 2016). The formation of 
bulky DNA adducts can result in breaks in the sugar-phosphate backbone of the 
molecule, either in one of the strands of the double helix (single strand breaks; SSB) 
or in both strands of the double helix (double strand breaks; DSB) (Phillips and Arlt, 
2008). Some carcinogens, particularly cancer drugs such as cisplatin, intercalate into 
DNA to generate inter- or intra-strand crosslinks (Enoiu et al., 2012). These DNA 
crosslinks block DNA strand separation therefore interrupting essential DNA 
metabolic processes such as replication and transcription and can also prevent DNA 
replication leading to cell death (Huang and Li, 2013). Exposure to ultraviolet and 
other types of radiation can result in the production of pyrimidine dimers, where 
covalent crosslinks occur in cytosine and thymine residues (Douki et al., 2017).   
Upon damage of DNA, there are a number of potential outcomes. Firstly, DNA repair 
mechanisms within mammalian cells detect the damage and restore the DNA sequence 
to its original state. Secondly, the DNA damage may trigger mechanisms that lead to 
programmed cell death (apoptosis). The third outcome is that DNA repair or apoptosis 
does not occur and the damaged DNA template is replicated incorrectly potentially 
resulting in mutations (Phillips and Venitt, 2012). Mutagen-mediated DNA damage 
results in nucleotide mutations (such as A > C, A > G, A > T, C > A). Compounds that 
form adducts on guanine residues often lead to G > T mutations as is the case with 
aflatoxin B1 and BaP (Poon et al., 2014, O’Brien et al., 2016). If these mutations affect 
the functionality of genes critical for cellular homeostasis (e.g. tumour suppressor 
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genes, mismatch repair genes and proto-oncogenes) then the likelihood of the mutation 
giving rise to malignancy increases. 
1.4 Methods of investigating contribution of XMEs to carcinogen 
activation 
There are a variety of experimental tools that allow the assessment of the contribution 
of XMEs to the activation of carcinogens both in vitro and in vivo. The development 
of targeted gene disruption methodologies have also allowed the investigation into the 
role of single or multiple enzymes in bioactivation pathways through knocking out 
enzymes or enzyme activity in in vitro or in vivo systems.   
1.4.1 Gene targeted disruption methodologies 
1.4.1.1 Homologous recombination in embryonic stem cells 
The method is based upon homologous recombination between a targeting vector and 
the gene of interest and was developed in the late 1980s (Capecchi, 1989, Smithies et 
al., 1985). The selection for the appropriate gene targeting event is carried out in petri 
dishes as opposed to whole organisms, making the process more efficient. The 
selection process is divided into two steps; the first step identifies embryonic stem 
(ES) cells cultured from the inner cell mass of mouse blastocycts, whose genome 
contained the incorporated targeting vector. An engineered neomycin resistance-
conferring cassette was incorporated into the homology region of the targeting vector, 
generally into the region that would correspond to an important and upstream exon of 
the targeted gene (Cheah and Behringer, 2000). In order to ensure that the 




Figure 1.8: The homologous recombination in embryonic cells method of producing knockout mice. 
See text for details. 

























replacing the endogenous gene as opposed to insertion into a random locus an 
additional step was added. This was achieved by the inclusion of the thymidine kinase 
cassette downstream of the homology region of the construct as a negative selectable 
marker (Mansour et al., 1988). Once successful selection of gene-targeted ES cells has 
been carried out they are injected into the cavity of blastocysts to produce embryos 
containing the disrupted gene. These embryos are implanted into foster mothers who 
go on to give birth to chimeric offspring. These offspring are then test bred to identify 
germline chimeras where some of the progeny result from ES cell-derived gametes 
(Figure 1.8) (Melton, 1994). Due to the insertion of a non-native sequence, e.g., the 
neomycin cassette, in the middle of an important exon of the gene of interest or a stop 
codon upstream of coding regions, or both, the endogenous gene was ultimately 
disrupted. Therefore, there was either no protein expression from it, or the translated 
protein was structurally so abnormal that it could not serve the original biological 
function. Thus, the mutation induced with this technology was called null mutation, 
and the transgenic mouse carrying such a mutation, the knock-out or null mutant 
mouse (Gerlai, 2016). 
1.4.1.2 The Cre-lox system 
Early gene targeting technology was limited to relatively simple genetic 
manipulations, i.e. introducing a mutation into a gene, or globally deleting the function 
of a single gene. With the introduction of site-specific recombination strategies came 
with the possibility of gene deletion in a spatially (with a tissue- or cell- specific 
promoter) and/or temporally (with an inducible system) controlled fashion, helping to 
circumvent the problem of embryonic lethality (Arlt et al., 2015a). One of the most 





















modification to be targeted to a specific cell type or be triggered by a specific external 
stimulus and can be utilised in both prokaryotic and eukaryotic systems. Cre is the 38-
kDa product of the cre gene of bacteriophage P1 and is a site-specific DNA 
recombinase. Cre recognises a 34-bp site on the P1 genome called loxP (locus of X-
over of P1) and is able to efficiently catalyse reciprocal conservative DNA 
recombination between pairs of loxP sites. The gene of interest that is flanked by loxP 
sites is considered to be ‘floxed’. The loxP site consists of two 13-bp inverted repeats 
flanking an 8-bp nonpalindromic core region. These regions give the loxP sites 
directionality and, depending on the orientation of these sites, Cre either inverts the 
fragment in between the two loxP sites or expels it as a circular fragment. Excision of 
the DNA as a covalently closed circle results from Cre-mediated recombination 
between two directly repeated loxP sites (reviewed by: (Sauer, 1998)). This system 
can be utilised in mice to generate knockout models. In order to do this, two mouse 
lines are needed. One mouse line contains the two loxP sites flanking the gene of 
interest that needs to be deleted. The other line expresses the Cre recombinase, either 
in the whole organism or a target tissue. By crossing the two mouse lines the loxP sites 
and the Cre are combined, activating the recombination system and deleting the gene 
of interest (GOI) (Figure 1.9). Inducible Cre recombinases have also been developed 
that are fusion proteins that contain the original Cre recombinase and a specific ligand 
binding domain that is activated by an exogenous ligand (Jaisser, 2000). Binding of 
the ligand is thought to produce conformational changes in the fusion protein and/or 
changes in the intracellular localisation associated with targeting of the recombinase 
to the nucleus (Metzger and Feil, 1999, Sauer, 1998). 
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1.4.1.3 CRISPR/Cas9  
Archea and bacteria are able to develop future resistance to bacteriophage invasion by 
integrating short fragments of the viral nucleic acid into clusters of regularly 
interspaced short palindromic repeats (CRISPRs) (van der Oost et al., 2014). Three 
types (I-III) of CRISPR systems have been identified, with each system consisting of 
a cluster of CRISPR-associated (Cas) genes, non-coding RNAs and a distinctive array 
of repetitive elements (direct repeats). These repeats are interspaced by the short 
fragments derived from foreign DNA targets known as protospacers (Makarova et al., 
2011). Together, the protospacers and the direct repeats make up the CRISPR RNA 
(crRNA) array. Out of the CRISPR systems, the type II CRISPR system is one of the 
best understood and possesses the CRISPR-associated protein 9 (Cas9) nuclease. Cas9 
has an RNA binding domain, an alpha helix recognition lobe (REC), a nuclease lobe 
that includes the RuvC and HNH nuclease domains for DNA cleavage, and a 
protospacer adjacent motif (PAM) interacting site. Cas9 binds to the crRNA, creating 
a complex, causing conformational changes that create a channel that allows for DNA 
binding (Brouns et al., 2008). The Cas9/crRNA complex scans the DNA searching for 
the DNA target for a PAM, a 2-6 base pair DNA sequence (5’NGG) immediately 
following the target DNA sequence. Cas9 will not successfully bind or cleave the 
target DNA if it is not followed by the PAM sequence (Mojica et al., 2009). 
Recognition of a PAM site by the Cas9/crRNA complex leads to unwinding of the 
DNA allowing the crRNA to check the adjacent DNA via complementary base pairing 
(Sternberg et al., 2014). If the crRNA is not complementary the Cas9 releases, if it is 
the bridge helix within the REC lobe creates an RNA-DNA heteroduplex with the 
target DNA (Nishimasu et al., 2014). The PAM site recognition activates the 
nucleolytic HNH and RuvC domains that create a DSB in the target DNA. These DSBs 
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are repaired via the non-homologous end joining (NHEJ) repair pathway, which often 
creates errors by introducing insertion or deletions, or the homology directed repair 
(HDR) pathway.  
The CRISPR system has been adapted for use within the laboratory by using synthetic, 
easily designed single guide RNAs (gRNA) instead of crRNAs. CRISPR/Cas9 
plasmids allow an efficient gene targeted disruption method (Figure 1.10). The 
plasmids encode the 20 nucleotide non-coding gRNA sequence alongside the gRNA 
scaffold that helps Cas9 bind to target DNA. A marker for successful transfection is 
also expressed in the plasmid, in most cases this is red or green fluorescent protein to 
allow visual verification of transfection. A second plasmid is often present in 
transfection mixtures that still encodes for the gRNA and Cas9, but contains a gene 
that confers resistance to an antibiotic, i.e. puromycin, to allow selection of 
successfully transfected cells (Ran et al., 2013b). Whilst the CRISPR-Cas9 system is 
highly efficient, a considerable disadvantage is the number of off-target effects which 
reduces the specificity of CRISPR/Cas9 editing. This has been overcome with the 
development of a CRISPR double nickase system whereby a pair of plasmids encode 
a Cas9 (D10A) nickase mutant (Cas9n). Each plasmid also encodes a gRNA and each 
Cas9n/gRNA complex creates only one nick in the DNA strand that is complementary 
to the gRNA. Each pair of gRNAs is offset by around 20 base pairs and recognise 
target sequences on opposite strands of the target DNA. The resulting double nick 
created by the pair of Cas9n/gRNA complexes mimics a DSB and DNA repair by 
NHEJ lead to errors from insertions, deletions or frameshifts that act to disrupt the 
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Figure 1.11: Schematic of the double nickase CRISPR/Cas9 plasmid method of gene disruption. See 
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1.4.2 In vitro systems 
1.4.2.1 Cell-free systems 
In order to study the reactions catalysed by a single cytochrome P450 experimentally 
that protein be isolated from animal and plant tissues or large volumes of biological 
fluids, with kilograms being needed to yield a small amount of a given protein. In the 
late 1980s and early 1990s the technology for the excision of complete cytochrome 
P450 genes as well as their reductases and insertion into bacterial, eukaryotic or viral 
vectors was developed, E. coli often the vector of choice, bringing forth a new 
experimental tool in carcinogenesis studies (Rosano and Ceccarelli, 2014, Stringer et 
al., 2009). The purified P450s can be used to reconstitute catalytic activities when 
mixed with redox partners such as POR, with both recombinant proteins purified from 
bacterial sources. Bacteria are normally devoid of redox partners such as POR so a 
tac/tac promoter is used to produce a single RNA containing both the P450 and 
reductase messages, each with an independent site for ribosome binding. Such systems 
yield cytochrome P450 and redox proteins in ~1:1 ratio (Parikh et al., 1997, 
Guengerich et al., 1997)  
Microsomes are comprised of fragments of the ER that form micelles rich in ER-bound 
enzymes. These microsomal fractions are isolated by centrifugation of homogenised 
organs, predominantly the liver, at around 10,000 g to remove cellular and nuclear 
membranes, as well as larger cellular organelles. The supernatant is then centrifuged 
at around 100,000 g to provide a pellet that contains the smooth ER, and thus the 
membrane bound XMEs associated with it. The microsomal fractions can be isolated 
from a range of tissues (Scotcher et al., 2017, Heilmann et al., 2012, Asha and 
Vidyavathi, 2010) and incubated in the presence of an NADPH-regenerating system 
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in the form of enzymatic cofactors. This reaction mixture can be used for the 
evaluation of phase I oxidative reactions and, with the use of inhibitors, the influence 
of specific isozymes on the in vitro activation of procarcinogens (Nirogi et al., 2015). 
Microsomal fractions are widely used as an experimental tool in xenobiotic 
metabolism and have been utilised for chemical carcinogenesis studies since 1948 
when it was discovered that the biotransformation of N,N-dimethyl-4-
aminoazobenzene could be catalysed in a cell free system using rat hepatic 
microsomes (Mueller and Miller, 1948). At that time the enzymes present in 
microsomal fractions were known as mixed function oxidases until the 1960s when 
the cytochrome P450 nomenclature was developed (Brodie et al., 1955, Omura and 
Sato, 1962). Due to microsomes being an isolated part of the cell and the enrichment 
of P450s in the fractions, it is difficult to extrapolate to in vivo metabolism as the 
absence of competing enzymes and cytosolic cofactors can leave some metabolic 
outcomes unnoticed (Brandon et al., 2003).  
Supersomes are microsomes prepared from insect cells containing cDNA of a single 
cytochrome P450. They are also a valuable experimental tool as insect cells lack 
endogenous cytochrome P450 activity, allowing transfection and subsequent activity 
of the selected P450 to be assessed without competition from endogenous enzymes. 
They can also be referred to as baculosomes due to the infection of the insect cells by 
baculo virus (Chen et al., 1997). Supersomes are used as tools in biotransformation 
studies as they have the added advantage of unique specification by expressing 
enzyme activity of one single CYP isoform and also find a solution to the problem of 
limited tissue availability needed to harvest microsomes. As with microsomes, an 




1.4.2.2 Cell culture  
In vitro cell-free systems are very useful for identifying substrates and reactions 
catalysed by individual P450 enzymes, however they do not represent the cell as a 
whole in metabolism. In vitro models cannot replicate the complex interactions that 
occur in vivo; however they are valuable in providing a quick insight into the 
metabolism of a large number of compounds (White, 2000). Intact primary 
hepatocytes represent a strong option as a compromise between an isolated system and 
the necessity to be as close as possible to the in vivo situation. There is evidence that 
for the study of toxicological endpoints other than metabolism, a typical freshly 
isolated suspension is an incomplete model, as non-parenchymal cells are very poorly 
represented (<1%) whilst in the intact organ they account for 20-40% of the total cell 
number (Ammann and Maier, 1997). Primary cultures can be isolated from tissues of 
humans or animals, but they require access to donors, can be difficult to handle and 
can be short lived due to expression of specialised features of the cells being gradually 
lost once separated from the organism (Coleman, 2010). Immortalised cell lines that 
originate from tumours were introduced as an alternative to overcome the limitations 
of primary cells. With advances in biochemistry, molecular biology and cell biology, 
it became possible to introduce new techniques that enable the production of different 
cell lines and the characterisation and differentiation of them in order to better 
understand intracellular processes. Animal cell culture technology is now generally 
considered a reliable, robust and relatively mature technology (Li et al., 2010). Due to 
their origins, cell lines often display abnormal characteristics of their parent tumour, 
e.g. resistance to toxicity, overexpression of detoxification and transport systems and 
rapid and continuous growth. These abnormalities, however, can be exploited for 
experimental xenobiotic metabolism focussing on activation or detoxification 
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mechanisms. Cell lines have an unlimited lifespan, high reproducibility and are much 
easier to standardise making them an advantageous in vitro tool (Jennings, 2015).  
Culturing cells within a 2D model as a monolayer or within a suspension is the 
predominant method in vitro. In order to make the model more representative of in 
vivo conditions, cells can be cultured in 3D culture systems. In conventional 2D 
conditions the extracellular matrix components, cell-to-cell and cell-to-matrix 
interactions that are important for differentiation, proliferation and cellular functions 
in vivo are lost (Mazzoleni et al., 2009). Cells are cultured on a 3D scaffold that can 
be generated using various natural and synthetic polymers, i.e. collagen, gelatin and 
elastin). These composites mimic the native extracellular matrix by porosity, fibrous, 
permeability and mechanical stability and enhances the biophysical and biochemical 
interaction of the adhered cells. This in turn provides a biologically active environment 
for the cells to proliferate and differentiate (Ravi et al., 2015). Cells cultured in a 3D 
environment also differ in gene, protein and cell receptor expression from 2D-cultured 
cells with various cancer cell lines displaying different gene expression profiles 
depending on the culture method (Baharvand et al., 2006). Cells are commonly 
cultured as aggregates, grown on 3D scaffold materials, or are embedded in gels (Lin 
and Chang, 2008, Moroni et al., 2008, Slaughter et al., 2009). Aggregates are 
commonly referred to as spheroids (Kunz-Schughart et al., 2004) but alternative 
names include  micromass and microfabricated tissues (Greco et al., 2011, Rivron et 
al., 2009). Whilst a single cell type can be cultured in a 3D system, studies have also 
been carried out that co-culture two or more different cell types in order to better 
mimic an in vivo system. (Campbell et al., 2011, Leisten et al., 2012, Susewind et al., 
2016). Co-culturing cells has also been shown to overcome the limitations of primary 
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hepatocytes as co-culturing with endothelial cells in order to preserve their normal 
function (Kim et al., 2012).  
A recent advance in 3D cell culturing is the development of organoids. Pluripotent 
stem cells (PSCs) and adult stem cells (ASCs), have been shown to assemble into 
complex structures that contain organised clusters of cells when placed within a 
hydrogel and in the presence of suitable exogenous factors (Lancaster and Knoblich, 
2014). Organoids exhibit the spatial organisation of heterogeneous tissue-specific 
cells, cell-cell interactions, cell-matrix interactions and certain physiological functions 
generated by tissue-specific cells within the organoid. This means they provide a stable 
system allowing extended cultivation and manipulation, a limitation of spheroids (Yin 
et al., 2016). If provided with the appropriate 3D scaffold and biochemical factors 
differentiated PSCs are able to self-organise to form tissue specific organoids 
including the liver (Takebe et al., 2013), kidney (Takasato et al., 2014), brain 
(Lancaster et al., 2013), intestine (Spence et al., 2011) and optic cup (Eiraku et al., 
2011).  Many tissues are maintained in vivo by tissue-specific ASCs through self-
renewal and differentiation followed by self-organisation. This process has been 
reproduced in vitro under specific culture conditions to produce self-organised tissue 
organoids including pancreas (Huch et al., 2013), stomach (Barker et al., 2010), 
intestine (Sato et al., 2009) and liver (Huch et al., 2013). Hepatic organoids have been 
shown to be capable of expressing constitutive and induced cytochrome P450s 
involved in carcinogen bioactivation, i.e. CYP1A1/2, CYP3A and CYP2E (Miyamoto 
et al., 2005) making organoids a potentially important in vitro tool for future chemical 
carcinogenesis studies.   
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1.4.3 In vivo: mouse models 
The development of targeted gene disruption methodologies (Capecchi, 1989, Le and 
Sauer, 2001) has given rise to numerous transgenic mouse lines (e.g. CYP-knockout 
or CYP-humanised) that allow investigation into the contribution of individual 
cytochrome P450s to chemical-induced genotoxicity and carcinogenesis. A number of 
knockout and humanised mouse lines have been developed to study the role of P450 
enzymes in metabolism (Arlt et al., 2011, Buters et al., 1999, Kimura et al., 1999, 
Kimura et al., 2003, Uno et al., 2004).  
1.4.3.1 P450 null mice 
Mice lacking an individual P450 have been widely utilised in metabolism studies. 
Using the Cre-lox system, Cyp1a1(‒/‒) knockout mice on a C57BL/6J and 129/J 
background were developed through the deletion of the Cyp1a1 gene (Dalton et al., 
2000). These mice are described as being viable and show no obvious phenotype 
compared to WT littermates. ES cells have also been used to develop P450 null mice. 
Cyp3a(‒/‒) mice developed using this technology were expected to possess marked 
physiological changes due to the deletion of Cyp3a, however, the mice were shown to 
be viable and fertile. Haematological, plasma clinical chemistry and pathological 
examination of male and female mice at approximately 12 weeks of age did not reveal 
any marked abnormalities, nor did pathological examination between 67 and 84 weeks 
of age (van Herwaarden, 2007). Cyp1b1(‒/‒) mice were also shown to be 
indistinguishable from their WT and heterozygous littermates, and gross pathological 
examination revealed no apparent abnormalities. The mice were also fertile and 
produced normal-sized litters (Buters et al., 1999). Cyp1a2(‒/‒) mice produced by 
homologous recombination in ES cells were also shown to have no developmental 
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issues despite lacking Cyp1a2 activity (Liang et al., 1996). Once these stable P450 
knockout mice have been attained it is possible to crossbreed them to create double-
knockout lines. Thus Cyp1a1/1b1(‒/‒) and Cyp1a2/1b1(‒/‒) mice have been bred 
successfully, although simple genetic crosses were not initially able to produce 
Cyp1a1/1a2(‒/‒) mice due to the genes being located only 13.3 kilobases apart on 
mouse chromosome 9 (Uno et al., 2006). However, use of the Cre-lox system via two 
loxP sites situated 26 kilobase pairs apart proved to be successful, resulting not only 
in double knockout Cyp1a1/1a2(‒/‒) mice but also in a Cyp1a1/1a2/1b1(‒/‒) triple 
knockout line (Dragin et al., 2008).  
Disruption of Cyp genes encoding for P450 enzymes in mice can result in models with 
no developmental abnormalities or deleterious phenotype (Gonzalez, 2003). However, 
this disruption can be problematic in the study of BaP metabolism as Cyp1a1(‒/‒) 
mice were found to die within approximately 28 days due to immunosuppression when 
administered repeated oral doses of BaP whereas WT mice remained healthy for at 
least one year (Uno et al., 2004). Another limitation of knocking out an individual 
P450 is the substrate overlap seen in this class of enzymes where loss of a single P450 
enzyme can be compensated for by remaining P450 enzymes (Henderson et al., 2006).  
1.4.3.2 Electron donor null mice 
A new approach to investigating the role of P450s in in vivo metabolism is to delete 
the electron donors to P450s, rather than the XMEs themselves. In the absence of the 
electron donors, P450s cannot complete the catalytic cycle and therefore activity is 
lost. Global deletion of POR in mice was found to lead to embryonic lethality; 
however, knocking out POR activity in a single organ creates a much more stable 
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mouse model (Otto et al., 2003). By utilising inducible Cre recombinases, the Cprlox 
allele can be deleted resulting in the Cprnull allele in a variety of cells and organs via 
Cre-mediated recombination, following intercrosses between the Cpr-lox mouse and 
a Cre-transgenic mouse. Mice with tissue-specific Cpr deletion have been generated, 
with Cpr-lox as a parental strain, for many organs, including the liver (Gu et al., 2003), 
lung (Weng et al., 2007), heart (Fang et al., 2008), intestine (Zhang et al., 2009), brain 
(Conroy et al., 2010), mammary gland (Lin et al., 2012), and bone (Panda et al., 2012). 
The Hepatic Reductase Null (HRN) mouse model (Table 1.3) was produced by 
crossing floxed POR mice with a line carrying Cre recombinase under the control of 
the hepatocyte-specific albumin promoter (Postic et al., 1999). In these mice POR is 
deleted specifically in the hepatocytes (Henderson et al., 2003). The HRN mouse is 
crossed onto a C57BL/6 background and displays no overtly changed phenotype aside 
from steatotic livers, significantly lowered blood lipids and virtually no bile acid 
production as a consequence of non-functioning P450-housekeeping activity involved 
in cholesterol metabolism (Henderson et al., 2003). By preventing the transfer of 
electrons to the P450 catalytic cycle, the liver is practically devoid of P450 enzyme 
activity despite having substantially elevated levels of P450s (Henderson et al., 2006).  
The use of the albumin promoter in HRN mice to drive Cre expression does however 
have limitations. The albumin promoter switches on soon after birth, and in the case 
of HRN mice, drives POR deletion to completion by adulthood. This results in a great 
inability to control or regulate gene deletion. The Reductase Conditional Null (RCN) 
mouse (Table 1.3) was developed to overcome this limitation. The RCN mouse is a 
variant on the HRN mouse line (Porlox/lox/CreCYP1A1) whereby POR can be deleted 
conditionally in the liver and gastrointestinal tract using the rat CYP1A1 promoter to 
drive Cre recombinase expression (Finn et al., 2007). Administration of the CYP1A1 
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inducers TCDD or β-naphthoflavone results in deletion of both hepatic and 
gastrointestinal POR, whereas administration of 3-methylcholanthrene (3MC) results 
in the loss only of hepatic POR expression, essentially recapitulated the phenotype of 
the HRN mouse (Finn et al., 2007, Arlt et al., 2011). POR is not the only electron 
donor to cytochrome P450s. In order to investigate the role of Cyb5 in P450 
metabolism in vivo, two mouse models were developed. The first of these was 
developed using the ES homologous recombination method to produce the Hepatic 
Cytochrome b5 null (HBN) mouse (Table 1.3) whereby Cyb5 is conditionally deleted 
in the hepatocytes (Finn, 2008). The mice developed normally and displayed no overt 
phenotype when compared with their WT littermates and livers from the adult HBN 
mice looked similar to those of WT mice, with no gross changes in general 
morphology or pathology. Unlike the HRN mouse, although some expression of P450s 
was slightly elevated in HBN mice, the changes were not significantly different (Finn, 
2008, Finn et al., 2011). The HBN mouse is a valuable tool for investigating the role 
of Cyb5 in hepatocytes, however the cytochrome b5 complete null (BCN) mouse 
(Table 1.3) was later generated, using the same ES system as the HBN mice, which 
possessed a global Cyb5 knockout. Whereas a global deletion of POR led to 
embryonic lethality the global deletion of Cyb5 resulted in a viable mouse 
(McLaughlin et al., 2010). Whilst the HBN and BCN mouse models assess the role of 
Cyb5 in P450-mediated metabolism, POR is still present and contributing to the 
catalytic activity of P450s. In order to investigate the role of both electron donors 
simultaneously the Hepatic Cytochrome b5/P450 Reductase Null (HBRN) mouse 
model (Table 1.3) was generated by crossing HRN mice with the Hepatic Cytochrome 
b5 Null (HBN) mouse. This produced a mouse line that lacks both electron donors 
POR and Cyb5 and thus the activity of P450 enzymes was further reduced relative to  
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Table 1.3: Selection of single or double electron donor null mouse models. See text for details. 
Mouse model Phenotype Reference 
Hepatic Reductase 
Null (HRN) 
POR deleted specifically in 
hepatocytes 
(Henderson et al., 2003) 
Reductase Conditional 
Null (RCN) 
POR conditionally deleted in 
hepatocytes upon 
administration of 3-MC 
(Finn et al., 2007) 
Hepatic Cytochrome 
b5 Null (HBN) 




Complete Null (BCN) 




POR and Cyb5 deleted 
specifically in hepatocytes 




The HRN and HBN model (Henderson et al., 2013). Collectively, these mouse models 
are powerful in vivo tools of investigating the role of hepatic versus extra-hepatic P450 
enzymes in xenobiotic metabolism (Henderson et al., 2013, Arlt et al., 2012, Arlt et 





1.5 Aims of the project 
The first part of this project aims to investigate the role of P450 enzymes and 
the contribution of electron donor proteins in the bioactivation of environmental 
carcinogens. This project utilises both the HRN and HBRN mouse models to 
investigate the contribution of the electron donors POR and Cyb5 to the P450-
mediated metabolic activation of the environmental carcinogen BaP and the anticancer 
drug ellipticine both in vivo and in vitro. BaP and ellipticine have both been studied 
previously in HRN mice and, although they are both activated via P450-mediated 
pathways, the experiments with HRN mice yielded contrasting results. Utilising the 
HBRN mouse in this study will help to assess whether the contrast in results is 
attributable to the contribution of Cyb5 in one reaction but not the other. The use of 
the two carcinogens side by side will also provide greater mechanistic insights into 
host factors regulating P450 catalysed carcinogen metabolism. As BaP and ellipticine 
are activated by P450-mediated pathways so in the absence of electron donors and 
P450 activity I hypothesise that activation of these carcinogens to form reactive 
metabolites and DNA-adducts would be reduced compared to WT mice. In order to 
assess P450-mediated activation in the mice in vivo, DNA adduct formation will be 
assessed across a range of organs. In order to investigate the in vitro activation of BaP 
and ellipticine, hepatic microsomal fractions will be used in reaction mixtures to assess 
enzyme activity using both colorimetric assays and HPLC, metabolite formation 
analysed using HPLC and DNA adduct formation analyse using 32P-postlabelling. 
Protein expression of electron donors and XMEs in the hepatic microsomal fractions 
will also be investigated using Western blotting.  
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The second part of the thesis aims to develop an in vitro model of the HRN 
mouse in order to allow further investigation of the accumulation of BPDE-DNA-
adduct formation seen in HRN mouse hepatocytes. This model will be developed in 
immortalised murine hepatocytes, Hepa-1c1c7, originating from a mouse hepatoma. 
POR expression will be knocked out of Hepa-1c1c7 cells using CRISPR/Cas9 
technology. An attempt to create a new cell line from a single clone, to ensure 
uniformity and reproducibility, will be done using single cell isolation. This cell line 
will then utilised to investigate the effect of POR on the P450-mediated bioactivation 
of BaP in vitro by assessing metabolite formation using HPLC, DNA damage using 
the comet assay and DNA adduct formation using 32P-postlabelling. In order to assess 
whether the disruption of POR in the Hepa-1c1c7 cells will have an effect of protein 
expression of electron donors and XMEs in the cells, with or without treatment of BaP, 
Western blotting will be carried out on cell lysates.  
The final part of the thesis attempts to compare the responses of mouse 
hepatoma Hepa-1c1c7 POR-knockout cells with that of human hepatoma HepG2 
POR-knockout cells to BaP. This will help to provide insight as to whether the 
unexpected accumulation of BPDE-DNA-adducts in hepatocytes lacking POR is 
limited to mouse models or is also experienced within a human hepatocyte model. The 
effect of POR on the P450-mediated bioactivation of BaP in vitro will be studied by 
assessing metabolite formation using HPLC, DNA damage using the comet assay and 
DNA adduct formation by 32P-postlabelling. In order to compare protein expression 
of electron donors and XMEs in the cells in the absence of POR with that seen in the 




Whilst it is important to understand the mechanisms of P450-mediated 
bioactivation of carcinogenic agents into reactive metabolites, there are also wider 
reaching implications into fields such as epidemiology and drug development. Drug 
candidates with strong P450-inducing activity have a lower chance of surviving the 
preclinical and clinical stage testing. The assessment of risk-benefit ratio before 
determining a molecule’s suitability for development shows increasing awareness of 
chemically reactive metabolites that are able to react with essential cellular 
components (Mohutsky et al., 2010, Baillie and Rettie, 2011, Guengerich, 2010). 
P450-mediated bioactivation is also taken into consideration when identifying groups 
at risk of certain cancers, particularly in the relationship between PAHs and lung 
cancer (Mollerup et al., 2006, Hara et al., 2009, Hung et al., 2003, Gsur et al., 2001).  
It is also important to assess how representative animal models are in mirroring P450-
mediated bioactivation pathways in humans. If in vitro-in vivo models being used to 
investigate P450-mediated bioactivation pathways are not representative, then the 
identification and assessment of risk-benefit ratios and risk groups for developing 
cancer may be inaccurate. The work included within this project will contribute 
towards the understanding of P450-mediated metabolism in animal and human 
models.   
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2 Materials and Methods 
2.1 Chemicals 
Benzo[a]pyrene (BaP; CAS no. 50-32-8; purity >96%), ellipticine (CAS no. 519-23-
3; purity >99%), NADH (as disodium salt; purity 95%), NADPH (as tetrasodium 
salt; 98% purity), Sudan I and 7-methoxyresorufin were obtained from Sigma-
Aldrich (St Louis, MO, USA). Testosterone and 6-hydroxytestosterone were 
purchased from Merck (Darmstadt, Germany). All other chemicals used were 
analytical grade. 
2.2 Animal treatment  
All animal experiments were carried out at the University of Dundee under licence in 
accordance with the Animal (Scientific Procedures) Act (1986), as amended by EU 
Directive 2010/63/EU, and with local ethical approval. HRN (Porlox/lox/CreCYP1A1) 
mice and HBRN (Cytb5
lox/lox/Porlox/lox±CreALB) mice on a C57BL/6 background were 
derived as described previously (Henderson et al. 2003; Henderson et al. 2013). 
Animals were maintained in open-top cages, with free access to food (RM1 diet, 
Special Diet Services, Essex, UK) and water, and a 12-hour light/dark cycle. Mice 
homozygous for the floxed Por locus (Porlox/lox) were used as WT.  
2.2.1 Animal treatment with BaP 
For the BaP study, groups of female HRN, HBRN and WT mice (3 months old, 25-30 
g) were treated intraperitoneally (i.p.) with 125 mg/kg body wt (n = 3/group) of BaP 
for 1 day following a treatment protocol used previously to study BaP metabolism in 
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HRN mice (Arlt et al., 2008; 2012). In the present study, i.p. administration was used 
such that BaP uptake is directly to the liver via mesenteric veins and the lymphatic 
system, bypassing the gastrointestinal tract and metabolism by extrahepatic CYPs. 
BaP was dissolved in corn oil at a concentration of 12.5 mg/mL. Control mice (n = 3) 
received solvent (corn oil) only. Animals were killed 24 hours after the single dose 
and their tissues (liver, lung, forestomach, glandular stomach, kidney, spleen, small 
intestine, bladder and colon) were collected, snap-frozen and stored at ‒80°C until 
analysis. 
2.2.2 Animal treatment with ellipticine 
For the ellipticine study groups of female HRN, HBRN and WT mice (3 months old, 
25-30 g) were treated i.p. with 10 mg/kg body wt (n = 4/group) of ellipticine for 1 day 
following a treatment protocol used previously to study ellipticine metabolism in HRN 
mice (Stiborova et al., 2008). Ellipticine was administered dissolved in 1% acetic acid 
at a concentration of 2.5 mg/ml. Control mice (n = 3/group) received the solvent only. 
Animals were killed 24 hours after the single dose and their tissues (liver, lung, small 
intestine, kidney, spleen, bladder and colon) were collected, snap-frozen and stored at 
‒80°C until analysis. 
2.3  Genotyping  
 To extract DNA for genotyping, pieces of liver tissue were suspended in 400 µL of 
50 mM NaOH and heated to 95°C for 15 minutes, followed by vortexing for 5 seconds 
at the middle and end of the incubation. Next, 35 µL of 1 M Tris-HCL (pH 8.0) was 
added to each sample, followed by mixing and centrifugation at 13,000 rpm for 20 
minutes. The supernatant was either used immediately or stored at ‒20°C. The primers 
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and PCR reaction conditions to genotype for WT, HRN and HBRN mice are described 
in Table 2.1. In the case of WT and HRN mice, PCR was carried out with Illustra 
PuReTaq PCR beads (27955801, GE Healthcare Life Sciences). To visualise
Table 2.1: Primer sequences and PCR conditions for the PCR reactions for the different genes of 
interest.  
Gene Primer Primer sequence PCR Conditions 
Control 
OMIR 15 
CAA ATG TTG 
CTT GTC TGG 
TG  
1: 95°C 5 minutes 
2: 95°C 30 seconds 
3: 50°C 1 minute 
4: 72°C 1 minute 
5: steps 2-4: 34 times 
6: 72°C 5 minutes 
7: 4°C forever 
OMIR 16 
GTC AGT CGA 




ACC TGA AGA 
TGT TCG CGA 
TTA TCT 
1: 94°C 4 minutes 
2: 94°C 30 seconds 
3: 53°C 1 minute 
4: 72°C 30 seconds 
5: steps 2-4: 29 times 
6: 4°C forever 
Cre 1054 
ACC GTC AGT 




AGG CAG GCT 
GCT CAG GTC 
GGC 
1: 94°C 3 minutes 
2: 94°C 30 seconds 
3: 60°C 20 seconds 
4: 72°C 45 seconds 
5: steps 2-4: 34 times 
6: 72°C 5 minutes 
7: 4°C forever 
Red 1105 
GAC CCT GAA 
GAG TAT GAC 
TTG 
Red 1184 
GCT TCC TCT 
TGC AAA ACC 
ACA CTG C 
Cyb5  
B100 
CCA ATG GTC 
TCT CCT TGG 
TC 
WT + HRN mice 
 
1: 95°C 5 minutes 
2: 95°C 1 minute 
3: 56°C 1 minute 
4: 72°C 1 minute 
5: steps 2-4: 39 times 
6: 72°C 5 minutes 
7: 4°C forever 
HBRN mice 
 
1: 95°C 5 minutes 
2: 95°C 30 seconds 
3: 50°C 1 minute 
4: 72°C 1 minute 
5: steps 2-4: 34 times 
6: 72°C 5 minutes 
7: 4°C forever 
B102  
(WT + HRN) 
GAT GGA GTT 




CAA TAG CAG 




PCR Reaction Mix 
(Per reaction) 
RedTaq 2X Ready Mix (R2523, Sigma)             12.5 µL 
Primer 1                                                                  0.5 µL 
Primer 2                                                                  0.5 µL 
DNA                                                                       2.0 µL 
Nuclease Free Water                                              9.5 µL 
 
(In the case of reactions using 3 primers, 9 µL of water used) 
 
the PCR products, reactions were resolved on 2% agarose gels containing 0.5 µg/mL 
ethidium bromide. Band size was monitored by loading 3 µL of Gel Pilot 100 bp Plus 
marker (239045, Qiagen) onto each gel. Electrophoresis was performed at 140 V in 
TBE buffer (15581044, ThermoFisher) for 45 minutes, and then gels were exposed to 
UV light for image capture.  
2.4 Preparation of hepatic microsomes 
The microsomal fraction of tissues comprises fragments of the ER that form micelle 
structures called microsomes, which contain XMEs such as those found in the mixed-
function oxidase system (e.g. P450 enzymes). Microsomal fractions were isolated 
from the livers of HRN, HBRN and WT mice using standard differential 
centrifugation. The livers from each mouse line were pooled for each microsomal 
preparation. The procedure was carried out in a cold room at 4°C with all buffers and 
materials being brought down to temperature prior to use. The livers were weighed 
prior to homogenisation in B1 buffer (0.15 M KCL, 0.05 M Tris/HCL; pH 7.4; 50 µm 
tocopherol in methanol) in a Potter-Elvehjem glass homogeniser. The volume of B1 
buffer was dependent on tissue mass with 4 mL B1 per 1 g of tissue being used. The 
pooled homogenised livers were centrifuged at 2000 rpm for 10 minutes at 4°C 
(Janetzi K-23 swing-out rotor 470 mL) and the supernatant was then collected. 
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Pellets were resuspended in 250 µL of B1 buffer per 1 g of tissue and then centrifuged 
again under the same conditions. Both supernatants collected were pooled and 
centrifuged at 13,500 rpm for 20 minutes at 4°C (Janetski K-24, fixed-angle rotor 635 
mL). The supernatants were collected and weighed to balance before being 
ultracentrifuged at 45,000 rpm for 1 hour at 4°C (Beckman Coulter-Optima LE-80K, 
fixed angle rotor Ti45, 664 mL). The supernatants were discarded. Pellets were 
resuspended and homogenised in 2 mL of B2 buffer (0.1 M Na4P2O7.10H2O; pH 7.2) 
per 1 g tissue using a small Elvehjem glass homogeniser. The resuspended pellets were 
then ultracentrifuged at 60,000 rpm for 1 hour at 4°C (Beckman Coulter-Optima LE-
80K, fixed angle rotor Ti70, 836 mL). The supernatants were discarded and the final 
pellets were resuspended in 200 µL B3 buffer (0.15 M KCL, 0.05 M Tris/HCL, 20% 
(v/v) glycerol; pH 7.4) per 1 g of tissue. Microsomal fractions were aliquoted, 
immediately frozen in liquid nitrogen and stored at ‒80°C (Stiborova et al., 2003b). 
The protein concentration of the fractions was determined using the bicinchoninic 
protein assay (BCA) (Wiechelman et al., 1988) with the Thermo ScientificTM PierceTM 
BCA Protein Kit and bovine serum albumin as a standard.   
2.5 Enzyme activity 
2.5.1 Cytochrome c reduction 
POR is able to reduce cytochrome c in the presence of NADPH that can be measured 
colorimetrically allowing the activity of POR enzymes in a sample to be determined 
over a set time (Figure 2.1). The reaction mixture containing 955 µL of potassium 
phosphate buffer (0.3 M KH2PO4 with 1 mM EDTA; pH 7.5) with 25 µL 20 mg/ml 
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cytochrome c and 10 µL 10 mM NADPH was measured at the wavelength 550 nm as 
a blank. Ten µL of microsomal fraction was then added, the reaction mixture mixed 
 
Figure 2.1: Schematic of the reduction of cytochrome c by POR in the presence of the enzymatic 
cofactor NADPH. 
slightly and the measurement of ΔA0-60 at 550 nm was started. The activity of POR 
was then calculated using the following equation: 
𝑎 =
∆𝐴0−60
𝜀 𝑥 𝑙 𝑥 𝑐𝑝𝑟 𝑥 𝑡 
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
ε = extinction coefficient (21,010 dm3.mol-1.cm-1, l = length of cuvette, cpr = 
concentration of protein (mg/ml) , t = time, a = mmol cytochrome c/mgpr/min 
2.5.2 EROD and MROD  
CYP1A1 and CYP1A2 are able to metabolise the substrate 7-ethoxyresorufin (EROD 
assay) and 7-methoxyresorufin (MROD assay), respectively, by a dealkylation 
reaction to a fluorescent product, resorufin (Figure 2.2). The amount of resorufin 
produced within a set time can be used to measure CYP1A enzyme activity, with the 










Figure 2.2: Schematic of the dealkylation of 7-ethoxyresorufin and 7-methoxyresorufin by Cyp1a1 and 
Cyp1a2, respectively, in the presence of the enzymatic cofactors NADPH or NADH.  
CYP1A1/2 activity and MROD assay as a measure for CYP1A2 activity (Guengerich 
and Shimada, 1991). Microsomal fractions (see section 2.3) at a concentration of 0.5 
mg/mL of protein were incubated with 2.2 µM of 7-ethoxyresorufin or 7-
methoxyresorufin for 2 minutes at room temperature; total incubation volume was 500 
µL with potassium phosphate buffer (0.1 M KH2PO4; pH 7.4). Aliquots (150 µL) of 
the reaction mixture were loaded into a 96-well plate and the reaction was initiated 
with the addition of 17 µL 5 mM NADPH or NADH. The fluorescence was measured 
for 10 minutes at room temperature on a Luminescence Spectrometer PerkinElmer 
LS-55 equipped with 96-well plate reader using the excitation wavelengths 530 nm 
and the emission wavelengths 585 nm. Enzyme activities were quantified using a 
resorufin standard curve. 
2.5.3 Sudan I oxidation 
CYP1A1 enzymes are able to metabolise the substrate Sudan I to 4’-hydroxy-, 
6’hydroxy-, 3’4-dihydroxy- and 4’6-dihydroxy-Sudan I by hydroxylation (Figure 2.3) 









measure CYP1A1 activity. Microsomal fractions (see section 2.3) at a concentration 
of 0.5 mg/ml of protein were preincubated with 100 µM Sudan I for 5 minutes at 37°C; 
total incubation volume was 500 µL with phosphate buffer (50 mM NaH2PO4; pH 
7.4). The reaction was initiated with the addition of 50 µL of 10 mM NADPH or 
NADH. The samples were incubated for 30 minutes at 37°C, shaking at 250 rpm. The 
reaction was stopped with the addition of 1 mL of ethyl acetate and the metabolites 
extracted by shaking for 2 minutes at 1400 rpm and centrifuged at 4000 rpm for 5 
minutes. The upper layer of ethyl acetate was collected and the process repeated a 
second time with 750 µL ethyl acetate. The collected ethyl acetate layers were pooled 
and evaporated to dryness and stored at ‒20°C. The samples were resuspended in 30 
µL of HPLC grade methanol and analysed by HPLC on a Nucleosil® C18 reverse 
phase column, (250  4 mm, 5 µm; Machery-Nagel, Düren, Germany) using a Dionex  
 
Figure 2.3: Schematic of the hydroxylation of Sudan I by Cyp1a1 to the metabolites 4’-hydroxy-, 6’-
hydroxy-, 3’,4-dihydroxy- and 4’,6-dihydroxy-Sudan I in the presence of the enzymatic cofactors 
NADPH or NADH. 
system consisting of a P580 pump, a UV/VIS Detector UVD 170S/340S, an ASI-100 
Automated Sample Injector a thermobox column oven LCO 101 and an In-Line 










build 490 software. The chromatographic separation of Sudan I metabolites was 
carried out under the following conditions: 100% 200 mM NH4HCO3; pH 8.5 at a flow 
rate of 0.7 mL/min. Metabolites were detected at 480 nm.  
2.5.4 Testosterone hydroxylation 
CYP3A4 is able to catalyse the hydroxylation of testosterone in the presence of 
NADPH and NADH and the resulting metabolites can be measured using HPLC 
allowing the activity of CYP3A4 enzymes to be determined (Figure 2.4). The 
incubation mixture contained in a final volume of 500 µL: phosphate buffer (100 mM 
KH2PO4; pH 7.4), 50 µM testosterone (10 mM stock in 100% methanol) and 0.5 
mg/ml hepatic microsomal protein (see section 2.3). Negative control reactions lacked 
either microsomal protein, testosterone or enzymatic cofactor. The samples are 
preincubated for 5 minutes at 37 °C and then the reaction started with the addition of 
1 mM NADPH or NADH. The incubation is carried out for 15 minutes at 37°C at 400 
rpm. After incubation the reaction was terminated by the addition of 100 µL 1 M 
aqueous Na2CO3 containing 2 M NaCl. Five µL of 1 mM phenacetine (PA) was added 
as an internal standard. The metabolites were extracted by adding 1 mL of 
dichloromethane (DCM) to the reaction mixture, shaking for 2 minutes at 1400 rpm 
before centrifuging for 5 minutes at 13,000 rpm. The DCM layer was removed and 
collected before the extraction process was repeated. The pooled DCM was then 
evaporated to dryness using a speedvac evaporator and the samples stored at ‒20°C. 
Testosterone and its metabolite 6-β-hydroxytestosterone were separated on Nucleosil 
(C18) HPLC column (4.6  25 mm, 5 µm, Macherey-Nagel, Germany) using a Dionex 
system consisting of a P580 pump, a UV/VIS Detector UVD 170S/340S, an ASI-100 
Automated Sample Injector a thermobox COLUMN OVEN LCO 101 and an In-Line 
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Mobile Phase Degasser Degasys DG-1210 Dionex controlled with Chromeleon™ 6.11 
build 490 software.  
 
Figure 2.4: Schematic of the hydroxylation of testosterone by Cyp3a in the presence of the enzymatic 
cofactors NADPH or NADH.  
 
The chromatographic separation of testosterone metabolites was carried out under the 
following conditions: 75% Methanol (in water) at a flow rate of 0.5 mL/min. 
Metabolites were detected at 254 nm.  
2.6 Microsome in vitro incubations 
2.6.1 Metabolite formation 
2.6.1.1 BaP 
Incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4), NADPH 
or NADH, pooled hepatic microsomal fraction (0.5 mg protein) and 50 µM BaP 
(dissolved in 5 µL dimethyl sulfoxide [DMSO]) in a final volume of 500 µL. Control 
incubations were carried out (i) without microsomes; (ii) without NADPH or NADH; 
(iii) without BaP. Incubations were carried out at 37°C for 20 minutes. After the 






metabolites were extracted twice with ethyl acetate (1 mL), solvent evaporated to 
dryness and stored at ‒20°C. 
HPLC analysis was performed on the dried ethyl acetate extract of BaP metabolites 
(see section 3.3) on a Nucleosil® C18 reverse phase column, (250  4 mm, 5 µm; 
Machery-Nagel, Düren, Germany) using a Dionex system consisting of a P580 pump, 
a UV/VIS Detector UVD 170S/340S, an ASI-100 Automated Sample Injector a 
termobox column oven LCO 101 and an In-Line Mobile Phase Degasser Degasys DG-
1210 Dionex controlled with Chromeleon™ 6.11 build 490 software. The dried 
samples were resuspended in 25 µL of HPLC-grade methanol and an aliquot of 20 µL 
was injected onto the HPLC. The chromatographic separation of BaP metabolites were 
carried out under the following conditions: 50% acetonitrile (aqueous) (v/v), with a 
linear gradient of 0-100% of 85% acetonitrile at a flow rate of 0.6 mL/minute. 
Metabolites were detected by UV absorption at 254 nm and the areas under the curve 
were calculated relative to the peak area of the internal standard phenacetin and 
expressed as relative peak areas. Total metabolite values were calculated by 
combining the values for all peak areas relative to phenacetin for each sample. This 
approach for measuring metabolite formation does not allow accurate quantification 
of metabolites, therefore results are expressed as a relative comparison between the 
different mouse models. BaP metabolite peaks were identified previously through 
collection of fractions that were analysed by NMR and/or mass spectrometry 




Incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4), NADPH 
or NADH (1 mM), 25 µM ellipticine dissolved in 5 µL DMSO and pooled hepatic 
microsomal fraction (0.5 mg/mL protein) in a final volume of 500 µL. Incubations 
were carried out at 37°C for 20 minutes. Control incubations were carried out (i) 
without microsomes; (ii) without NADPH or NADH; (iii) without ellipticine. After 
incubation, 5 µL of 1 mM PA in methanol was added as an internal standard. 
Ellipticine metabolites were extracted twice with ethyl acetate (1 mL), solvent 
evaporated to dryness. 
HPLC analysis was performed on the dried ethyl acetate extract of ellipticine 
metabolites on a Ultrasphere ODS C18 column, (250  4.6 mm, 5 µm preceded by a 
C18 guard column; Beckman) using a Dionex system consisting of a P580 pump, a 
UV/VIS Detector UVD 170S/340S, an ASI-100 automated sample injector a 
termobox column oven LCO 101 and an In-Line Mobile Phase Degasser Degasys DG-
1210 Dionex controlled with Chromeleon™ 6.11 build 490 software. The eluent was 
64% methanol plus 36% of 5 mM heptane sulfonic acid in 32 mM acetic acid in water 
with a flow rate of 0.8 mL/minute and detection was at 296 nm. Three ellipticine 
metabolites with the retention times of 6.3, 6.9 and 7.8 minutes were separated and 
areas under the curve were calculated relative to the peak area of the internal standard 
phenacetin and expressed as relative peak areas. Total metabolite values were 
calculated by combining the values for all peak areas relative to phenacetin for each 
sample. As indicated above, this approach does not allow accurate quantification of 
metabolites, therefore results are expressed as a relative comparison between the 
different mouse models. Ellipticine metabolite peaks were previously identified 
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through collection of fractions that were analysed by NMR and/or mass spectrometry 
(Stiborova et al. 2004). Ellipticine metabolites were identified based on this study.  
2.6.2 DNA adduct formation 
2.6.2.1 BaP 
Incubation mixtures consisted of 50 mM potassium phosphate buffer (pH 7.4). One 
mM NADPH or NADH, pooled hepatic microsomal fraction (0.5 mg protein) from 
HRN, HBRN and WT mice (either untreated or pretreated with BaP), 0.1 mM BaP 
(dissolved in 7.5 µL DMSO) and calf thymus DNA (0.5 mg) in a final volume of 750 
µL. Control incubations were carried out (i) without microsomes; (ii) without NADPH 
or NADH; (iii) without DNA and (iv) without BaP. Incubations were carried out at 
37°C for 90 minutes (Arlt et al., 2008). After the incubation, DNA was isolated by a 
standard phenol-chloroform extraction method as described in section 2.13.1. BaP-
DNA adduct formation was determined by 32P-postlabelling as described in section 
2.14. 
2.6.2.2 Ellipticine 
Incubation mixtures consisted of 100 mM potassium phosphate buffer (pH 7.4). 
NADPH or NADH (10 mM in each case), pooled hepatic microsomal fraction (0.5 
mg/mL protein) from ellipticine-pretreated HRN, HBRN and WT mice, 0.1 mM 
ellipticine dissolved in 7.5 µL methanol and calf thymus DNA (0.5 mg) in a final 
volume of 750 µL. Incubations were carried out at 37°C for 90 minutes (Stiborova et 
al., 2008). Control incubations were carried out (i) without microsomes; (ii) without 
NADPH or NADH; (iii) without DNA and (iv) without ellipticine. After incubation, 
DNA was isolated by a standard phenol-chloroform extraction method. Ellipticine-
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DNA adduct formation was determined by 32P-postlabelling as described in section 
2.14. 
2.7 Cell culture  
2.7.1 Cell lines 
Mouse hepatoma Hepa-1c1c7 and human hepatocarcinoma HepG2 cells were 
originally obtained from the American Type Culture Collection (ATCC). HepG2 POR 
KO cells were obtained from HeraBioLabs, USA. Hepa-1c1c7 cells were cultured in 
75-cm2 flasks (Thermo Scientific) using minimum essential medium (MEM) alpha 
medium (Life technologies) with 10% foetal bovine serum (FBS; Invitrogen) and 1% 
penicillin streptomycin (Life technologies). HepG2 cells were cultured in 75-cm2 
flasks (Thermo Scientific) using MEM (Life Technologies) with 10% FBS 
(Invitrogen), 1% 100 mM sodium pyruvate, 1% 100X non-essential amino acids and 
1% penicillin streptomycin (Life Technologies).The cells were grown in a Heraeus 
HERAcell humidified incubator which was set at 37°C, 5% CO2 and 95% air.  
2.7.2 Maintenance of cell lines 
All cell lines were cultured as adherent mono-layers in flasks with the media regularly 
changed every 2-3 days. When the adherent cells became confluent (~80-90%) they 
were sub-cultured to maintain continuous growth. To sub-culture all cell lines, media 
was removed through aspiration and cells washed with 10 mL of phosphate buffer 
solution (PBS) which was aspirated before 2.5 ml of 0.05% trypsin-
ethylenediaminetetraacetic acid (EDTA, Thermo Fisher) was added. The flask was 
placed into the incubator for 5-10 minutes in order to detach the adherent cells from 
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the plastic surface. To protect cells, the trypsin was neutralised with 7.5 mL of FBS-
containing media and the cell suspension was transferred to a 50-mL conical tube. The 
tube was centrifuged at 1500 rpm for 5 minutes using an Eppendorf centrifuge 5804 
in order to obtain a cell pellet. The supernatant was removed and the cell pellet 
resuspended in 5 mL of media. An appropriate volume of the cell suspension was 
added to a new flask and fresh culture media to reach a total volume of 12 mL.  
2.7.3  Counting cells 
For seeding cells, cells were counted after detachment with trypsin and subsequent 
centrifugation. Cell pellets were resuspended in an appropriate amount of fresh cell 
media. Ten µL of the cell suspension was added to 10 µL of trypan blue stain 0.4% 
(Life technologies) and the cell number was counted using the CountessTM II 
automated cell counter (Life Technologies) to give total, live and dead cells per mL. 
For cell seeding calculations the live count was used.   
2.7.4 Preparation of frozen stocks and resurrection for cell culture 
For the storage of cell lines, cells were harvested using trypsin-EDTA and collected 
by centrifugation as described in section 2.4.2. Excess media was aspirated and cell 
pellets were resuspended in a freezing solution consisting of cell media with 10% (v/v) 
DMSO. Aliquots (1 mL) of the cell suspension were transferred into cryovials and 
frozen for 24 hours at ‒80°C in a Thermo Scientific™ Mr. Frosty™ Freezing 
Container to achieve a slow freezing rate. Slow freezing and the presence of DMSO 
in the freezing solution help to minimise the formation of ice crystals which could 
potentially damage the cells. After initial freezing the cells were transferred to liquid 
nitrogen. For the resuscitation of frozen cells, aliquots (1 mL) stored in liquid nitrogen 
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were thoroughly thawed to 37°C and immediately added to 9 mL of fresh cell culture 
medium. Cells were washed by centrifugation before being inoculated into tissue 
culture flasks. Cells were not used for experimentation for at least one week to ensure 
recovery from the effects of cryopreservation.  
2.7.5 Treatment of cells with carcinogens 
The day prior to carcinogen treatment, cells were seeded into 6 well plates or T75 cm2 
cell culture flasks so as to be sub-confluent on the day of harvest. Hepa-1c1c7 cells 
were seeded at approximately 0.48  105 cells per well for 6 well plates and treated 48 
hours post seeding. HepG2 cells were seeded at approximately 2  105 cells per well 
for 6 well plates and 15  105 cells per 75-cm2 cell culture flask. 
As further described in chapter 5, BaP was diluted in complete growth medium to 
expose Hepa-1c1c7 cells with 0.5 µM BaP (0.1% DMSO final). Cells grown in 
medium containing 0.1% DMSO alone served as control. Cells were incubated with 
BaP for 24 hours under standard conditions (37°C, 5% CO2 and 95% air). 
As further described in chapter 6 BaP was diluted in complete growth medium to 
expose HepG2 cells to 2.5 and 5 µM BaP (0.1% DMSO final). Cells grown in medium 
containing 0.1% DMSO alone served as control. Cells were incubated with BaP for 
24 and 48 hours under standard conditions (37°C, 5% CO2 and 95% air). 
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2.8 Generation of CRISPR/Cas9 POR knockout Hepa-1c1c7 cell line 
2.8.1 Transfection and selection for genetically modified cells 
Hepa-1c1c7 cells were seeded at a density of 1.5  105 cells/well. Twenty four hours 
later they were incubated with 5 µL of transfection reagent (sc-395739; Santa Cruz 
Biotech) and 1 µg of either the cypor KO (sc-422345; Santa Cruz Biotech) or control 
double nickase plasmid (sc-418922; Santa Cruz Biotech) that possessed a scrambled 
guide RNA sequence. The transfection reagent and the plasmid were diluted in 
Plasmid Transfection Medium (sc-108062; Santa Cruz Biotech) for a total 
concentration of 300 µL and the solution was left to incubate for 20 minutes at room 
temperature. The cell medium was aspirated from each of the wells and 3 mL of 
antibiotic-free medium was added. Transfection solution (300 µL) was added to each 
well. To confirm successful transfection, cells expressing GFP were visualised using 
fluorescence microscopy with the Nikon eclipse Te2000-S and the programme NIS 
Elements D23. The exposure was set at 1 second, the gain at 2.00 and the 4 objective 
was used. The images were subsequently analysed using NIS Elements D23 to outline 
and measure the fluorescence of the green areas seen. The background fluorescence 
of each image was subtracted from each identified fluorescent point which were then 
summed. Seventy two hours post incubation, successfully transfected cells were 
selected for using 2.5 µg/mL puromycin (sc-108071; Santa Cruz Biotech) in antibiotic 
free medium.  
2.8.2 Isolation of single cell clones 
In order to ensure that a cell line is generated whereby all cells exhibit a uniform level 
of Por disruption, single cells were isolated following successful transfection. 
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Dilutions of transfected cells potentially consisting of cells not expressing POR were 
prepared at 5 cells/mL in growth medium and seeded onto 96-well plates (200 
µL/well) and the plates were incubated at 37°C, 5% CO2 and 95% air. The medium 
was changed every 5 days and within 2 weeks it was possible to visualise expanding 
populations of single cell clones. Wells that contained none or more than one 
expanding colony were discarded. Wells containing a single expanding colony were 
selected, trypsinised and transferred to 24-well plates. As cells approached 
confluency, they were progressively passaged into larger vessels (24-well to 6-well to 
25-cm2 flask to 75-cm2 flask). Once cells had reached 80-90% confluency in a 75-cm2 
flask, cells were harvested to produce a frozen stock as described in section 2.4.4 with 
the reminder of the culture being seeded and harvested for Western blot analysis to 
confirm the absence of POR protein expression, as described in section 2.8.  
2.9 Crystal violet staining assay 
The crystal violet (CV) staining assay is a method for determining relative cell survival 
of a treated population of cells compared to a control population that is inexpensive 
and rapid (Dooley et al., 1994). Crystal violet (4[(4-dimethylaminophenyl)-phenyl-
methyl]-N,N-dimethyl-aniline) is a dye that stains proteins and DNA. The relative 
density of an adherent cell culture is a function of the amount of crystal violet staining, 
measured as absorbance at 595 nm.  
Cells were seeded onto 6-well plates and treated, as described in section 2.4.5. Twenty 
four or 48 hours post exposure, the cell culture media was removed by aspiration and 
cells were rinsed with PBS and after removal, adherent cells were fixed and stained 
with 1 mL/well of 0.1% (w/v) crystal violet (Sigma #C3886) in 10% ethanol for 10 
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minutes. Cells were washed with PBS to remove excess crystal violet and allowed to 
dry. For quantification, the dye was resolubilised in 5 mL of 50% ethanol per well and 
absorbance at 595 nm was determined using an ELx800 plate reader. Data are 
presented as the amount of absorbance in wells of treated cells relative to that of 
DMSO-treated cells and are representative of at least three independent experiments.   
2.10 Western blot analysis 
Following cell harvesting, 300 µL of lysis buffer [62.5 mM 
tris(hydroxymethyl)aminomethane (Tris, pH 6.8), 1 mM EDTA (pH 8.0), 2% sodium 
dodecyl sulphate (SDS), 10% sterile glycerol with protease and phosphatase inhibitors 
(Thermo Scientific)] was added to each of the samples. The samples were sonicated 
using the Sonic Dismembrator Ultrasonic Processor (Thermo Scientific) at 20% 
amplitude for 10 seconds. The protein concentration of each sample was determined 
using the Pierce Bicinchoninic acid (BCA) protein assay (Thermo Scientific), using a 
ELx800 (BioTek) plate reader. The protein concentration of each sample was 
normalised to obtain equal concentrations of each sample using lysis buffer, β-
mercaptoethanol and bromophenol blue. The samples were heated at 95°C for 10 
minutes to denature proteins. Once the samples cooled to room temperature they could 
then be stored at ‒20°C for further analysis. 
For SDS-polyacrylamide gel electrophoresis (SDS-PAGE) protein separation 
NuPAGETM4-12% Bis-Tris Gels (Invitrogen) were used. As running buffer, a 1X 
solution was made up by diluting the 20X stock solution of 2-(N-morpholino) 
ethanesulfonic acid (MES) (Life Technologies) by adding deionised water. An 
appropriate volume containing 10 µg of protein per sample was loaded into the wells 
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of the gel, and 2 µL of the size marker (PageRulerTM Prestained Protein Ladder, 
Thermo Scientific) was also loaded. The gel was run at 130 V for 1.5 hours. Following 
this, the proteins were transferred from the gel to a nitrocellulose membrane (Bio-Rad) 
using 1X transfer buffer prepared from a 20X NuPAGE stock solution (Invitrogen) 
along with methanol in a 1:2:17 dilution of stock:methanol:water. During the transfer 
the XCell II Blot Module (Invitrogen) was run at 110 V for 1.5 hours. The protein 
transfer was checked by staining the membrane with Ponceau S solution (Sigma). The 
membrane was washed briefly with deionised water and then with 1X TBST made by 
diluting the 10X TBS stock solution (Alpha Diagnostic Intl) with 0.1% Tween 
(Sigma). The membrane was left to blot in 3% dry skimmed milk dissolved in TBST 
for 1 hour on an orbital mixer (Denley, UK). 
The blots were incubated with primary antibodies overnight. These included the 
primary antibody to the housekeeping gene glyceraldehyde phosphate dehydrogenase 
(GAPDH; MAB374 Chemicon) in a 1:2500 dilution in 3% TBST milk to be used as a 
loading control. The antibodies used were all diluted in 3% TBST milk with a dilution 
factor of 1:1000 for anti-POR (ab39995, abcam), 1:1000 for anti-CYP1A1 (sc-20772 
(H-70); Santa Cruz Biotech), 1:500 for anti-Cyb5 (sc-33174 (H-114) Santa Cruz 
Biotech) and 1:1000 for anti-Cyb5R (ABIN453978, Antibodies-online.com). These 
antibodies were separately incubated with the membrane at 4°C overnight, with the 
exception of GAPDH which was incubated at room temperature for 30 min. After 
incubation, the membranes were washed three times with TBST for 5-10 minutes each 
time. The membranes were incubated with the corresponding secondary antibody for 
1 hour. The secondary antibodies used were diluted 1:10,000 with 3% TBST milk and 
included the anti-rabbit horse radish peroxidase (HRP)-conjugated secondary antibody 
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(Cell Signalling Technology), the anti-goat HRP-conjugated antibody (Santa Cruz 
Biotech), the anti-mouse HRP-conjugated antibody (Cell Signalling Technology). 
Subsequent to secondary antibody incubation, the membranes were washed for 10 
minutes three times with TBST. To detect the probed proteins, chemiluminescence 
detection was carried out using the ECLTM Western Blotting reagents (GE Healthcare, 
Amersham) in accordance with the manufacturer’s instructions. Equal volumes of 
Detection Reagents 1 and 2 were mixed and used to cover the membrane for 3-5 
minutes. The membranes were placed in a film cassette, and the films were developed 
in a dark room using a Konica Minolta SRX-101A processor. 
2.11 Detection of metabolites in cell culture 
For the analysis of metabolite formation, culture medium (1 mL) from exposed cells 
were collected and stored at ‒20°C until further processing. Prior to the extraction of 
metabolites, 5 µL of 1 mM phenacetine was added to each of the culture medium 
aliquots and vortexed. Ethyl acetate (900 µL) was then added to each aliquot and 
shaken at 1400 rpm for 2 minutes before being centrifuged for 5 minutes at 13,000 
rpm. The upper ethyl acetate phase was removed and transferred to a new Eppendorf 
tube. Another 900 µL was added to the culture medium and the process repeated, 
pooling the ethyl acetate layers from each extraction and discarding the culture 
medium. The ethyl acetate was then evaporated to dryness using a speedvac evaporator 
and samples stored at ‒20°C. 
For the analysis of BaP metabolites, extracts were resuspended in 30 µL methanol, of 
which 25-µL aliquots were injected on HPLC. HPLC analysis was performed using a 
HPLC Agilent 1100 System (Agilent Technologies) with a SunFire™ C18 reverse 
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phase column (250 × 4.6 mm, 5 µm with a column guard; Waters). The conditions 
used for the chromatographic separation of BaP metabolites were as follows: mobile 
phase A: 100% water, mobile phase B: 100% acetonitrile. The separation started with 
an isocratic elution of 50% of mobile phase B. Then a linear gradient to 98.5% of 
mobile phase B in 34.5 minutes was followed by isocratic elution for 6 min, a linear 
gradient from 98.5% to 1.4% of mobile phase B in 3 minutes, followed by an isocratic 
elution for 1.5 minutes. Total run time was 45 minutes at a flow rate of 1 mL/minute. 
The metabolites were analysed by fluorescence detection (0-6 min excitation 341 nm, 
emission 381 nm and 6-45 minutes excitation 380 nm, emission 431 nm). Areas under 
the curve were calculated relative to the peak area of the internal standard phenacetin 
and expressed as relative peak areas. As outlined above, results are expressed as a 
relative comparison between the different cell models. BaP metabolites were 
identified as described (Stiborova et al., 2014c).  
2.12 Single-cell gel electrophoresis (comet) assay 
The alkaline version of the comet assay was used to detect DNA damage including 
single- and double-strand breaks and alkali-labile (e.g. apurinic) sites (Arlt et al., 2004, 
Dusinska and Collins, 2008). These strand breaks may be induced directly by a 
reactive compound or caused indirectly during the excision step of base/nucleotide 
excision repair or by processes such as reactive oxygen species (ROS) generated 
during metabolism of a compound. 
Cells were seeded in a 6-well plate and exposed as described in section 2.4.5. After 
treatment cells were harvested using trypsin, pelleted and resuspended in PBS. Twenty 
µL of cell suspension was embedded in 180 µl of 0.6% low melting-point agarose (w/v 
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PBS) at 37°C. Thirty µL of the agarose mixture was transferred to a glass slide pre-
coated with 1.5% agarose and allowed to set on a cold plate (4°C). The slides were 
then immersed in lysis buffer (1% Triton 100-X, 2.5 M NaCl, 10 mM Tris and 0.1 M 
EDTA, pH 10.0) and kept at 4°C in the dark for 1 hour. DNA was then unwound by 
immersing the slides in alkaline buffer (0.3 NaOH, 1 mM EDTA, pH 13.0) for 40 
minutes at 4°C before electrophoresis in a tank (27.5  21.5 cm; Scie-Plas, 
Warwickshire, UK) fitted with a cooling unit to maintain the buffer temperature of 
4°C. Electrophoresis was performed at 0.3 A for 20 minutes. Slides were then 
neutralised by immersing in PBS for 5 minutes, washed by immersing in distilled 
water for 5 minutes and fixed by immersion in methanol for 5 minutes before being 
left to dry at room temperature overnight. Nuclei were stained by immersing the slide 
in ethidium bromide for 5 minutes and washing in distilled water for 5 minutes (Figure 
2.5). DNA damage was scored using the Comet IV capture system (version 4.11; 
Perceptive Instruments, UK). At least 50 nuclei were assessed per slide, and tail 
intensity (% tail DNA) was used as the measure of DNA damage induced, as 
recommended (Collins et al., 2008). The average tail intensity of three replicate 




Figure 2.5: Schematic of the single-cell gel electrophoresis (comet) assay.  
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2.13 DNA isolation using phenol-chloroform extraction 
2.13.1 DNA isolation from microsomal incubations 
DNA was extracted from incubation mixtures stepwise with equal volumes (400 µL) 
of phenol (P4557, Sigma), phenol:chloroform:isoamyl alcohol (25:24:1; v/v) (P2069, 
Sigma) and chloroform:isoamyl alcohol (24:1; v/v). DNA was precipitated after 
adding 1/10th volume NaCl (5 M) and 2 volumes of ice-cold ethanol. The DNA was 
fished, pelleted and washed with 300 µL 70% ethanol. DNA was resuspended in 100-
250 µL TE buffer (10 mM, 1 mM, pH 8.0) and dissolved overnight at 4°C. Finally, 
samples were incubated at 37°C for 3 hours before DNA concentration and purity were 
determined spectrophotometrically by measuring UV absorbance at 260, 280 and 230 
nm. DNA was stored at ‒20°C. 
2.13.2 DNA isolation from cells 
Cell pellets were thawed and resuspended in 400 µL of Tris-EDTA (50 mM, 1 mM, 
pH 8.0). Each sample was then mixed with 45 µg RNase A (R4875, Sigma) 225 U 
RNase T1 (R1003, Sigma) and 40 µL 10% SDS in 10 mM EDTA and vortexed and 
incubated at 37°C for 30 minutes. Next, 40 µL proteinase K (10 mg/mL; P6550, 
Sigma) was added, resuming incubation at 37°C overnight. Samples were extracted 
stepwise with equal volumes (400 µL) of phenol, phenol:chloroform:isoamyl alcohol 
(25:24:1; v/v) and chloroform:isoamyl alcohol (24:1; v/v). DNA was precipitated after 
adding 1/10th volume NaCl (5 M) and 2 volumes of ice-cold ethanol. The DNA was 
fished, pelleted and washed with 300 µL 70% ethanol. DNA was resuspended in 100-
250 µL TE buffer (10 mM, 1 mM, pH 8.0) and dissolved overnight at 4°C. Finally, 
samples were incubated at 37°C for 3 hours before DNA concentration and purity were 
72 
 
determined spectrophotometrically by measuring UV absorbance at 260, 280 and 230 
nm. DNA was stored at ‒20°C (Arlt et al., 2001). 
2.13.3 DNA isolation from animal tissue  
Tissue samples (~30 mg) were homogenised in 400 µL of Tris-EDTA buffer (50 mM, 
1 mM, pH 8.0). After the addition of 40 µL proteinase K (10 mg/ml) and 40 µL of 
10% SDS in 10 mM EDTA samples were vortexed and incubated at 37°C overnight. 
Samples were extracted stepwise with equal volumes (400 µl) of phenol, 
phenol:chloroform:isoamyl alcohol (25:24:1; v/v) and chloroform:isoamyl alcohol 
(24:1; v/v). DNA was precipitated after adding 1/10th volume NaCl (5 M) and 2 
volumes of ice-cold ethanol. The DNA was fished, pelleted and washed with 300 µL 
70% ethanol. Pellets were resuspended in 300 µL of Tris-EDTA buffer (50 mM, 1 
mM, pH 8.0) and dissolved overnight at 4°C. Subsequently, samples were incubated 
at 37°C for 2 hours before adding 45 µg RNase A, 225 U RNase T1 and incubating at 
37°C for a further 30 min. Residual proteins were removed at 37°C for 2 hours by 
proteinase K digestion (40 µL; 1 mg/mL) before samples were again extracted with 
phenol, phenol:chloroform:isoamyl alcohol and chloroform:isoamyl alcohol. After 
adding 1/10th volume NaCl (5 M) and 2 volumes of ice-cold ethanol, the DNA was 
fished, pelleted and washed with 300 µL 70% ethanol. DNA was resuspended in 100-
300 µL TE buffer and dissolved overnight at 4°C. Finally, samples were incubated at 
37°C for 3 hours before DNA concentration and purity were determined 
spectrophotometrically by measuring UV absorbance at 260, 280 and 230 nm. DNA 
was stored at ‒20°C.  
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2.14 DNA adduct analysis 
2.14.1 DNA adduct analysis by 32P-postlabelling  
The 32P-postlabelling assay provides an ultrasensitive method for the detection of 
DNA adducts (Phillips and Arlt, 2007).  
2.14.2 DNA digestion 
DNA samples (4 µg) were evaporated to dryness under vacuum in a speedvac 
evaporator and digested with 4 µg micrococcal nuclease (30 mU/µL; N3755, Sigma) 
and calf spleen phosphodiesterase (10 mU/µL; 02100977, MP Biomedical, UK) mixed 
with 0.8 µL digestion buffer (100 mM sodium succinate, 50 mM CaCl2, pH 6.0) and 
incubated overnight at 37°C (Figure 2.6).  
2.14.3 Nuclease P1 digestion enrichment 
Nuclease P1 digestion was used to enrich for adducted deoxyribonucleoside 3’-
monophosphates. This procedure is based on the principle that some bulky adducts, 
such as those formed by BPDE, create a steric hindrance that inhibits nuclease P1 
binding, thereby leaving the 3’-phosphate group intact in the adducted 
deoxyribonucleoside 3’monophosphates, while it is cleaved in normal (unmodified) 
deoxyribonucleoside 3’-monophosphates (Reddy and Randerath, 1986) (Figure 2.6). 
DNA digests (see section 2.12.2) were incubated with 0.96 µL nuclease P1 (1.25 
µg/µL, Sigma #N8639), 1.44 µl zinc chloride (2 mM) and 2.4 µL sodium acetate (0.25 
M, pH 5.0) for 1 hour at 37°C. Reactions were terminated by the addition of 1.92 µL 
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Quantitation by relative adduct labelling
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2.14.4 32P-postlabelling reaction 
In this reaction T4 polynucleotide kinase phosphorylates nucleoside-3’-
monophosphates at the 5’-position with 32P-orthophosphate. Enriched samples (see 
section 2.12.4) were 32P-postlabelled using carrier-free [γ-32P]ATP (50 µCi, ~7000 
Ci/mmol, Hartmann Analytic, Braunschweig, Germany) in a mixture consisting of 1 
µL 10X digestion buffer (200 mM bicine (pH 9.0), 100 mM MgCl2, 100 mM 
dithiothreitol (DTT), 10 mM spermidine) and 0.2 µL T4 polynucleotide kinase (30 
U/µl, USB, Ohio, USA) for 30 minutes at 37°C.   
2.14.5 Thin-layer chromatography 
Resolution of 32P-postlabelled adducted deoxyribonucleoside 3’-monophosphates was 
carried out by multi-directional thin-layer chromatography (TLC) on 10  20 cm 
polyethyleneimine cellulose plates (Macherey-Nagel, Düren, Germany) with a paper 
wick stapled to the top, as previously described (Figure 2.7) (Phillips and Arlt, 2007). 
The solvent compositions for the resolution of BaP- or BPDE-DNA adducts were D1: 
1.0 M sodium phosphate (pH 6.0); D2: 3.5 M lithium formate, 8.5 M urea (pH 3.5); 
D3: 0.8 M lithium chloride, 0.5 M Tris-HCl, 8.5 M urea (pH 8.0). The solvent 
compositions for ellipticine-DNA adducts were D1: 1.0 M sodium phosphate, (pH 
6.8); D2: 3.5 M lithium formate, 8.5 M urea (pH 4.0); D3: 0.8 M Lithium Chloride, 
0.5 M Tris, 8.5 M urea (pH 9.0). 
Each labelling reaction mixture was spotted onto a TLC plate at the origin and placed 
into a glass tank containing 70 mL solvent D1 overnight, with the paper wick hanging 
over the edge of the tank. The following day the paper wicks were removed and TLC 
plates cut at the 10-cm centre line, discarding the top half (containing the excess of 
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unlabelled [γ-32P]ATP). Plates were washed in water and dried. The plates were 
positioned 180° to the direction of D1 and run in 70 ml of solvent D3 for ~1.5 hr (until 
the solvent front reached the top of the plate). Plates were again washed in water and 
dried. Finally, plates were positioned 90° counter clockwise to the direction of D3 and 
run in 70 mL of solvent D4 as done for D3. Plates were then washed in water and dried 
prior to quantitation.  
 
Figure 2.7: Schematic of the multidirectional TLC. Adapted from Phillips et al. 2005.  
 
2.14.6 Quantitation of 32P-postlabelled DNA adducts 
After chromatography, TLC plates were scanned using a Packard Instant Imager 
(Dowers Grove, IL, USA) to image and quantify DNA adduct levels. The imager 










measures β particle emission from adduct spots as counts per minute (cpm). 
Background readings from the TLC plate were subtracted. 
DNA adduct levels (RAL, relative adduct labelling) were calculated from adduct cpm, 
the specific activity of [γ-32P]ATP and the amount of DNA (pmol) used. Results were 




3 Cytochrome b5 impacts on cytochrome P450-mediated 
metabolism of benzo[a]pyrene and its DNA adduct 
formation: studies in Hepatic Cytochrome b5/P450 
Reductase Null (HBRN) mice 
3.1 Introduction 
BaP is a procarcinogen that requires metabolic activation via a P450-dependent 
pathway before reacting with DNA and exerting its genotoxic effects (Figure 3.1) 
(Luch and Baird, 2005, Phillips, 2005). CYP1A1 and CYP1B1 play a major role in 
this pathway, catalysing the initial oxidation of BaP to BaP-7,8-epoxide, which is then 
converted to BaP-7,8-dihydrodiol by epoxide hydrolase (Baird et al., 2005, Luch and 
Baird, 2005). BaP-7,8-dihydrodiol then undergoes further bioactivation by CYP1A1 
and CYP1B1 to form the ultimately reactive species, BaP-7,8-dihydrodiol-9,10-
epoxide (BPDE). BPDE reacts with DNA to form the pre-mutagenic adduct 10-
(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-BaP (dG-N2-BPDE) 
(Arlt et al., 2008, Kucab et al., 2015, Long et al., 2017).  
The HRN mouse model has been used previously to investigate the role of hepatic 
P450 enzymes in the bioactivation of BaP (Arlt et al., 2015a). HRN mice treated with 
BaP formed up to 13-fold higher levels of BaP-DNA adducts than WT mice indicating 
that hepatic P450 enzymes play a more important role in the detoxification of BaP in 
vivo despite their importance for BaP activation in vitro (Arlt et al., 2008). This result 
was investigated further by using immunohistochemistry that showed HRN mice have 
ample capacity for the formation of BaP-DNA adducts (i.e. d-N2-BPDE) in the liver 
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and no differences in BaP-DNA adduct formation was observed between hepatocytes 
(i.e. POR-deficient cells) and non-hepatocytes (i.e. POR-proficient cells) (Arlt et al., 
2012). 
 
Figure 3.1: Pathways of biotransformation and DNA adduct formation of BaP catalysed by CYP1A1 
and mEH. The three-stage pathway, involving mEH, forming the ultimately reactive species BPDE that 
binds to guanine to form the dG-N2-BPDE adduct (adduct 2) is shown on the right. The two-stage 
pathway that does not involve mEH forms the second adduct that is seen in in vitro studies. The diagram 
in the centre shows the roles of POR, Cyb5R and Cyb5 as electron donors to P450 enzymes such as 
CYP1A1 that are central to the biotransformation of BaP.   
 
Although the specific enzyme(s) involved in the generation of BaP-DNA-binding 
species in the liver of HRN mice is not known, it is clear that the process does not 
produce a different reactive species from that formed in WT mice (Arlt et al., 2008, 
Arlt et al., 2012). Although POR is deemed to be the predominant electron donor to 
P450 enzymes (Guengerich, 2008), Cyb5 has also been shown to act as the electron 
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donor both in vitro and in vivo (Finn et al., 2008, Yamazaki et al., 2002), and could be 
contributing to BaP-DNA adduct formation in the livers of HRN mice.  
Previously it was found that HRN mice exhibited a higher protein expression of Cyb5 
than in WT mice after repeated BaP exposure. Similar results were found for mEH, 
another important enzyme involved in the formation of the DNA-reactive intermediate 
BPDE (Arlt et al., 2012). Reconstituted systems utilising CYP1A1, POR, Cyb5, and 
mEH in different ratios were used to investigate the role of Cyb5 in the metabolic 
activation of BaP in vitro. The results showed that even when levels of POR were low, 
CYP1A1, Cyb5, and mEH were able to activate BaP into reactive species that bind to 
DNA (Stiborova et al., 2014c). In addition to this, both the enzymatic cofactors 
NADPH (cofactor for the POR system) and NADH (cofactor for the Cyb5/Cyb5R 
system) stimulated CYP1A1-mediated BaP bioactivation in vitro, suggesting that the 
NADH/Cyb5R/Cyb5 system is able to act as sole electron donor to CYP1A1-catalysed 
BaP bioactivation (Stiborova et al., 2016a, Stiborova et al., 2016b). The findings from 
the reconstituted systems suggest that even low POR expression in the livers of HRN 
mice (probably in non-parenchymal cells), in combination with the induction of 
Cyp1a1, Cyb5 and mEH by BaP, might be sufficient for efficient BaP bioactivation in 
vivo, replacing NADPH-dependent POR in the CYP1A1-catalysed activation of BaP 
(Stiborova et al., 2014c). Given the increased protein expression of Cyb5 in HRN mice 
after repeated BaP exposure (Arlt et al., 2012), it is possible that Cyb5 could 
compensate for the absence of POR in the HRN mice and stimulate P450-mediated 
BaP bioactivation.  
In the present study both the HRN and HBRN mouse models have been used to 
investigate the contribution of Cyb5 to the metabolic activation of BaP both in vitro 
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and in vivo by isolating the hepatic microsomal fractions from WT, HRN and HBRN 
mice and assessing enzyme activity and BaP-metabolite formation. BaP-DNA adduct 
formation was analysed to try and elucidate the role of Cyb5 in the activation of BaP 




3.2 Materials and Methods 
WT, HRN and HBRN mice were treated as described in section 2.2.1 and the hepatic 
microsomal fractions were isolated according to section 2.4. The Western blotting was 
carried out on pooled microsomal fractions according to section 2.10. Similarly, for 
all enzyme activity assays and incubations pooled microsomal fractions were used. It 
was not possible to carry out biological repeats due to tissue limitations impacting on 
the yield of microsomal fractions. Enzyme activities were analysed by determining the 
reduction of cytochrome c (i.e. POR), dealkylation of 7-ethoxyresorufin to resorufin 
(i.e. CYP1A) and the hydroxylation of Sudan I (i.e. CYP1A1), as described in sections 
2.5.1, 2.5.2 and 2.5.3, respectively. Microsomal incubations were used to study the 
formation of BaP metabolites, described in section 2.6.1, and analysed using HPLC as 
described in section 2.6.1.1. DNA adduct formation in vitro was studied using 
microsomal incubations as described in section 2.6.2.1. DNA was isolated using the 
phenol-chloroform method described in section 2.13.1 and analysed using 32P-
postlabelling as described in section 2.14. In vivo DNA adduct formation was studied 
by isolating DNA from tissues as described in 2.13.3 and analysed using the 32P-





3.3.1 Protein expression of XMEs 
Expression of the electron donor proteins POR, Cyb5 and Cyb5R and the P450 
isoenzyme CYP1A1 were probed for in the hepatic microsomal fractions from BaP-
treated and untreated WT, HRN and HBRN mice (Figure 3.2). POR was expressed 
only in the WT microsomal fractions and Cyb5 was expressed only in the WT and 
HRN microsomal fractions, as expected (Henderson et al., 2013, Henderson et al., 
2006). Cyb5R was expressed uniformly in all mouse lines and was not altered by 
treatment with BaP. Treatment with BaP was not also found to alter the levels of POR, 
Cyb5 and Cyb5R expression relative to controls. Cyp1a1 protein, however, was 
greatly induced in all mouse lines by BaP treatment and the extent of Cyp1a1 protein 
induction by BaP was similar in all mouse lines. Whilst a previous study showed 
increased protein expression of Cyb5 in HRN mice after repeated (i.e. 5 days) BaP 
treatment (Arlt et al., 2012) there was no observed induction of Cyb5 in HRN 
microsomal fractions after BaP treatment in this study, probably due to the single 24-
hour administration selected here.  
3.3.2 Enzyme activity of XMEs  
POR activity was detected in the hepatic microsomal fractions from WT mice but not 
in those from HRN or HBRN mice (Figure 3.3a and 3.4a), as expected (Henderson et 
al., 2013, Henderson et al., 2006). POR activity in BaP-treated WT mice was slightly 





Figure 3.2: Western blot analysis of Cyp1a1, POR, Cyb5 and Cyb5R in the pooled microsomal 
fractions of untreated (lanes 1-3) and BaP-treated (lanes 4-6) WT, HRN and HBRN mice. Gapdh protein 
expression was used as a loading control. 
 
Cyp1a (Cyp1a1 and Cyp1a2) activity and Cyp1a1 enzyme activity was measured 
using EROD (Figure 3.3b and 3.4b) and Sudan I oxidation (Figure 3.3c and 3.4c), 
respectively. Cyp1a activity was substantially higher in hepatic microsomes from mice 
treated with BaP than those from untreated mice, regardless of whether NADPH or 











Figure 3.3: Enzyme activity in the pooled hepatic fractions of untreated WT, HRN and HBRN mice 
using either NADPH or NADH as cofactor. (A) POR activity was measured as nmol of cytochrome 
c/mg/min and was detected only in microsomal fractions from WT mice. (B) Cyp1a enzyme activity 
was determined using the EROD assay with activity being observed as pmol of resorufin/mg 
protein/min. (C) Cyp1a1 enzyme activity was determined by the oxidation of Sudan I to hydroxylated 
metabolites with activity being measured as nmol of total C-hydroxylated metabolites/mg protein/min. 
Values are given as mean ± SD (n=3). Repeat determinations were carried out within the same week. 
Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* = 





















































































































































Figure 3.4: Enzyme activity in the pooled hepatic fractions of BaP-treated WT, HRN and HBRN mice 
using either NADPH or NADH as the enzymatic cofactor. (A) Por activity was observed as nmol of 
cytochrome c/mg/min and was only detected in microsomal fractions from WT mice. (B) CYP1A 
activity was determined using the EROD assay with activity being observed as pmol of resorufin/mg 
protein/min. (C) CYP1A1 activity was determined by the oxidation of Sudan I to hydroxylated 
metabolites with activity being observed as nmol of total C-hydroxylated metabolites/mg protein/min. 
Values are given as ± SD (n=3). Repeat determinations were carried out within the same week. 
Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* = 
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When NADPH was used in the reaction mixture, hepatic microsomes from BaP-
treated WT mice exhibited the highest levels of Cyp1a activity (Figure 3.4b and 3.4c). 
Cyp1a activity was substantially  lower in the hepatic microsomes from BaP-treated 
HRN mice, correlating with the lack of POR activity in these mice. Cyp1a activity in 
hepatic microsomes from BaP-treated HBRN mice was significantly lower compared 
to both BaP-treated WT and HRN mice and showed the lowest level of Cyp1a activity 
when NADPH was used in the reaction mixture. In the hepatic microsomal fractions 
from untreated mice Cyp1a activity was also lower in HRN and HBRN mice than in 
WT mice, but the effect was less pronounced compared with mice treated with BaP 
(Figure 3.3b and 3.3c).  
When EROD was used as a measure of Cyp1a activity and NADH was used in the 
reaction mixture, hepatic microsomes from BaP-treated HRN mice showed 
significantly higher Cyp1a activity than the hepatic microsomal fractions from BaP-
treated WT and HBRN mice (Figure 3.4b). Hepatic microsomes from BaP-treated 
HBRN mice exhibited the lowest level of Cyp1a activity in the presence of NADH. 
When Sudan I oxidation was used as a measure for Cyp1a1 activity, BaP-treated WT 
and HBRN mice showed a similar level of Cyp1a1 activity (Figure 3.4c).  
In untreated WT, HRN and HBRN mice Cyp1a activity was lower in the absence of 
the electron donors when NADPH was used in the reaction mixture, with activity 
highest in WT mice and lowest in HBRN mice. When NADH was used in the reaction 
mixtures, however, Cyp1a activity was highest in the hepatic microsomal fractions 
from HRN mice and lowest in those from WT mice. Cyp1a1 activity measured by 
Sudan I oxidation, however, was lowest in the HBRN mice (Figure 3.3b and 3.3c). 
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3.3.3 Analysis of BaP metabolites by HPLC  
Hepatic microsomes isolated from WT, HRN and HBRN mice were incubated with 
BaP and either NADPH or NADH before being analysed by HPLC to determine the 
BaP metabolite profile. The highest level of total metabolite formation in vitro was 
observed in the hepatic microsomal fraction from BaP-pretreated WT mice when 
NADPH was used as cofactor (Figure 3.5a). Total metabolite formation in 
microsomal fractions from WT mice was around 3-fold lower than when NADH was 
used. Levels of total metabolite formation in microsomal fractions from untreated 
mice were lower but followed the same pattern (Figure 3.5b). 
 
Figure 3.5: Total formation of BaP metabolites during in vitro incubations with hepatic microsomal 
fractions from (A) BaP-pretreated WT HRN and HBRN mice using either NADPH or NADH as 
cofactor and from (B) untreated WT HRN and HBRN mice using either NADPH or NADH as cofactor. 
Values are given as mean ± SD (n=3). Repeat incubations were carried out and analysed within the 
same week. Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison 



























































































































































































Figure 3.6: Structures of BaP metabolites detected from in vitro incubations of BaP with hepatic 
microsomal fractions. 
 
Hydroxylated BaP metabolites and BaP-dihydrodiols, as well as BaP-diones, were 
identified (Figure 3.6). A metabolite, Mx, whose structure has yet to be elucidated, 
was detected also. Residual BaP and/or BaP metabolites were not detected in hepatic 
microsomes isolated from BaP-treated mice. No BaP metabolites were detected by 
HPLC in control incubations without microsomes, without NADPH/NADH-
generating system or without BaP (Figure 3.7c and 3.7d). Representative HPLC 
chromatograms showing the BaP metabolite profiles are shown in Figure 3.7a and 
3.7b.  
When incubations were carried out using hepatic microsomal fractions from untreated 
mice the overall formation of BaP metabolites was highest in WT mice when NADPH 
was used in the reaction mixture, whereas when NADH was used the highest 
formation of metabolites was seen in HRN mice (Figure 3.5b and 3.8). Although the 
BaP-9,10-dihydrodiol (M1) BaP-4,5-dihydrodiol (M2) BaP-7,8-dihydrodiol (M3)
BaP-1,6-dione (M4) BaP-3,6-dione (M5)
9-hydroxy-BaP (M6) 3-hydroxy-BaP (M7)
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amount of metabolites detected was lower, this pattern is similar to that observed in 
microsomes from BaP-pretreated mice, again correlating with Cyp1a activity 
 
 
Figure 3.7: Representative HPLC chromatograms from in vitro incubations with hepatic microsomal 
fractions from BaP-pretreated WT mice with BaP and either NADPH or NADH as cofactor. BaP-9,10-
dihydrodiol (M1), BaP-4,5-dihydrodiol (M2), BaP-7,8-dihydrodiol (M3), 1,6-BaP-dione (M4), 3,6-
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Figure 3.8: Formation of BaP metabolites from in vitro incubations with hepatic microsomal fractions from BaP-untreated WT, HRN and HBRN mice with BaP and 
either NADPH or NADH as cofactor. Values are given as mean ± SD (n=3). Repeat incubations were carried out and analysed within the same week. Statistical 
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Figure 3.9: Formation of BaP metabolites from in vitro incubations with hepatic microsomal fractions from BaP-pretreated WT, HRN and HBRN mice with BaP 
and either NADPH or NADH as cofactor. Values are given as mean ± SD (n=3). Repeat incubations were carried out and analysed within the same week. Statistical 
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The two major metabolites formed in all incubations with microsomal fractions from 
BaP pre-treated mice were 3-hydroxy-BaP and BaP-7,8-dihydrodiol (Figure 3.9). 
With NADPH as the cofactor, the overall formation of BaP metabolites was 
significantly lower in hepatic microsomal fractions from BaP-pretreated HRN mice 
with formation of BaP-3,6-dione, 9-hydroxy-BaP, 3-hydroxy-BaP and the 
unidentified metabolite Mx being significantly lower than with BaP-pretreated WT 
mice (Figure 3. 9). 
Except for BaP-9,10-dihydrodiol, all metabolites were detected at significantly lower 
amounts compared with hepatic microsomes from BaP-pretreated WT mice. 
Formation of the metabolites BaP-9,10-dihydrodiol, BaP-4,5-dihydrodiol, BaP-7,8-
dihydrodiol and 3-hydroxy-BaP were at lower levels than with BaP-pretreated HRN 
hepatic microsomes (Figure 3.9).  
When NADH was used as the enzymatic cofactor the overall formation of BaP 
metabolites in hepatic microsomal fractions from BaP-pretreated HRN mice was  
higher than with microsomal fractions from BaP-pretreated WT mice with all 
metabolites being formed in higher quantities. Overall metabolite formation in hepatic 
fractions from BaP-pretreated WT and HBRN mice was not significantly different 
with only BaP-9,10-dihydrodiol being significantly lower (Figure 3.5 and 3.9). All 
metabolites except for BaP-1,6-dione and Mx were significantly lower compared with 
BaP-pretreated HRN hepatic microsomes (Figure 3.9). The rate of BaP metabolite 
formation in the hepatic microsomal fractions correlated with the levels of Cyp1a 
enzymatic activity and the enzymatic cofactor used (NADPH or NADH). 
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3.3.4 BaP-DNA adduct formation in vitro 
The ability of hepatic microsomes isolated from control and BaP-treated WT, HRN 
and HBRN mice to catalyse BaP-DNA adduct formation in vitro was investigated 
(Figure 3.10).  
 
Figure 3.10: Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE (adduct 1) and adduct 2 from 
in vitro incubations with DNA, BaP and hepatic microsomal fractions from BaP-pretreated or untreated 
WT, HRN and HBRN mice using either NADPH (A) or NADH (B) as cofactor. Duplicate incubations 
were carried out within the same week and DNA stored at ‒20°C until analysis. Values are given as 
mean ± SD (n=4); DNA from two separate incubations were measured in duplicate in separate 32P-
postlabelling analyses. Statistical analysis was performed by one-way Anova with Tukey’s multiple 
comparison test (* = compared to WT; # = compared to HRN. * P ≤ 0.05 *** P ≤ 0.001).  
 
The BaP-DNA adduct pattern obtained by 32P-postlabelling analysis from in vitro 
microsomal incubations consisted of up to two major adduct spots (Figure 3.11). One 
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2008). The other spot (assigned adduct 2), has not yet been fully structurally identified 
and is likely derived from the reaction of 9-hydroxy-BaP-4,5-epoxide with guanine 
residues in DNA (Schoket et al., 1989; Nesnow et al., 1993; Fang et al., 2003). These 
two adducts are the results of the biotransformation pathways illustrated in Figure 3.1. 
Essentially no BaP-DNA adducts were formed in control incubations with microsomes 
of BaP-pretreated WT mice without BaP, but were detectable in control incubations 
with microsomes of BaP-pretreated HRN and HRBN mice. These findings indicate 
that some BaP that was not detectable by HPLC is retained in hepatic microsomes of 
BaP-pretreated HRN and HRBN mice, and is activated to form BaP-DNA adducts.  
 
Figure 3.11: Autoradiograms showing adduct profiles by TLC 32P-postlabelling analysis from in vitro 
incubations with hepatic microsomal fractions from BaP-pretreated WT, HRN and HBRN mice, DNA 
and BaP. The origin on the TLC plate, at the bottom left-hand corners, was cut off before exposure.  
 
During in vitro incubations with WT microsomal fractions from BaP-pretreated mice 
and with NADPH as the enzymatic cofactor, adduct 2 was the predominant DNA 
adduct formed. Formation of dG-N2-BPDE (adduct 1) was much lower (Figure 
3.10a). This was not observed with hepatic microsomal fractions from BaP-pretreated 
96 
 
HRN and HBRN mice, where formation of the dG-N2-BPDE adduct was greater than 
adduct 2 when NADPH was used in the reaction mix (Figure 3.10b). When NADH 
was used as the enzymatic cofactor adduct 2 was not detected. When NADPH was 
used the greatest BaP-DNA adduct formation was seen with microsomal fractions 
from BaP-pretreated WT mice.  
Levels of adduct 1 (dG-N2-BPDE) in vitro strongly correlated with the amounts of 
BaP-7,8-dihydrodiol formed in hepatic microsomal fractions from BaP-pretreated 
mice, both with NADPH and NADH as cofactor. When NADPH was used as cofactor, 
the formation of BaP-7,8-dihydrodiol was lower in HRN microsomal fractions and 
lowest in HBRN microsomal fractions relative to WT, correlating with dG-N2-BPDE 
(adduct 1) formation in these microsomal fractions. The highest levels of BaP-7,8-
dihydrodiol were observed in HRN microsomal fractions with NADH as cofactor, 
with similar amounts being formed in WT and HBRN hepatic microsomal fractions.  
When NADPH was used as cofactor the amounts of 9-hydroxy-BaP correlated with 
the levels of adduct 2 in hepatic microsomal fractions from BaP-pretreated mice. The 
levels of 9-hydroxy-BaP detected were also the highest in HRN microsomal fractions 
when NADH was used as cofactor. As adduct 2 was not detectable in microsomal 
fractions of either HRN or HBRN BaP-pretreated mice there was no correlation found 
to the amount of 9-hydroxy-BaP formed. Because DNA adduct formation was low in 





3.3.5 BaP-DNA adduct formation in vivo 
The BaP-DNA adduct pattern obtained from in vivo treatments consisted of one major 
adduct spot in all tissues, dG-N2-BPDE (assigned spot 1), as well as minor adduct 
spots 2 and 3 in some extrahepatic tissues. Adduct spot 2 was the same as that 
identified in the in vitro incubations (Figure 3.11); however adduct 3 has not been 
structurally identified and it was detected only in colon and small intestine (Figure 
3.12). No DNA adducts were detected in tissues of untreated mice (data not shown).  
 
Figure 3.12: Autoradiograms showing adduct profiles by TLC 32P-postlabelling in organs of WT, HRN 
and HBRN mice treated i.p with 125 mg/kg bw BaP for 24 h. The origin on the TLC plate, at the bottom 
left-hand corners, was cut off before exposure.  
 
Of the organs tested (liver, lung, small intestine, kidney, spleen, colon, forestomach, 
glandular stomach and bladder) no significant difference was exhibited between the 
mouse models with the exception of the small intestine and the liver (Figure 3.13). In 
the small intestines there were significantly higher levels of BaP-DNA adducts in 
HBRN mice than in WT mice. BaP-DNA adduct formation in the livers of HRN mice 
was ~7-fold higher than in WT mice. BaP-DNA adduct formation in HBRN mice was 
significantly lower than that observed in HRN mice, although no significant difference 
between WT and HBRN mice was found. This supports the results demonstrated in 
previous studies with BaP-treated HRN mice (Arlt et al., 2012, Arlt et al., 2008). BaP-
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DNA adduct formation in the livers of BaP-treated WT, HRN and HBRN mice in vivo 
strongly correlated with the formation of BaP-7,8-dihydrodiol and dG-N2-BPDE in 
hepatic microsomal fractions of BaP-pretreated mice. Collectively, these results 
support the notion that the Cypb5/Cyb5R systems strongly contributes to BaP-DNA 
adduct formation in HRN mice. 
 
Figure 3.13: Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE adducts in organs of WT, 
HRN and HBRN mice treated i.p with 125 mg/kg bw BaP for 24 h. Values are given as ± SD (n=3); 
each DNA sample isolated from tissue of individual animals was analysed once. Statistical analysis was 
performed by one-way anova with Tukey’s multiple comparison test (* = compared to WT; # = 
compared to HRN. * P ≤ 0.05 *** P ≤ 0.001**** P ≤ 0.0001).  




























































































































































































































































































































































The in vitro experiments using pooled hepatic microsomal fractions clearly 
demonstrated that Cyb5 contributes to the bioactivation of BaP. The formation of BaP-
DNA adducts and BaP metabolites correlated with Cyp1a enzyme activity, and were 
lessened by the loss of electron donors when NADPH was used as cofactor to examine 
the POR-dependent pathway. When the NADH-dependent Cyb5R pathway was 
investigated, Cyp1a enzyme activity was higher in the hepatic microsomal fractions 
of HRN mice than in those of WT mice. In the microsomal fractions from HBRN mice 
the activity was significantly lower relative to WT mice, indicating that the increased 
expression of Cyb5 is contributing to increased NADH-dependent activity. These 
results correlate with those from experiments with reconstituted enzyme systems 
(Stiborova et al., 2016a, Stiborova et al., 2014c) supporting the hypothesis that Cyb5 
is contributing to the bioactivation of BaP in the livers of HRN mice in the absence of 
POR.  
The in vivo results, however, contrast with the observations from the in vitro 
experiments when NADPH was used as cofactor. Whereas bioactivation of BaP was 
reduced with the loss of electron donors and P450 activity in vitro, in vivo the results 
were different. HRN mice displayed a 7-fold increase in hepatic DNA adduct 
formation compared with WT mice, reflecting findings seen in previous studies (Arlt 
et al., 2012, Arlt et al., 2008). DNA adduct formation in the livers of HBRN mice was 
significantly lower than in HRN mice, further suggesting a role for Cyb5 in BaP-DNA 
adduct formation in HRN mice. When NADH was used as cofactor, bioactivation of 
BaP in vitro (i.e. BPDE-DNA adduct formation) correlated with P450 activity and the 
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formation of BaP-7,8-dihydrodiol (precursor of BPDE) in hepatic microsomal 
fractions. Levels of BPDE-DNA adduct formation in vitro was highest in the hepatic 
microsomal fraction from BaP-pretreated HRN mice and correlated with hepatic 
BPDE-DNA adduct formation in vivo, i.e. highest levels of dG-N2-BPDE were seen 
in the livers of BaP-treated HRN mice. These results again support the conclusion that 
the Cyb5/Cyb5R system strongly contributes to BPDE-DNA adduct formation in the 
livers of HRN mice. The level of DNA adducts in the livers of HBRN mice, however, 
was not significantly different from that observed in the livers of WT mice, which was 
unexpected.  
Both the HRN and HBRN mice display no overt changes in phenotype, except for 
steatotic livers as a consequence of the loss of P450-housekeeping activity involved 
in cholesterol metabolism (Henderson et al., 2003). Potentially the high dose of BaP 
combined with the steatotic livers could mean that some BaP is retained in the livers 
being released and metabolised over a longer period when normally detoxication 
mechanisms would have allowed any remaining BaP to be excreted. Treatment of mice 
with doses of 125 mg/kg bw BaP has been shown to be carcinogenic when 
administered daily for 5 days (Hakura et al., 1998) and is why this dose was used in 
the present study. A 10-fold lower dose of BaP has also been shown to result in 
increased BaP-DNA adduct formation in the livers of HRN mice relative to WT mice 
(Arlt et al., 2012). Similar models with liver-specific deletion of POR (liver-Por-null 
mouse models) have been developed (Wu et al., 2003). Administration of 40 mg/kg 
bw to liver-Por-null mice did not result in a significant change in liver retention of 
BaP relative to WT mice (Wang et al., 2017). Furthermore, there was no significant 
difference in the clearance of BaP in HRN mice compared to WT mice (Arlt et al., 
2008). Clearance of BaP in HBRN mice has not been investigated in this study.  
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The increased formation of hepatic BaP-DNA adducts in the HRN mice indicates that, 
in accordance with other studies (Uno et al., 2001, Uno et al., 2004, Uno et al., 2006, 
Shi et al., 2010), P450 activity in hepatocytes in vivo is more important for BaP 
detoxication than bioactivation. Evidence for this hypothesis came from a study of 
BaP bioactivation in Cyp1a1(‒/‒) mice. Treatment of these mice i.p. with BaP (500 
mg/kg bw) resulted in a 4-fold increase in hepatic DNA adduct formation relative to 
WT mice (Uno et al., 2001). Some WT and Cyp1a1(‒/‒) in the study were pre-treated 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in order to assess whether any other 
dioxin-inducible enzymes were able to contribute to BaP activation. These TCDD-
pre-treated mice had decreased levels of BaP-DNA adducts and enhanced clearance 
of BaP from the blood, indicating that the accumulation of BaP-DNA adducts in 
Cyp1a1(‒/‒) mice could be due to the lack of Cyp1a1-mediated detoxication (Uno et 
al., 2001). Further studies with Cyp1a1(‒/‒), Cyp1a2(‒/‒) and Cyp1b1(‒/‒) single-
knockout, Cyp1a1/1b1(‒/‒) and Cyp1a2/1b1(‒/‒) double-knockout mice suggested 
that Cyp1b1 was responsible for the activation of BaP whilst Cyp1a1 was responsible 
for detoxication (Nebert et al., 2013). Although these studies provide a rationale for 
the increased BaP-DNA adduct levels in the livers of HRN relative to WT mice, they 
do not explain the formation of BaP-DNA adducts in the livers of HRBN mice. These 
findings may suggest that a P450-independent mechanism contributes to the activation 
of BaP in HBRN mice. It is noteworthy that DNA adduct formation of the dietary 
carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was similar in 
the livers of Reductase Conditional Null (RCN) and WT mice (Arlt et al., 2011) 
whereas RCN mice treated with BaP formed 5.6-fold higher liver DNA adduct levels 
than WT mice (Arlt et al., 2012). Like HRN mice, RCN mice have a liver-specific 
deletion of POR and thus show the same phenotype (Arlt et al., 2015a). Although PhIP 
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bioactivation is considered to be catalysed by CYP1A2, the results in the RCN model 
suggested that PhIP may be activated mainly by a non-P450 pathway in the livers or 
extrahepatic P450s of RCN mice (Arlt et al., 2011).  
Previous investigations showed that there was no difference in Ptgs1 and Ptgs2 
expression between HRN and WT mice when exposed to BaP (Arlt et al., 2008). 
Hepatic Ptgs2 expression was also compared between Cyp1a1(‒/‒) and Cyp1a1(+/+) 
mice treated with BaP and no differences were found (Uno et al., 2004). Nevertheless, 
it may be possible that basal expression of Ptgs/Cox in the livers of HRN and HBRN 
contributes to the bioactivation of BaP-7,8-dihydrodiol to BPDE, with oxidation of 
BaP to BaP-7,8-dihydrodiol still needing to be catalysed by a non-P450/non-Ptgs/Cox 
pathway. AKRs have also been implicated in the formation of BaP-DNA adducts, 
competing with P450 enzymes to activate dihydrodiols. The products of AKR-
catalysed reactions are o-quinones that produce BaP-7,8-dione-DNA adducts (Jiang et 
al., 2005, Jiang et al., 2006, Huang et al., 2013) distinctly different from those detected 
in this study. The analysis of BaP-7,8-dione-DNA adducts was beyond the scope of 
the present study. As indicated above AKRs metabolise dihydrodiols, but not BaP 
itself, which further questions their involvement in the processes observed in the 
current study.  
Wang and colleagues (Wang et al., 2017) have proposed that, besides Ptgs/Cox and 
Akr, 5-lipoxygenase contribute to the hepatic bioactivation of BaP in liver-Por-null 
mice. These conclusions were based on in vitro experiments measuring BPDE-DNA 
adduct formation (i.e. detection of BaP-tetrols by LC-MS/MS analysis after DNA 
hydrolysis) using S9 fractions isolated from WT and liver-Por-null mice and using 
inhibitors of these enzymes. Although useful, mimicking in vivo phenotypes with 
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inhibition profiles in vitro is not straightforward. Firstly, inhibitors are usually not 
wholly specific. Secondly, as seen again in this study using hepatic microsomes, 
extrapolating in vitro data to in vivo results is often not straightforward. However, it 
may be appropriate to test some inhibitors of other oxidoreductases (e.g. Ptgs/Cox or 
Akr) in BaP-treated HBRN mice in vivo and determine the subsequent BPDE-DNA 
adduct formation in the livers of these animals.  
Conversely, the results of this study in BaP-treated HBRN mice may suggest a role 
for systemic transport of reactive BaP intermediates (e.g. BPDE) to the liver. Besides 
the liver, other organs (e.g. lung) have been shown to mediate CYP-catalysed 
bioactivation of BaP (Arlt et al., 2015b). Other studies in mice have demonstrated that 
blood components (i.e. serum) can facilitate the systemic transport of BPDE (Ginsberg 
and Atherholt, 1989). Thus the livers of BaP-treated HBRN mice, which are 
considered largely deficient in CYP-mediated BaP activation, may still receive 
substantial quantities of DNA-reactive BaP intermediates (i.e. BPDE) or the proximate 
carcinogen (i.e. BaP-7,8-dihydrodiol) that originate from their CYP-mediated 
formation in extra-hepatic tissues. It is noteworthy that reactive BaP metabolites have 
been shown to be transferred from an activator cell to another target cell (Sebti et al., 
1982), again illustrating efficient transfer of BPDE despite its reactivity. Other studies 
have shown that hepatocytes and non-parenchymal liver cells have capacity to catalyse 
BaP-derived DNA adduct formation (Horton et al., 1985). Thus, it is possible that BaP 
bioactivation in CYP-expressing non-parenchymal liver cells may contribute to BaP-
DNA adduct formation the livers of HBRN mice. To investigate this would require 
isolation and culture of hepatocytes and non-parenchymal liver cells from HBRN mice 
and exposure of these cells to BaP for subsequent BaP-DNA adduct analysis.    
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In summary, this study has shown that both Por and Cyb5 contribute to the 
bioactivation of BaP in vitro and that Cyb5 also plays an important role in vivo for 
BaP activation in the HRN mice. The presence of BPDE-DNA adducts in the livers of 
HBRN mice, however, raises the fundamental question of how BaP is being 
metabolically activated in the livers of HBRN mice despite the absence of both 
electron donors. It is clear that HBRN mice possess ample capacity to form hepatic 
BaP-DNA adducts that arise from BPDE, the same process that occurs in WT mice. 
The results from this study continue to question the role of P450 enzymes in the 
bioactivation and detoxication of BaP, as well as to suggest the potential for a P450-
independent BaP activation mechanism which will require further investigation. 
Alternatively, our results may also suggest the systemic circulation of DNA-reactive 
BaP intermediate (i.e. BPDE) which originate from P450-mediated activation in extra-
hepatic tissues contributing to the detection of BaP-DNA adducts in the livers of 
HBRN mice. Likewise, non-parenchymal liver cells may play a role in catalysing 




4 Application of hepatic cytochrome b5/P450 reductase null 
(HBRN) mice to study the role of cytochrome b5 in the 
cytochrome P450-mediated bioactivation of the 
anticancer drug ellipticine  
4.1 Introduction 
Ellipticine (5,11-dimethyl-6H-pyrido[4,5-b]carbazole) is a cytotoxic alkaloid isolated 
from the Apocynaceae family of plants. Both ellipticine and its derivatives possess 
anti-HIV and anti-tumour properties allowing it to be used against several cancers with 
limited toxic side effects and no haematological toxicity by functioning through 
multiple mechanisms that result in cell cycle arrest and initiation of apoptosis 
(Martinkova et al., 2010, Stiborova et al., 2011, Miller and McCarthy, 2012, Stiborova 
and Frei, 2014). The main mechanisms by which ellipticine exerts its anti-tumour, 
cytotoxic and mutagenic effects are inhibition of topoisomerase II, intercalation into 
DNA and enzyme-mediated formation of covalent ellipticine-derived DNA adducts 
(Garbett and Graves, 2004, Stiborova and Frei, 2014, Banerjee et al., 2015, Vann et 
al., 2016). Although ellipticine was initially found to be a promising anticancer drug 
there were a number of problematic toxic side effects. It has, however, proved to be 
amenable to systematic structural modification to produce a number of analogues with 
lower toxicities and improved anticancer activities (Garbett and Graves, 2004). 
Activation of ellipticine is catalysed by cytochrome P450 (CYP) enzymes and 
peroxidases, which generate reactive intermediates capable of damaging DNA by 
forming covalent adducts (Stiborova et al., 2008, Stiborová et al., 2001, Stiborova et 
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al., 2003a, Stiborova et al., 2012b, Stiborová et al., 2012, Stiborova et al., 2007, 
Stiborová et al., 2007, Stiborova et al., 2003b). As shown in Figure 1.7 (see 
Introduction), ellipticine is oxidised by cytochrome P450 enzymes to form five 
metabolites, including the reactive metabolites 12-hydroxy- and 13-hydroxy-
ellipticine which dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind 
to DNA (Aimová et al., 2008, Stiborova et al., 2015, Stiborova et al., 2014a, Stiborova 
and Frei, 2014, Stiborova et al., 2004). The N2-oxide is also considered an active 
ellipticine metabolite as it converts to 12-hydroxy-ellipticine by the Polonowski 
rearrangement (Stiborova et al., 2004, Kotrbova et al., 2006). 7-Hydroxy- and 9-
hydroxy-ellipticine are considered detoxication metabolites due to their efficient 
excretion shown in experimental animals (Stiborova et al., 2012a, Stiborová et al., 
2012).. Although ellipticine is not currently in use as an anticancer drug, it holds value 
as a compound for studying P450-mediated activation. Understanding the role of 
cytochrome P450 enzymes in ellipticine metabolism is important both 
pharmacologically and toxicologically and may help in the development of clinically 
useful ellipticine analogues.  
Previous studies using reconstituted systems investigated the role of Cyb5 in the 
metabolic activation of ellipticine in vitro showed that the presence of Cyb5 resulted 
in a considerable increase in the activation metabolites 12-hydroxy- and 13-
hydroxyellipticine (Kotrbova et al., 2011, Stiborova et al., 2012a, Stiborová et al., 
2012, Stiborová et al., 2017). The formation of ellipticine-DNA adducts was also 
shown to increase ~6-fold in the case of CYP1A1, ~4-fold for CYP1A2 and ~3-fold 
for CYP3A4 (Stiborova et al., 2012a, Kotrbova et al., 2011). These findings were 
supported by studies using human recombinant cytochrome P450s in Supersomes™ 
with CYP3A4 and 1A1 being the most efficient at forming ellipticine-DNA adduct 1 
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and with adduct 2 being formed by CYP2C19, 2C9 and 2D6  in the presence of Cyb5 
(Stiborová et al., 2012). Rats exposed to ellipticine have also shown a significant 
increase in the expression of both Cyb5 mRNA and protein, and hepatic microsomes 
isolated from these rats catalysed ellipticine oxidation more efficiently (Stiborova et 
al., 2016c). Together these studies provide evidence for the role of Cyb5 in the 
bioactivation of ellipticine both in vitro and in vivo.  
In the present study we have used both the HRN and HBRN mouse lines to investigate 
the contribution of Cyb5 to the metabolic activation of ellipticine to form DNA 
adducts in vivo alongside microsomal incubations to investigate metabolite and DNA 
adduct formation in vitro. Hepatic microsomal cytochrome P450 enzyme activity and 
protein expression have also been assessed.      
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4.2 Materials and methods 
WT, HRN and HBRN mice were treated as described in section 2.2.2 and the hepatic 
microsomal fractions were isolated according to section 2.4. Western blotting was 
carried out on pooled microsomal fractions according to section 2.10. Similarly, for 
all enzyme activity assays and incubations pooled microsomal fractions were used. It 
was not possible to carry out biological repeats due to tissue limitations impacting on 
the yield of microsomal fractions. Genotyping of the untreated mice was carried out 
according to section 2.3. Enzyme activities were analysed by determining the 
reduction of cytochrome c (i.e. POR), dealkylation of 7-ethoxyresorufin/7-
methoxyresorufin to resorufin (i.e. CYP1A/1A2), testosterone hydroxylation (i.e. 
CYP3A), and the hydroxylation of Sudan I (i.e. CYP1A1), respectively and are all 
described in sections 2.5.1, 2.5.2, 2.5.3 and 2.5.4. Microsomal incubations were used 
to study the formation of ellipticine metabolites, described in section 2.6.1, and 
analysed using HPLC as described in section 2.6.1.2. DNA adduct formation in vitro 
was studied using microsomal incubations as described in section 2.6.2 with DNA 
being isolated using the phenol-chloroform method described in section 2.13.1.  In 
vivo DNA adduct formation was studied by isolating DNA from tissues as described 
in 2.13.3. DNA adduct formation was analysed using the 32P-postlabelling method as 





4.3.1 Protein expression of XMEs 
Expression of electron donor proteins (i.e. POR, Cyb5, Cyb5R) associated with the 
mixed-function oxidase system (i.e. cytochrome P450) were probed for in the hepatic 
microsomal fractions from WT, HRN and HBRN mice exposed to ellipticine (Figure 
4.1). In the mice exposed to ellipticine POR was expressed in the WT mice only and 
Cyb5 was expressed only in WT and HRN mice, as expected (Henderson et al., 2013, 
Reed et al., 2018b). In the untreated mice however, POR was unexpectedly detected 
in the pooled microsomal fractions of both HRN and HBRN mice. A faint band of 
Cyb5 was also detectable in the microsomal fraction from the untreated HBRN mice. 
These findings indicate that, in untreated HRN and HBRN mice used as controls, 
complete deletion of POR and Cyb5 was not achieved. In order to investigate these 
findings further the genotype of the control animals was re-analysed (see section 4.3.2) 
as shown in Figure 4.2. Cyb5R was expressed uniformly across all mouse lines. 
Cyp1a1 expression was greater in HRN and HBRN hepatic microsomal fractions after 
ellipticine treatment compared to WT. Cyp1a1 protein was not detected in the 
untreated microsomal fractions across all mouse lines. Cyp3a protein was 
constitutively expressed across all mouse lines but expression was increased in both 




Figure 4.1: Western blot analysis of Cyp1a1, Cyp3a, POR, Cyb5 and Cyb5R in the pooled microsomal 
fractions of untreated (lanes 1-3) and ellipticine-treated (lanes 4-6) WT, HRN and HBRN mice. Gapdh 
protein expression was used as a loading control. Representative images of the Western blotting are 
shown, and at least duplicate analysis was performed in separate experiments. 
 
4.3.2 Genotyping of WT, HRN and HBRN mice 
Due to the unexpected detection of POR protein in the pooled hepatic microsomal 
fractions isolated from HRN and HBRN mice during Western blot analysis (Figure 
4.1), genotyping was carried out on the livers of the individual untreated mice. The 
Por, Cyb5 and Cre genes were investigated (Figure 4.2). Although both Por and Cyb5 
appeared to be excised, a very faint Cre band was detected in one of the untreated 
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HRN and one of the untreated HBRN mice (see Figure 4.2). Mus musculus adult male 
thymus sequence was used as control. One potential explanation as to why some POR 
expression and activity was detectable in the hepatic microsomal fractions could be 
due to Cre mosaicism, which can arise in one of at least two ways. First, Cre might 
not be expressed in every cell in the organ of interest. Second, Cre might be expressed 
but fail to recombine the floxed allele in every cell. However the successful knockout 
of Cyb5 in the hepatocytes further complicates the results. Due to the schedule of 
experimental work, 32P-postlabelling was the only experiment carried out after 
Western blotting had revealed the inconsistencies in POR expression. If time and 
financial considerations had allowed it, the study would have been repeated. The 
untreated microsomal fractions were however used for enzyme activity assays and 
incubations for metabolite formation, but not for ellipticine-DNA adduct formation in 
vitro. Despite the presence of POR, enzyme activity was reduced in the microsomal 
fractions apart from in the case of Sudan I oxidation where there was no pronounced 





Figure 4.2: Genotyping of the DNA isolated from the livers of untreated WT, HRN and HBRN mice. 
Por gene was not detected in any of the HRN or HBRN mice and Cyb5 gene was not detected in the 
HBRN mice. The Cre gene was present in only the HRN and HBRN mice however only a faint band 
was detected for in the HRN #1 mouse and the HBRN #3 mouse.  
 
4.3.3 Enzyme activity of XMEs  
POR activity was detected in all hepatic microsomal fractions isolated from untreated 
mice, with the highest level of activity highest in WT mice (Figure 4.3a). In the 
ellipticine-treated mice, POR activity was detected in the microsomal fractions from 
WT mice but not in knockout animals (Figure 4.4a), which is as expected given the 
deletion of POR in the hepatocytes of HRN and HBRN mice (Arlt et al., 2015a, 
Henderson et al., 2013). Sudan I oxidation (Figure 4.3b and 4.4b), MROD activity 
(Figure 4.3b and 4.4c) and EROD activity (Figure 4.3d and 4.4d) were used as 
measures of Cyp1a1, Cyp1a2 and Cyp1a enzyme activity, respectively, and 
testosterone 6βhydroxylation (Figure 4.3e and 4.4e) as a measure of Cyp3a enzyme 
activity. When the cofactor for POR, NADPH, was used in the reaction mixture, 
hepatic microsomes from WT mice exhibited the highest levels of Cyp1a activity, 
except for in EROD where the levels of activity were equal in WT and HRN hepatic 
microsomal fractions isolated from ellipticine-treated animals (compare Figure 4.4d). 







According to the Sudan I oxidation and MROD assays (Figure 4.4b and c) Cyp1a1/2 
activity was significantly lower in the hepatic microsomes from HRN mice which 
correlated with the lack of POR activity in HRN mice relative to WT mice. Cyp1a1/2 
activity in hepatic microsomes from HBRN mice was significantly lower compared to 
WT and HRN mice and showed the lowest level of Cyp1a1/2 activity when NADPH 
was present. When NADPH was used in the reaction mixture, hepatic microsomes 
from WT mice exhibited the highest level of Cyp3a activity, with levels being greatly 
lower than in the HRN and HBRN fractions. In the hepatic microsomal fractions from 
untreated mice Cyp1a/1a2/3a activity was highest in the WT mice and lowest in the 
HBRN mice but the effect was less pronounced compared with mice treated with 
ellipticine (compare Figure 4.3b, c, d and e and Figure 4.4b, c, d and e).  
When the cofactor for Cyb5R, NADH, was used in the reaction mixture, hepatic 




Figure 4.3: Enzyme activity in the pooled hepatic fractions of untreated WT, HRN and HBRN mice 
using either NADPH or NADH as the enzymatic cofactor. (A) POR activity was observed as nmol of 
cytochrome c/mg/min and was only detected in microsomal fractions from WT mice. (B) Cyp1a1 
activity was determined by the oxidation of Sudan I to hydroxylated metabolites with activity being 
observed as nmol of total C-hydroxylated metabolites/mg protein/min. (C) Cyp1a2 activity was 
determined using the MROD assay with activity being observed as pmol of resorufin/mg protein/min. 
(D) Cyp1a activity was determined using the EROD assay with activity being observed as pmol of 
resorufin/mg protein/min. (E) Cyp3a activity was determined by the oxidation of testosterone to 
hydroxylated metabolites with activity being observed as nmol of total C-hydroxylated metabolites/mg 
protein/min. Values are given as ± SD (n=3). Repeat determinations were carried out within the same 
week.Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* 
= compared to WT; # = compared to HRN. * (#) P ≤ 0.05 ** (##) P ≤ 0.01 *** (###) P ≤ 0.001**** (####) 





































































































































































































































































Figure 4.4: Enzyme activity in the pooled hepatic fractions of ellipticine-treated WT, HRN and HBRN 
mice using either NADPH or NADH as the enzymatic cofactor. (A) POR activity was observed as nmol 
of cytochrome c/mg/min and was only detected in microsomal fractions from WT mice. (B) Cyp1a1 
activity was determined by the oxidation of Sudan I to hydroxylated metabolites with activity being 
observed as nmol of total C-hydroxylated metabolites/mg protein/min. (C) Cyp1a2 activity was 
determined using the MROD assay with activity being observed as pmol of resorufin/mg protein/min. 
(D) Cyp1a activity was determined using the EROD assay with activity being observed as pmol of 
resorufin/mg protein/min. (E) Cyp3a activity was determined by the oxidation of testosterone to 
hydroxylated metabolites with activity being observed as nmol of total C-hydroxylated metabolites/mg 
protein/min. Values are given as ± SD (n=3). Repeat determinations were carried out within the same 
week. Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* 
= compared to WT; # = compared to HRN. * (#) P ≤ 0.05 ** (##) P ≤ 0.01 *** (###) P ≤ 0.001**** (####) 




































































































































































































































































activity than the hepatic microsomal fractions from ellipticine-treated WT and HBRN 
mice (Figure 4.4b, c and d). Using MROD as a measure for Cyp1a2 activity, enzyme 
activity was similar in ellipticine-treated WT and HBRN mice (Figure 4.4c). When 
EROD and Sudan I oxidation were used as a measure for Cyp1a activity hepatic 
microsomes from ellipticine-treated HBRN mice exhibited the lowest level of Cyp1a 
activity in the presence of NADH (Figure 4.4b and d). When NADH was used in the 
reaction mixture, hepatic microsomes from ellipticine-treated HRN mice showed 
significantly higher Cyp3a activity than the hepatic microsomal fractions from HBRN 
mice but not WT mice treated with ellipticine (Figure 4.4e). In the hepatic microsomal 
fractions from untreated mice Cyp1a/1a2 activity was highest in the HRN mice but 
was less pronounced compared with ellipticine-treated mice (Figure 4.3c and d). This 
pattern was not observed with Cyp1a1/3a activity with hepatic microsomal fractions 
from WT mice exhibiting higher levels of activity compared to HRN mice and the 
lowest activity levels in HBRN mice (Figure 4.3b and e).  
4.3.4 Analysis of ellipticine metabolites by HPLC  
Hepatic microsomes isolated from WT, HRN and HBRN mice were incubated with 
ellipticine and subsequently analysed by HPLC to determine the ellipticine metabolite 
profile. Representative HPLC chromatograms are shown in Figure 4.5. Three 
metabolites were formed in the microsomal incubations; 9-hydroxyellipticine 
(assigned to peak M1), 12-hydroxyellipticine (assigned to peak M2) and 13-
hydroxyellipticine (assigned peak to M3) (Figure 4.5a and b). No metabolites were 
detected in control incubations without microsomes, without NADPH/NADH-
generating system or without ellipticine (Figure 4.5c and d). There was still a large 
amount of unchanged ellipticine detected, indicating that only a small percentage was 
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metabolised during the incubation. The total formation of metabolites was highest in 




Figure 4.5: Representative HPLC chromatograms from in vitro incubations with hepatic microsomal 
fractions from ellipticine-pretreated WT mice with ellipticine (ELLI) and either NADPH or NADH as 
cofactor. M1: 9-hydroxyellipticine; M2: 12-hydroxyellipticine; M3: 13-hydroxyellipticine. Phenacetin 
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NADPH was used in the reaction mix (Figure 4.5a). Total ellipticine metabolite 
formation in hepatic microsomal fractions from WT mice was around 3-fold higher 
compared to when NADH was used (Figure 4.5a). Hydroxylated ellipticine 
metabolites were identified and the structures are shown in Figure 1.7. When NADPH 
was used as cofactor the overall formation of metabolites was significantly lower in 
hepatic microsomal fractions from untreated HRN mice with production of 9-
hydroxyellipticine and 13-hydroxyellipticine being significantly lower compared with 
untreated WT, and 12-hydroxyellipticine not being detected (Figure 4.6). The lowest 
level of overall ellipticine metabolite formation was with the hepatic microsomal 
fractions isolated from untreated HBRN mice (Figure 4.6a). All metabolites were 
detected at significantly lower amounts than with WT hepatic microsomes and 9-  
 
Figure 4.6: Total formation of ellipticine metabolites and formation of individual metabolites during 
in vitro incubations with hepatic microsomal fractions from untreated WT, HRN and HBRN mice using 
either A, NADPH or B, NADH as an enzymatic cofactor. Values given as ± SD (n=3). Repeat 
incubations were carried out and analysed within the same week. Statistical analysis was performed by 
one-way Anova with Tukey’s multiple comparison test (* = compared to WT; # = compared to HRN. 


















































































































































































































































































































































































































































hydroxyellipticine was lower compared with HRN hepatic microsomes isolated from 
control (untreated) animals (Figure 4.6). 
 
Figure 4.7: Total formation of ellipticine metabolites and formation of individual metabolites during 
in vitro incubations with hepatic microsomal fractions from ellipticine-treated WT, HRN and HBRN 
mice using either A, NADPH or B, NADH as an enzymatic cofactor. Values given as ± SD (n=3). 
Repeat incubations were carried out and analysed within the same week. Statistical analysis was 
performed by one-way Anova with Tukey’s multiple comparison test (* = compared to WT; # = 
compared to HRN. * (#) P ≤ 0.05 ** (##) P ≤ 0.01 *** (###) P ≤ 0.001 **** (####) P ≤ 0.0001). ND, not 
detected. 
 
When NADH was used as cofactor the overall formation of metabolites in hepatic 
microsomal fractions isolated from untreated HRN mice was not significantly 
different to fractions from untreated WT with 9-hydroxyellipticine being significantly 
higher but 12-hydroxyellipticine being significantly lower and no significant 
difference in the levels of 13-hydroxyellipticine. Overall metabolite formation in 
hepatic fractions isolated from untreated HBRN mice was significantly lower than 

































































































































































































































































































































































































































































9-hydroxyellipticine being significantly lower compared with both WT and HRN 
fractions and 12-hydroxyellipticine being significantly lower compared with WT 
(Figure 4.6b). When incubations were carried out using hepatic microsomal fractions 
from treated mice (Figure 4.7), the overall formation of ellipticine metabolites was 
highest in WT mice when NADPH was used in the reaction mixture (Figure 4.7a), 
whereas when NADH was used the highest formation of metabolites was seen in HRN 
mice (Figure 4.7b). The rate of ellipticine metabolism in the hepatic microsomal 
fractions correlated with the levels of Cyp1a/3a enzymatic activity and the particular 
enzymatic cofactor used (compare Figures 4.4 and 4.6). 
4.3.5 Ellipticine-DNA adduct formation in vitro 
The ability of hepatic microsomes isolated from WT, HRN and HBRN mice to 
catalyse ellipticine-DNA adduct formation in vitro was investigated (Figure 4.8a). 
The ellipticine-DNA adduct pattern obtained by 32P-postlabelling analysis from 
microsomal incubations consisted of one major and one minor adduct spot (assigned 
adduct 1 and 2) previously detected in vitro and in vivo (Stiborova et al., 2008, 
Stiborova et al., 2012b, Stiborová et al., 2012).  Because the adduct spots were 
incompletely separated total ellipticine-DNA adduct levels were determined. When 
NADPH was used the highest ellipticine-DNA adduct formation was seen in 
microsomal fractions from WT mice. There was significantly less DNA adduct 
formation with the microsomal fractions isolated from ellipticine-pretreated HRN and 
HBRN mice (Figure 4.9). The degree of total ellipticine-DNA adduct formation in the 
hepatic microsomal fractions correlated with the amounts of ellipticine metabolites 
formed (compare Figure 4.7a). When NADH was used there was no significant 






Figure 4.8: Autoradiograms showing adduct profiles by TLC 32P-postlabelling analysis from in vitro 
incubations with hepatic microsomal fractions from ellipticine (ELLI)-pretreated WT, HRN and HBRN 
mice, DNA and ellipticine. The origin on the TLC plate, at the bottom left-hand corners, was cut off 
before exposure. See text for details. Adduct spots 1 and 2 are formed in deoxyguanosine residues of 
DNA by metabolites 13-hydroxyellipticine and 12-hydroxyellipticine, respectively. 
 














Figure 4.9: Total formation of ellipticine-DNA adducts during in vitro incubations with hepatic 
microsomal fractions from ellipticine-pretreated WT, HRN and HBRN mice using either NADPH or 
NADH as an enzymatic cofactor. Duplicate incubations were carried out within the same week and 
DNA stored at ‒20°C until analysis. Values are given as ± SD (n=4); DNA from two separate 
incubations were measured in duplicate in separate 32P-postlabelling analyses. Statistical analysis was 
performed by one-way Anova with Tukey’s multiple comparison test (* = compared to WT; ** P ≤ 
0.01). 
4.3.6 Ellipticine-DNA adduct formation in vivo 
The ellipticine-DNA adduct pattern obtained from in vivo treatments consisted of one 
major adduct spot (Figure 4.10) previously detected in vitro and in vivo (Stiborova et 
al., 2008, Stiborova et al., 2012b, Stiborová et al., 2012). Another adduct, tentative 
assigned adduct spot 4 (Figure 4.10), which was detected previously in ellipticine-
treated rats and mice (Stiborova et al., 2008, Stiborova et al., 2003a, Stiborova et al., 
2014a, Stiborová et al., 2007), was also formed in WT and HRN mice in selected 
tissues. As this adduct was detectable in only a few tissues (liver, lung and small 
intestine) in WT and HRN mice but not HBRN, its level was not quantified when 
adduct formation was compared between tissues. Of the organs tested (liver, lung, 














































































intestine exhibited any significant differences between the mouse models (Figure 
4.11). In the lung and small intestine the levels of ellipticine-DNA adducts were 
significantly higher in HRN mice compared with WT mice. DNA adduct formation in 
the livers of HRN and HBRN mice was significantly lower, by 62% and 73%, 
respectively, than in WT mice.  
 
Figure 4.10: Autoradiographs of ellipticine-DNA adducts in liver, lung, kidney, colon, small intestine, 
bladder and spleen tissues in ellipticine-treated WT, HRN and HBRN mice. The origin on the TLC 
plate, at the bottom left-hand corners, was cut off before exposure. Adduct spot 1 is formed in 
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Figure 4.11: Quantitative TLC 32P-postlabelling analysis of ellipticine-DNA adducts in organs of WT, 
HRN and HBRN mice treated i.p with 10 mg/kg bw ellipticine for 24 h. Values are given as ± SD (n=4); 
each DNA sample isolated from tissue of individual animals was analysed once. Statistical analysis was 







































































































































































































































































Although the role of the electron donor protein Cyb5 in the metabolic activation of 
ellipticine has been well characterised in vitro, its role in vivo is less understood. In 
the present study both HRN mice, which lack expression of hepatic POR, and HBRN 
mice, which lack expression of hepatic POR and Cyb5, have been used to investigate 
the contribution of Cyb5 to the metabolic activation of ellipticine in vivo and in vitro.  
The in vitro experiments in this study were carried out using pooled hepatic 
microsomal fractions. When NADPH was used as cofactor to examine the POR-
dependent pathway in hepatic microsomal fractions from ellipticine-treated mice, 
cytochrome P450 enzyme activity assays clearly showed a reduction in Cyp1a activity 
as electron donors were lost. However, whilst significant reductions in total ellipticine 
metabolite and ellipticine-DNA adduct formation were found compared to WT there 
was no significant difference between HRN and HBRN fractions themselves, 
correlating with the results from Cyp3a marker activity. When the NADH-dependent 
Cyb5R pathway was investigated, there was higher Cyp1a enzyme activity in the 
microsomal fractions of HRN mice than in those of WT mice. In the microsomal 
fractions from HBRN mice the activity was significantly lower relative to WT mice, 
indicating that increased NADH-dependent activity is caused by the increased 
expression of Cyb5. Cyp1a activity did not correlate with total ellipticine metabolite 
formation as there was no significant difference between the WT and HRN fractions 
with only HBRN fractions showing significant reductions compared to both WT and 
HRN. Although this reduction in total metabolite formation would be suggestive of 
the contribution of Cyb5 to the activation of ellipticine, whilst all metabolites formed 
by HBRN fractions were reduced compared to WT, the only metabolite significantly 
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reduced in HBRN fractions compared to HRN fractions was 9-hydroxyellipticine, a 
detoxication metabolite. This supports previous results in the HRN mouse with 9-
hydroxyellipticine being affected by the absence of POR and cytochrome P450 
activity more than other metabolites (Stiborova et al., 2008). Total ellipticine-DNA 
adduct formation in vitro in the presence of NADH was lower than when NADPH was 
present, but not significantly different between the mouse lines.  
In the in vitro experiments carried out in hepatic microsomal fractions from untreated 
mice, POR activity was detected in both the HRN and HBRN fractions. It was 
postulated that this could be due to contamination from a WT liver sample; however, 
no Cyb5 was detected, which would have been present in this case. Genotyping was 
carried out on retained liver samples from the untreated mice. Although both Por and 
Cyb5 appeared to be excised, a very faint Cre band was detected in one of the untreated 
HRN and one of the untreated HBRN mice (see Figure 4.12). One potential 
explanation as to why some POR expression and activity was detectable in the hepatic 
microsomal fractions could be due to Cre mosaicism, whereby there is variable or 
inconsistent Cre expression in different cells within the liver (Heffner et al., 2012). 
However the successful knockout of Cyb5 in the hepatocytes further complicates the 
results. Despite the presence of POR, enzyme activity was reduced in the microsomal 
fractions apart from in the case of Sudan I oxidation where there was no pronounced 
difference in the levels of activity between the treated and untreated microsomal 
fractions.  
Previous studies with reconstituted CYP1A1 and CYP1A2 showed that the presence 
of Cyb5 in the reaction mixture alters the resulting ellipticine metabolites profiles, 
with a shift from detoxication metabolites, 9-hydroxyellipticine and/or 7-
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hydroxyellipticine, to metabolites that can ultimately form DNA adducts, 12-
hydroxyellipticine and/or 13-hydroxyellipticine (Kotrbova et al., 2011). These 
findings were echoed in studies using human CYP3A4 in Supersomes™, which found 
that the presence of Cyb5 in the reaction mixture also led to an increase in formation 
of 12-hydroxyellipticine and 13-hydroxyellipticine (Stiborova et al., 2012a, Stiborová 
et al., 2012, Stiborová et al., 2017). In hepatic microsomal fractions from HBRN mice 
that do not possess either electron donor, metabolite formation was significantly lower 
than with WT fractions regardless of the cofactor used. In the hepatic microsomal 
fractions from HRN mice in the presence of NADH, however, the formation of 9-
hydroxyellipticine was significantly higher than with microsomal fractions from WT 
mice whilst metabolites associated with metabolic activation were significantly lower 
(i.e. 12-hydroxyellipticine). The absence of Cyb5 in hepatic microsomal fractions 
from HBRN mice correlates with the findings from reconstituted P450 enzymes 
suggesting Cyb5 contributes to the activation of ellipticine in vitro (Kotrbova et al., 
2011, Stiborová et al., 2017, Stiborova et al., 2012a, Stiborová et al., 2012). This 
correlation, however, does appear to be limited to ellipticine metabolite formation. 
Previous studies (Kotrbova et al., 2011, Poljakova et al., 2005, Stiborova et al., 2013a, 
Stiborová et al., 2017) found that the shift in metabolite production was coupled with 
an increase in in vitro ellipticine-DNA adduct formation. The hepatic microsomal 
fractions from the present study, however, found no significant difference between 
DNA adduct formation in HRN or HBRN hepatic microsomal fractions regardless of 
the enzymatic cofactor used.  
The present in vivo results correlated with in vitro ellipticine-DNA adduct formation 
when NADPH was used as cofactor. Both HRN and HBRN mice showed significantly 
lower (60-70%) hepatic ellipticine-DNA adduct formation than WT mice, but there 
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was no significant difference between the two knockout lines. The HRN results 
correlate with a previous study that found a 65% reduction in hepatic DNA-adduct 
formation in HRN mice (Stiborova et al., 2008) suggesting a greater contribution of 
the POR-dependent pathway to the bioactivation of ellipticine in vivo. In vitro 
experiments carried out in the present study with the cofactor NADH showing Cyb5R-
dependent pathways contributing to ellipticine bioactivation in HRN mice correlated 
with in vivo adduct formation in the lungs and small intestine of HRN mice, suggesting 
that the Cyb5/Cyb5R systems contributes to ellipticine-DNA adduct formation in 
these extrahepatic organs of HRN mice. Ellipticine-DNA adduct formation in the 
extrahepatic organs of WT and HRN mice has been observed previously with HRN 
mice showing higher levels than WT mice, suggesting that ellipticine or its metabolites 
are being distributed via the bloodstream to organs and tissues with the metabolic 
capacity to oxidatively activate ellipticine (Stiborova et al., 2008). In the present study 
there was a trend for ellipticine-DNA adduct levels to be higher in the extrahepatic 
organs, i.e. kidney, colon and bladder, of both HRN and HBRN mice than of WT mice, 
with levels of ellipticine-DNA adduct formation being significantly higher in the lungs 
and small intestines of HRN mice than of WT mice. This could be due to the decreased 
levels of P450-mediated ellipticine metabolism in the livers of HRN and HBRN mice 
causing higher amounts of ellipticine to be distributed to extrahepatic organs. Levels 
of ellipticine-DNA adduct formation were not greatly different in any of the 
extrahepatic organs of HBRN mice compared to WT mice, suggesting that increased 
levels of activated ellipticine in the extrahepatic organs could be attributed to Cyb5 
activity in the HRN mice.  
The significant reduction in DNA adduct formation in the livers of HRN and HBRN 
mice indicates that P450 enzymes are responsible for the majority of ellipticine 
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activation, although hepatic DNA adduct formation in HRN and HBRN mice is still 
detectable. It is possible that ellipticine activation still occurs due to the greater 
induction of hepatic cytochrome P450 enzymes in HRN and HBRN mice compared 
to WT mice combined with expression of POR and Cyb5 in the non-parenchymal liver 
cells. Further investigation of this would require isolation and culture of hepatocytes 
and non-parenchymal liver cells from HBRN mice and exposure of these cells to 
ellipticine for subsequent ellipticine-DNA adduct analysis, but this was beyond the 
scope of the present study. The bioactivation of ellipticine can also be catalysed via 
cytochrome P450-independent mechanisms that are not dependent on POR or Cyb5. 
Numerous peroxidases such as bovine LPO, human MPO, ovine COX-2 and plant 
HRP have previously been shown to activate ellipticine to reactive metabolites, which 
form two DNA adducts analogous to those generated by the P450-mediated reactions 
(Stiborova et al., 2007). Of the ellipticine metabolites, peroxidases predominantly 
form an ellipticine dimer (Stiborova et al., 2007), and generate the reactive 
intermediate ellipticine-13-ylium that is responsible for formation of adduct 1 (Figure 
1.7). Another metabolite detected was the N2-oxide (Figure 1.7), interestingly one that 
is also generated by the oxidation of ellipticine by P450s and forms adduct 2 in vitro 
after the N2-oxide undergoes the Polonowski re-arrangement to form 12-
hydroxyellipticine (Poljakova et al., 2005). In several tissues in ellipticine-treated WT 
and HRN mice (present study) we detected adduct 4, which has also been observed 
previously in ellipticine-treated  rats (Stiborova et al., 2003a, Stiborova et al., 2014a, 
Stiborová et al., 2007) and in vitro studying ellipticine-DNA adduct formation 
recombinant human CYP3A4 expressed in Supersomes™ (Stiborova et al., 2011). 
However, the structure of this adduct has not yet been elucidated. Peroxidase-mediated 
131 
 
ellipticine activation was also shown to generate two additional DNA adducts 
(Stiborova et al., 2007) that were, however, not detected in this study.  
Studies with hepatic microsomal fractions from WT and HRN mice from mice 
pretreated with BaP were carried out to investigate the effect of enzyme induction on 
activation of ellipticine in vitro (Stiborova et al., 2013a). Microsomal incubations with 
ellipticine, DNA and arachidonic acid, a cofactor for COX-dependent oxidation, 
showed DNA adduct formation at a level similar to that when POR, Cyp1a or Cyp3a 
enzymes were inhibited in hepatic microsomal fractions from untreated mice. In the 
hepatic microsomal fractions from mice pretreated with BaP, ellipticine-DNA adduct 
formation with arachidonic acid was higher, very likely due to induction of COX by 
BaP, with no significant difference between fractions from WT and HRN mice 
(Stiborova et al., 2013a). This participation of COX in hepatic microsomal fractions 
from HRN mice suggests that peroxidases could be responsible for the activation of 
ellipticine in the livers of HRN and HBRN mice. 
In summary, this study has shown that whilst POR contributes to the bioactivation of 
ellipticine in vitro, the role of Cyb5 is still rather unclear. The role of Cyb5 in the 
activation of ellipticine in vivo in both HRN and HBRN mice appears to be less 
important. These findings confirm the importance of P450 enzymes in the 
bioactivation of ellipticine. Whilst non-parenchymal liver cells may play a role in 
catalysing P450-mediated bioactivation of ellipticine in HRN and HBRN mice, the 
presence of ellipticine-DNA adducts in the livers of HRN and HBRN mice suggests 




5 The application of a murine cytochrome P450 
oxidoreductase null cell line for the assessment of 
cytochrome P450-mediated metabolism of 
benzo[a]pyrene and its DNA adduct formation in vitro  
5.1 Introduction 
Previous in vivo studies using a variety of different cytochrome P450, electron donor, 
or Ahr knockout mice treated with BaP yielded paradoxical results to in vitro studies. 
Whereas in vitro studies show that P450s are important for the bioactivation of BaP 
(Stiborova et al., 2017, Stiborova et al., 2016a, Stiborova et al., 2016b, Stiborova et 
al., 2014c), in vivo studies have demonstrated a more important role for P450s in 
detoxication (Arlt et al., 2012, Arlt et al., 2008, Sagredo et al., 2009, Sagredo et al., 
2006, Uno et al., 2004, Uno et al., 2006, Uno et al., 2001). This was also seen with the 
results from the study described in Chapter 3. In order for this paradoxical effect to be 
investigated further without the limitations of working with mouse models, such as 
limited tissue availability and ethical issues, an in vitro model would be required.  
Metabolism in a whole organism is complex, and although in vivo models are the most 
relevant, it is costly. The use of in vivo models has also come under scrutiny in recent 
years with schemes such as the 3Rs aiming to replace, reduce, and refine animal 
models within research. Cell culture models can be alternative experimental tools in 
understanding the role of enzymes in the bioactivation of carcinogens. A well-studied 
murine hepatocyte line is the Hepa-1c1c7 line, which was developed from a study that 
sought to isolate and generate a hepatoma cell line that produced serum albumin, a 
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characteristic of hepatocytes, at a higher rate than in pre-existing cultured hepatoma 
cells (Darlington et al., 1980). This cell line was derived from the clonal line Hepa-1 
from a hepatoma that arose in a C57L mouse line and propagated in C57L/J mice, and 
which was found to be stable over an extended period in continuous culture (Bernhard 
et al., 1973). One characteristic of this line is that it expresses Ahr and has highly 
inducible Cyp1a1 (Hankinson, 1979, Fong et al., 2005). This makes Hepa-1c1c7 cells 
suitable for studying BaP metabolism due to the importance of Cyp1a1 in the initial 
oxidation step of BaP to produce reactive metabolites (Baird et al., 2005). Hepa-1c1c7 
cells have been shown previously to be capable of metabolising BaP to numerous 
metabolites. High levels of 3-hydroxy-BaP formation were observed compared to 9-
hydroxy-BaP, which was attributed to Cyp1a1 being the predominant cytochrome 
P450 in these cells, as the same metabolic profile has been reported using cloned 
Cyp1a1 in the presence of BaP (Holme et al., 2007, Gautier et al., 1996). Previous 
studies using Hepa-1c1c7 cells have shown that BaP-induced apoptosis develops over 
a period of 24 hours with the main apoptotic steps being dependent on Cyp1a1 
induction and the formation of the reactive metabolite BPDE (Solhaug et al., 2005, 
Solhaug et al., 2004a, Solhaug et al., 2004b). The ability of the cells to form reactive 
metabolites was also demonstrated with the formation of the DNA adduct dG-N2-
BPDE (Holme et al., 2007), the same adduct that is formed in vivo (Arlt et al., 2012, 
Arlt et al., 2008). The importance of P450-mediated BaP activation was demonstrated 
in Hepa-1c1c7 cells as Cyp1a1 was shown to be accountable for cell cytotoxicity and 
apoptosis in studies using Cyp1a1 inhibitors α-naphthoflavone and ellipticine (Chung 
et al., 2007). 
The aim of the present study was to create an in vitro model that is able to mimic the 
HRN mouse model, which demonstrated high levels of DNA adduct accumulation in 
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multiple studies after BaP exposure (Arlt et al., 2012, Arlt et al., 2008, Reed et al., 
2018b), in order to investigate the role of cytochrome P450-mediated metabolism in 
the activation of BaP in vitro. POR expression was disrupted in the Hepa-1c1c7 cells 
using the CRISPR/Cas9 system and a single clone was isolated and expanded to 
produce a uniform cell line. The response of the cell model to BaP exposure was 
investigated by analysing the expression of XMEs and cytochrome P450 electron 
donors, BaP metabolite formation, DNA damage (comet assay) and DNA adduct 
formation. 
5.2 Methods 
Hepa-1c1c7 cells were cultured as described in section 2.7. Disruption of the Por gene 
was carried out using the CRIPSR/Cas9 system. Transfection of the cells and selection 
of transfected cells were carried out according to section 2.8.1. Isolation of single cell 
clones and the subsequent generation of a cell line were described in section 2.8.2. 
The response to BaP was investigated in WT cells exposed to a control double nickase 
plasmid and in the knockout cells from the single cell isolation in order to assess both 
the contribution of POR to BaP metabolism in the cell and any potential off-target 
effects of the double nickase plasmid. Hepa-1c1c7 cells were seeded and exposed to 
BaP according to section 2.7.5. Cytotoxicity to BaP in all three cell lines was assessed 
using crystal violet staining according to section 2.9. Upon selection of an appropriate 
concentration of BaP the expression of electron donor proteins and XMEs were 
investigated by Western blotting as described in section 2.10. Formation of BaP 
metabolites was investigated by HPLC analysis of metabolites extracted from the cell 
culture medium as described in section 2.11. DNA damage was investigated in the 
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cells after exposure to BaP using the comet assay as described in section 2.12. DNA 




5.3.1 Cell morphology 
Cells transfected with control plasmid (C) and POR knockout plasmid (POR KO) did 
not show any visual differences in cell morphology compared to WT Hepa-1c1c7 cells 
after having undergone transfection with CRISPR/Cas9 plasmids (Figure 5.1).   
 
Figure 5.1: Representative images of WT Hepa-1c1c7 cells (A), Hepa-1c1c7 cells transfected with 
control plasmid (B) and POR KO Hepa-1c1c7 cells (C). 
 
5.3.2 BaP-induced cytotoxicity 
WT, C and POR KO cells were treated with a range of concentrations of BaP over a 
24- and 48-hour period. WT and C cells displayed no pronounced difference in the 
threshold of cell viability. Cells lacking POR expression, however, did not display any 
substantial decrease in the percentage cell viability over 24 or 48 hours (Figure 5.2). 
Based on the cytotoxicity data in WT cells 0.5 µM BaP was selected for further 





Figure 5.2: Cytotoxicity of WT (a), C (b) and KO (c) Hepa-1c1c7 cell lines after treatment with a range 
of concentrations of BaP over a 24 and 48 hour period. Values are given as mean ± SD (n=3).  
 
5.3.3 Protein expression of XMEs 
Expression of POR, Cyb5 and Cyb5R and Cyp1a1 were probed for in BaP-treated (0.5 
µM) and untreated WT, C and KO cells (Fig. 5.3). POR was expressed in WT and C 
cells but no expression was observed in the POR KO cells. Cyb5 and Cyb5R were 
expressed across all cell lines. Treatment with BaP did not alter the levels of POR and 
Cyb5R expression relative to controls. Cyb5 and Cyp1a1, however, were induced in 
all cell lines by BaP treatment; and the extent of Cyp1a1 and Cyb5 induction by BaP 
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Figure 5.3: Western blot analysis of Cyp1a1, POR, Cyb5 and Cyb5R in untreated (lanes 1-3) and BaP-
treated (0.5 µM for 24 hours; lanes 4-6) WT, C and KO Hepa-1c1c7 cells. Representative images of 
the Western blotting are shown, and at least duplicate analysis was performed from independent 
experiments. Gapdh protein expression was used as a loading control. 
 
5.3.4 Analysis of BaP metabolites by HPLC 
WT, C and KO cells were treated with 0.5 µM BaP for 24 hours before the cell medium 
was removed and BaP metabolites extracted. Extracts were subsequently analysed by 
HPLC to determine the BaP metabolite profile. BaP-7,8-dihydrodiol, the precursor to 
BPDE, and BaP-tetrol-I-1, one hydrolysis product of BPDE, were the two metabolites 
detected along with unmetabolised BaP. The two BaP metabolites analysed were 
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identified using authentic standards as described previously (Wohak et al., 2016). The 
highest level of metabolite formation was seen in the KO cells with formation of both 
BaP-7,8-dihydrodiol and BaP-tetrol-I-1 being higher than that of WT and C cells 
(Figure 5.4). There was no significant difference in metabolite formation between WT 
and C cells for either BaP-7,8-dihydrodiol or BaP-tetrol-I-1. The level of 
unmetabolised BaP was not significantly different across any of the cell lines. No BaP 
or BaP metabolites were detected in untreated WT, C or KO cells (Figure 5.5a). 
Representative chromatograms showing the BaP metabolite profiles are shown in 
Figure 5.5. 
 
Figure 5.4: Formation of BaP-7,8-dihydrodiol (A), BaP-tetrol-I-1 (B) and BaP (C) in WT, C and POR 
KO Hepa-1c1c7 cells after treatment with 0.5 µM BaP for 24 hours. Values are given as mean ± SD 
(n=3). Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* 










































































































































Figure 5.5: Representative HPLC chromatograms from WT, C and KO Hepa-1c1c7 cells treated with 






























































5.3.5 Analysis of DNA damage by comet assay 
DNA damage caused by exposure to BaP in the different Hepa1c1c7 cell lines was 
assessed using the comet assay. WT, C and KO cells were treated with 0.25, 0.5 and 
1 µM BaP for 24 hours before analysing DNA damage with the comet assay (Figure 
5.6). In untreated cells, no difference was observed across any of the cell lines. No 
significant difference was observed in WT and C cells when exposed to any of the 
BaP concentrations tested. No significant difference was observed in WT, C or POR 
KO cells when exposed to 0.25 µM BaP. When treated with 0.5 and 1 µM BaP, POR 
KO cells exhibited significantly higher levels of DNA damage when compared to both 
WT and C cells.  
 
Figure 5.6: Assessment of DNA damage (% tail DNA) in WT, C and POR KO Hepa-1c1c7 cells using 
the comet assay. Cells were either untreated or treated with 0.25, 0.5 or 1 µM BaP for 24 hours. Values 
are given as ± SD (n=3); 50 nuclei/sample were scored and averaged. Statistical analysis was performed 
by one-way Anova with Tukey’s multiple comparison test (* = compared to WT; # = compared to C. * 







































5.3.6 BaP-DNA adduct formation 
The ability of WT, C and KO cells to catalyse BaP-DNA adduct formation was 
investigated. DNA isolated from untreated cells or those treated with 0.5 µM BaP for 
24 hours was analysed using the 32P-postlabelling method. The BaP-DNA adduct 
pattern obtained by 32P-postlabelling analysis consisted of one adduct spot previously 
identified as dG-N2-BPDE (Arlt et al., 2008) (Figure 5.7). An additional spot was 
present on the autoradiogram from POR KO Hepa-1c1c7 cells, however the structure 
has not yet been identified. No DNA adducts were detected in untreated cells (data not 
shown). BaP-DNA adduct formation was significantly higher in POR KO cells 
compared to both WT and C cells (Figure 5.8). There was no significant difference 
between WT and C cells. Levels of dG-N2-BPDE formation in the POR KO cells 
correlated with the formation of BaP-7,8-dihydrodiol and BaP-tetrol-I-1 (compare 
Figure 5.4 and Figure 5.8) and DNA damage as measured by the comet assay 
(compare Figure 5.6 and Figure 5.8).  
 
Figure 5.7: Autoradiograms showing adduct profiles by TLC 32P-postlabelling in WT, C and POR KO 
Hepa-1c1c7 cells treated with 0.5 µM BaP for 24 h. The origin on the TLC plate, at the bottom left-











Figure 5.8: Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE adducts in WT, C and POR 
KO Hepa-1c1c7 cells treated with 0.5 µM BaP for 24 h. Values are given as ± SD (n=3). Statistical 
analysis was performed by one-way Anova with Tukey’s multiple comparison test (* = compared to 






































The roles of the electron donors POR and Cyb5 have been investigated in vivo in the 
HRN and HBRN mouse models (see Chapters 3 and 4). Despite the absence of P450 
activity in the hepatocytes of the mouse models, HRN mice exhibited significantly 
higher levels of hepatic DNA formation, whilst HBRN mice showed no significant 
difference in hepatic DNA formation when compared to WT mice. In order to further 
investigate the paradoxical result seen in the livers of HRN mice, the Por gene was 
deleted in the murine hepatoma derived cell line Hepa-1c1c7 using CRISPR/Cas9 
technology leading to transfected cells not expressing POR. In order to assess any 
potential off-target effects of the transfection process, WT Hepa-1c1c7 cells were also 
transfected with a plasmid containing scrambled gRNA. The transfection process with 
scrambled gRNA did not affect expression of XMEs and electron donor proteins in 
the cells when compared with WT cells. No significant difference between WT and C 
cells was observed during metabolite formation, DNA damage (comet assay) and 
DNA adduct formation analysis. The expression of Cyb5 was induced in all cell lines 
after BaP treatment, this induction is in line with a higher protein expression of Cyb5 
in the livers of HRN mice after repeated BaP exposure. This effect was also seen in 
WT and C Hepa-1c1c7 cells, however, which was not observed in the livers of BaP-
treated WT mice (Arlt et al., 2012). POR KO Hepa-1c1c7 cells exhibited a resistance 
to BaP toxicity compared to WT and C cells, suggesting that BaP is not being activated 
to reactive, genotoxic metabolites. However, BaP metabolite formation was 
significantly higher in POR KO cells compared to both WT and C cells. This result 
was in contrast to the lower levels of metabolite formation in incubations with hepatic 
microsomal fractions from HRN mice compared to WT mice when NADPH was used 
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as cofactor (Reed et al., 2018b). DNA damage (comet assay) in the cells correlated 
with metabolite formation with significantly higher levels of DNA damage observed 
in POR KO cells than WT and C cells. This indicated that the BaP metabolites detected 
in the cell culture medium were exerting genotoxic effects in the cells which was 
confirmed by the formation of dG-N2-BPDE adducts, as this adduct is formed via the 
cytochrome P450-mediated pathway and proceeds via BaP-7,8-dihydrodiol formation. 
The dG-N2-BPDE adduct is the same adduct as seen in the HRN mouse model and the 
accumulation of BaP-DNA adducts in the absence of POR in POR KO cells correlates 
with previous studies carried out with the HRN mouse (Arlt et al., 2012, Arlt et al., 
2008). The second adduct observed in in vitro incubations with hepatic microsomal 
fractions, which is likely derived from the reaction of 9-hydroxy-BaP-4,5-epoxide 
with guanine (Reed et al., 2018b), was not detected in the Hepa-1c1c7 model.  
Due to the Hepa-1c1c7 model expressing Ahr and possessing highly inducible Cyp1a1 
(Hankinson, 1979, Fong et al., 2005), Hepa-1c1c7 cells that lack a functional Cyp1a1 
gene or the transcription factors controlling its expression have been developed 
previously (Hankinson, 1979, Hankinson, 1995, Ma and Whitlock, 1996). Hepa-1c1c7 
cells with an Ahr-defective (Ahr-D) phenotype were generated using targeted gene 
disruption (Ma and Whitlock, 1996). The phenotype of the cells was affected 
considerably, by the 90% reduction of Ahr expression in the Ahr-D Hepa-1c1c7 cells 
compared to WT. The Ahr-D Hepa-1c1c7 cells exhibited morphological changes, 
appearing less well-differentiated, more spindle shaped and failing to form well-
organised monolayers at high density. Ahr-D Hepa-1c1c7 cells exhibited decreased 
rates of proliferation in culture and showed barely detectable levels of albumin. 
Disruption of the Por gene in Hepa-1c1c7 cells in this study, however, contrasted with 
the Ahr-D Hepa-1c1c7 model as reduction of P450 activity did not noticeably affect 
146 
 
cell morphology in culture, the ability to form well-organised monolayers or cell 
growth and proliferation. Previous studies that selected BaP resistant clones of Hepa-
1c1c7 cells discovered that BaP resistant clones had greatly reduced specific activities 
of aryl hydrocarbon hydroxylase, now known as Cyp1a1, due to a defective induction 
mechanism (Hankinson, 1979, Hankinson, 1995). This correlates with the BaP-
induced cytotoxicity investigated in this study where cell viability in POR KO cells 
was higher compared to both WT and C cells.  
The POR KO Hepa-1c1c7 model demonstrated a resistance to BaP toxicity, a trait 
observed in Cyp1a1-defective Hepa1c1c7 cells (Hankinson, 1979, Hankinson, 1995). 
The ability of Cyp1a1-defective Hepa1c1c7 cells to catalyse BaP into reactive 
intermediates that form DNA adducts was investigated previously. In the absence of 
Cyp1a1 activity in these cells, BaP-DNA adducts were virtually undetectable (Uno et 
al., 2001). These results correlated with the hepatic microsomal fractions from HRN 
and HBRN mice incubated with BaP in vitro that had reduced levels of DNA adduct 
formation (Reed et al., 2018b). The results obtained from the present study contrast 
with these previous findings, with DNA adduct formation being greater in POR KO 
cells than in WT and C cells expressing POR, correlating instead with the findings in 
vivo with HRN mice (Arlt et al., 2012, Arlt et al., 2008, Reed et al., 2018b). Why both 
Cyp1a1-defective cells and POR KO cells exhibit resistance to BaP cytotoxicity yet 
demonstrate such substantial differences in levels of DNA adduct formation is not 
known. It is also unclear why cells that are resistance to BaP toxicity also exhibit 
increased DNA damage and DNA adduct formation. Tissues are protected from the 
effects of carcinogens by cell death such as apoptosis due to the removal of cells with 
extensive DNA damage. DNA damage often initiates various cell signalling pathways 
related to DNA repair activity, cell cycle arrest and cell survival or cell death 
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(apoptosis). The relative proportion of the different cell signalling pathways triggered 
by DNA damage upon exposure will, to a large degree, determine if the compound 
will give rise to predominantly mutagenic or cytotoxic effects (Holme et al., 2007). It 
is possible that the absence of POR-mediated P450 activity could alter the cell 
signalling response in the POR KO Hepa-1c1c7 cells. 
The metabolites detected in the cell medium, BaP-7,8-dihydrodiol and BaP-tetrol-I-1, 
are associated with BaP activation. WT Hepa-1c1c7 cells have previously been shown 
to form BaP tetrols, the hydrolysis products of BPDE metabolites, a reaction catalysed 
by Cyp1a1 (Holme et al., 2007, Gautier et al., 1996). However, POR KO Hepa-1c1c7 
cells were able to form the BaP-tetrol and dihydrodiol at a greater rate than WT and C 
Hepa-1c1c7 cells. By disrupting the Por gene as opposed to a single cytochrome P450 
enzyme, i.e. Cyp1a1, it was possible to overcome the issue of substrate overlap in 
hepatic P450s that could have also been activating BaP (Nebert and Dalton, 2006). 
Although POR is the predominant electron donor to P450s, Cyb5 is also able to act as 
the sole electron donor to P450s, enabling some catalytic activity. Reconstituted 
systems utilising CYP1A1, POR, Cyb5, and mEH in different ratios were used to 
investigate the role of Cyb5 in the metabolic activation of BaP in vitro. The results 
showed that even when levels of POR were low, CYP1A1, Cyb5, and mEH activated 
BaP efficiently to reactive species that bind to DNA (Stiborova et al., 2014c). In 
HBRN mice, the absence of Cyb5 was shown to result in significantly less hepatic 
DNA adduct formation than in HRN mice (Reed et al., 2018b) and it is possible that 
expression of Cyb5 is most likely contributing to the formation and accumulation of 
metabolites and DNA adducts in the POR KO Hepa-1c1c7 cells. HRN and HBRN 
mice were found to have steatotic livers that could have stored BaP. Lipid content of 
the Hepa-1c1c7 cells lacking POR was not assessed, however if a similar effect on 
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lipid metabolism were to occur in POR KO Hepa-1c1c7 cells it could alter the BaP 
bioavailability, BaP metabolism and elimination. BaP has been shown to be 
sequestered in Hepa-1c1c7 cells in lipid droplets throughout the intracellular space, 
with the highest percentage found attached to the ER near the nucleus (Rizwan et al., 
2015). In the present study, levels of unmetabolised BaP by HPLC were the same in 
all the cell lines; however, this only took into account BaP in the cell culture medium, 
not BaP sequestered in cells. 
One proposed explanation for the paradoxical results from previous in vitro and in 
vivo studies was the presence of a P450-independent bioactivation mechanism in 
hepatocytes (Reed et al., 2018a). The metabolites and adducts detected in POR KO 
Hepa-1c1c7 cells are all derived from the cytochrome P450-mediated pathway. Hepa-
1c1c7 cells have been shown to express inducible COX-2 (Puga et al., 1997). BaP is 
a good substrate for COX-2 as well as Cyp1a1 and Cyp1b1 and is capable of 
metabolising BaP to reactive intermediates that bind with DNA (Nemoto and 
Takayama, 1984, Marnett, 1990). Alongside COX-2, AKR and LOX-5 have also been 
implicated in the activation of BaP (Wang et al., 2017). The results from this study 
have demonstrated the role of P450 enzymes in the detoxication of BaP and the 




6 The application of a human cytochrome P450 
oxidoreductase null cell line for the assessment of 
cytochrome P450-mediated metabolism of 
benzo[a]pyrene and its DNA adduct formation in vitro  
6.1 Introduction 
Investigations of the role of P450 enzymes in the bioactivation of BaP in mice have 
yielded paradoxical results in in vivo studies to in vitro studies. Whereas in vitro 
studies show that P450s are important for the bioactivation of BaP (Stiborova et al., 
2017, Stiborova et al., 2016a, Stiborova et al., 2016b, Stiborova et al., 2014c), in vivo 
studies have demonstrated a more important role for P450s in detoxification (Arlt et 
al., 2012, Arlt et al., 2008, Sagredo et al., 2009, Sagredo et al., 2006, Uno et al., 2004, 
Uno et al., 2006, Uno et al., 2001). This was also seen with the results from the study 
described in Chapter 3. The POR KO Hepa-1c1c7 cell line used in Chapter 5 yielded 
results that correlate with the in vivo studies. Whilst these results bring into question 
the role of P450 enzymes in mice, it is unknown whether this is also observed in human 
models. 
A widely used and well-studied human hepatocyte cell line is HepG2. It is a 
hepatocellular carcinoma-derived cell line that is frequently used as in vitro alternative 
to primary human hepatocytes (Donato et al., 2015). Although HepG2 cells have 
reduced levels of some metabolic activities compared to primary human hepatocytes 
they have been shown to be capable of inducing phase I and phase II enzymes involved 
in BaP metabolism and DNA adduct formation (Wilkening et al., 2003). Generally, 
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HepG2 has been described as a sensitive model for identifying and quantifying DNA-
damaging properties of environmental and dietary agents (Knasmuller et al., 1998). 
Several studies have shown that BaP-DNA adduct formation increases in HepG2 cells 
in a concentration-dependent manner (Naspinski et al., 2008, Shiizaki et al., 2017, 
Hockley et al., 2006). BaP-DNA-adduct formation has been shown to be less 
dependent on time as no significant difference was observed within the time points of 
6, 25 and 48 hours studied (Hockley et al., 2006). Changes in gene expression, 
however, were shown to be time- and concentration-dependent with changes observed 
in genes involved in xenobiotic metabolism, cell cycle regulation, apoptosis/anti-
apoptosis, chromatin assembly and oxidative stress response. The overall response to 
BaP consisted of up-regulation of tumour suppressor genes and down-regulation of 
oncogenes promoting cell cycle arrest and apoptosis. Anti-apoptotic signalling that 
may increase cell survival and promote tumourigenesis was also evident (Hockley et 
al., 2006).  
P450 activity has also been shown to play an important role within the metabolism of 
BaP in HepG2 cells: when cells were pretreated with TCDD and subsequently exposed 
to BaP had BaP-DNA-adduct formation as well as HPRT mutation frequency were 
reduced through the induction of CYP1A1. These effects were shown to be even more 
pronounced in cells exposed to BPDE after TCDD pretreatment (Shiizaki et al., 2013), 
suggesting that increased levels of CYP1A1 are protective against BaP-induced DNA 
damage. This effect was also seen in HepG2 cells transfected with PXR that lead to 
increased levels of XME protein expression (e.g CYP1A2, GST and UGT). Levels of 
BaP-DNA-adducts were significantly reduced compared to WT HepG2 cells with 
lower levels of XME expression, again demonstrating the protective role of P450 
enzymes in the HepG2 model (Naspinski et al., 2008). Although the response of 
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HepG2 cells with increased levels of XME expression to BaP has been investigated, 
the response of cells after treatment with BaP in the absence of P450 activity is less 
well understood.  
The aim of the present study was to use a human cell culture model that lacks POR 
protein expression to investigate whether this human in vitro model mimics the results 
observed in the HRN mouse model in vivo (Arlt et al., 2012, Arlt et al., 2008, Reed et 
al., 2018b) and the POR KO Hepa-1c1c7 mouse model in vitro (Chapter 5), which 
both formed high levels of DNA adducts after BaP exposure. For this approach to 
examine the role of P450-mediated metabolism in the activation of BaP in a human in 
vitro model, a commercially available POR KO HepG2 cell line was used alongside 
WT HepG2 cells. The response of the cells to BaP exposure was investigated by 
analysing the expression of XMEs and P450 electron donors, BaP metabolite 




6.2 Materials and Methods 
HepG2 cells were cultured as described in section 2.7. The response to BaP was 
investigated in WT cells and POR KO cells in order to assess both the contribution of 
POR to BaP metabolism in the cell. HepG2 cells were seeded and exposed to BaP 
according to section 2.7.5. Cytotoxicity to BaP in both cell lines was assessed using 
crystal violet staining according to section 2.9. Upon selection of an appropriate 
concentration of BaP the expression of electron donor proteins and XMEs were 
investigated using Western blotting as described in section 2.10. Formation of BaP 
metabolites was investigated by extracting metabolites from cell media and analysed 
using HPLC as described in section 2.11. DNA damage in the cells after exposure to 
BaP was investigated using the comet assay as described in section 2.12. DNA adduct 






6.3.1 BaP-induced cytotoxicity 
WT and POR KO cells were treated with a range of BaP concentrations (0.5-10 µM) 
over a 24- or 48-hour period (Figure 6.1). POR KO cells showed a lesser degree of 
difference between 24- and 48-hour exposure times in the different concentrations 
when compared to WT cells. POR KO cells also showed less cytotoxicity in the 48-
hour exposure time at the higher concentrations of 5 and 10 µM (Figure 6.1b). Based 
on the cytotoxicity data in the WT cells, 2.5 and 5 µM BaP were selected for further 
experiments which led to ~70% cell viability over 24 or 48 hours.  
 
Figure 6.1: Cytotoxicity of WT (A) and POR KO (B) HepG2 cell lines after treatment with a range of 
BaP concentrations over a 24- and 48-hour period. Values are given as mean ± SD (n=3).  
 
6.3.2 Protein expression of XMEs 
Expression of the electron donor proteins POR, Cyb5 and Cyb5R and CYP1A1 were 
probed for in BaP-treated (2.5 and 5 µM) and untreated WT and POR KO HepG2 cells 
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KO cells. Cyb5 and Cyb5R were expressed in all cell lines. Treatment with BaP did 
not alter the levels of POR, Cyb5 and Cyb5R expression relative to controls. CYP1A1 
protein, however, was induced in both cell lines by BaP treatment; and the extent of 
CYP1A1 induction by BaP was greater in the POR KO HepG2 cells.  
 
Figure 6.2: Western blot analysis of CYP1A1, POR, Cyb5 and Cyb5R in untreated and BaP-treated 
(2.5 and 5 µM for 24 or 48 hours) WT and POR KO HepG2 cells. Representative images of the Western 
blotting are shown, and at least duplicate analysis was performed in independent experiments. Gapdh 
protein expression was used as a loading control. 
 
6.3.3 Analysis of BaP metabolites by HPLC 
WT and POR KO HepG2 cells were treated with 2.5 and 5 µM BaP for 24 and 48 
hours before the cell medium was removed and BaP metabolites extracted. Extracts 
were subsequently analysed by HPLC to determine the BaP metabolite profile. BaP-
7,8-dihydrodiol, the precursor to BPDE, and BaP-tetrol-I-1, one hydrolysis product of 
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BPDE, were the two metabolites detected along with unmetabolised BaP. The two 
BaP metabolites analysed were identified using authentic standards as described 
previously (Wohak et al., 2016). Representative chromatograms showing the BaP 
metabolite profiles are shown in Figure 6.3 and Figure 6.4. The highest level of 
metabolite formation was seen in the WT cells with formation of both BaP-7,8-
dihydrodiol and BaP-tetrol-I-1 being significantly higher than in POR KO cells after 
exposure to either 2.5 or 5 µM BaP for 24 hours (Figure 6.5a). After exposure to 2.5 
µM BaP for 48 hours, the levels of BaP-tetrol-I-1 formation was significantly higher 
in POR KO cells compared to WT cells. Exposure to 5 µM BaP for 48 hours resulted 
in no significant difference in BaP-tetrol-I-1 formation between the two cell lines. No 
BaP-7,8-dihydrodiol formation was detected in WT HepG2 cells after exposure to 
either BaP concentration for 48 hours. In the POR KO HepG2 cells, however, BaP-
7,8-dihydrodiol formation was detected (Figure 6.5b). Whilst levels of BaP-
metabolite formation decline in the WT cells from 24 to 48 hours after treatment with 
either 2.5 or 5 µM BaP, formation of BaP metabolites increases over the exposure time 
in the POR KO cells. The level of unmetabolised BaP was significantly higher in the 
medium from POR KO cell when compared to that of WT cells after exposure to either 
2.5 or 5 µM BaP for 24 or 48 hours (Figure 6.5). No BaP or BaP metabolites were 




Figure 6.3: Representative HPLC chromatograms from WT and POR KO HepG2 cells treated with 2.5 






Figure 6.4: Representative HPLC chromatograms from WT and POR KO HepG2 cells treated with 2.5 






Figure 6.5: Formation of BaP-7,8-dihydrodiol, BaP-tetrol-I-1 and BaP in WT and POR KO HepG2 
cells after treatment with 2.5 and 5 µM BaP for 24 (a) and 48 (b) hours. Values are given as mean ± SD 
(n=3). Statistical analysis was performed by one-way Anova with Tukey’s multiple comparison test (* 
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6.3.4 Analysis of DNA damage by comet assay 
DNA damage caused by exposure to BaP in WT and POR KO HepG2 cells was 
assessed using the comet assay. WT and POR KO cells were treated with 2.5, 5 and 
10 µM BaP for 24 and 48 hours before analysing DNA damage with the comet assay 
(Figure 6.6). In untreated cells, no difference was observed across either of the cell 
lines. No significant difference was observed in WT or POR KO cells when exposed 
to 2.5 or 5 µM BaP. When treated with 10 µM BaP, WT cells exhibited significantly 
higher levels of DNA damage when compared to KO cells at both 24 and 48 hours 
(Figure 6.6).  
 
Figure 6.3: Assessment of DNA damage (% tail DNA) in WT and POR KO HepG2 cells using the 
comet assay. Cells were either untreated or treated with 2.5, 5 or 10 µM BaP for 24 and 48 hours. Values 
are given as ± SD (n=3); 50 nuclei/sample were scored and averaged. Statistical analysis was performed 
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6.3.5 BaP-DNA adduct formation 
The ability of WT and POR KO HepG2 cells to catalyse BaP-DNA adduct formation 
was assessed by 32P-postlabelling. DNA isolated from untreated cells or those treated 
with 2.5 or 5 µM BaP for 24 and 48 hours was analysed. No DNA adducts were 
detected in untreated cells (data not shown). One major adduct spot was observed on 
TLC plates in all BaP-treated cells (Figure 6.7) which has previously been identified 
as dG-N2-BPDE (Arlt et al., 2008).  
 
Figure 6.4: Autoradiograms showing adduct profiles by TLC 32P-postlabelling in WT (a) and POR KO 
(b) HepG2 cells treated with 2.5 or 5 µM BaP for 24 and 48 hours. The origin on the TLC plate, at the 
bottom left-hand corners, was cut off before exposure. The arrow indicates the dG-N2-BPDE adduct.  
 
There was no significant difference between WT and POR KO cells in BaP-DNA 
adduct formation 24 hours after treatment with 2.5 µM BaP; however, BaP-DNA 
adduct formation was significantly higher in WT cells compared to POR KO cells 24 
hours after treatment with 5 µM BaP (Figure 6.8). Levels of BaP-DNA adducts were, 
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however, significantly higher in POR KO cells 48 hours after treatment with 2.5 and 
5 µM BaP than in WT cells (Figure 6.8). Levels of dG-N2-BPDE formation in the 
POR KO cells 24 hours post-exposure correlated with BaP-7,8-dihydrodiol formation 
(compare Figure 6.5 and Figure 6.8) and DNA damage as measured by the comet 
assay (compare Figure 6.6 and Figure 6.8). Levels of dG-N2-BPDE formation in the 
POR KO cells 48 hours post exposure correlated with the formation of BaP-7,8-
dihydrodiol (compare Figure 6.5 and Figure 6.8) but contrasted with DNA damage 
as measured by the comet assay (compare Figure 6.6 and Figure 6.8). 
 
 
Figure 6.5: Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE adducts in WT and POR KO 
cells treated with 2.5 and 5 µM BaP for 24 and 48 hours. Values are given as ± SD (n=3). Statistical 
analysis was performed by one-way Anova with Tukey’s multiple comparison test (* = compared to 
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The role of the P450 electron donor POR has been studied in mice, both in vivo (Arlt 
et al., 2012, Arlt et al., 2008) and in vitro; in hepatic microsomal fractions (Reed et 
al., 2018b); in reconstituted systems (Stiborova et al., 2014c); and in cells (see Chapter 
5). Collectively these studies have revealed paradoxical results regarding the role of 
P450 enzymes in the activation or detoxication of BaP. In order to investigate whether 
or not this extends into a human hepatic model, the human hepatoma cell line HepG2 
was used alongside POR KO HepG2 cells. Western blotting confirmed the absence of 
POR protein in the POR KO HepG2 cells. Expression of other electron donor proteins 
remained unchanged in both cell lines regardless of concentration or time. This 
contrasts with results seen with HRN mice and POR KO Hepa-1c1c7 cells, where 
Cyb5 expression was induced after treatment with BaP (See Chapter 3 and 5). 
CYP1A1 protein was not detectable in untreated WT and POR KO HepG2 cells under 
the experimental conditions used but was greatly induced after treatment with BaP. 
Expression of CYP1A1 was greater in POR KO HepG2 cells than in WT HepG2 cells, 
with expression of CYP1A1 higher in KO POR cells after 48 hours compared to 24 
hours. Despite the absence of POR expression, POR KO HepG2 cells did not exhibit 
the same degree of resistance to BaP toxicity that was seen in the POR KO Hepa-
1c1c7 cells over either a 24- or 48-hour period, which indicates that BaP is being 
activated into reactive genotoxic metabolites at similar levels as in WT HepG2 cells. 
However, BaP metabolite formation in POR KO HepG2 cells was significantly lower 
than in WT cells after exposure to either 2.5 or 5 µM for 24 hours, correlating with 
BaP metabolite formation in hepatic microsomal fractions from HRN mice (Chapter 
3). When cells were exposed to BaP for 48 hours however, BaP metabolite formation 
was significantly higher in POR KO HepG2 cells compared to WT HepG2 cells, 
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correlating with results seen in POR KO Hepa-1c1c7 cells (Chapter 5). BaP-tetrol-I-1 
levels were significantly higher in POR KO HepG2 cells than in WT HepG2 cells 
when treated with 2.5 µM BaP whilst no significant difference was observed in 
formation when treated with 5 µM BaP. No BaP-7,8-dihydrodiol formation was 
detected in WT HepG2 cells after 48 hours at either concentration of BaP, whilst 
formation was still detected in POR KO cells. No significant difference was observed 
in levels of DNA damage in WT and POR KO cells after treatment with 2.5 and 5 µM 
BaP for 24 or 48 hours. After treatment with 10 µM BaP levels of DNA damage were 
significantly higher in WT cells than in POR KO cells after both 24 and 48 hours. This 
correlates with BaP metabolite formation after 24 hours, indicating that not enough 
BaP is being activated into reactive, genotoxic metabolites to cause  DNA damage. 
Levels of DNA damage after 48 hours however, contrast with levels of BaP metabolite 
formation in POR KO HepG2 cells. Treatment with 2.5 µM BaP for 24 hours resulted 
in no significant difference in dG-N2-BPDE adduct formation in WT and POR KO 
HepG2 cells. However, after treatment with 5 µM BaP there was significantly higher 
levels of dG-N2-BPDE adduct formation in WT cells, correlating with BaP-7,8-
dihydrodiol formation and DNA damage (comet assay) after 24 hours. This also 
correlates with dG-N2-BPDE adduct formation in hepatic microsomal fractions from 
HRN mice (Chapter 3). After 48 hours treatment however, regardless of concentration 
the levels of BaP-DNA adduct formation were significantly higher in the POR KO 
HepG2 cells compared to WT HepG2 cells. The dG-N2-BPDE adduct is the same 
adduct as seen in the HRN mouse model and the accumulation of BaP-DNA adducts 
in the absence of POR in POR KO HepG2 cells correlates with previous studies carried 
out with the HRN mouse (Arlt et al., 2012, Arlt et al., 2008) and POR KO Hepa-1c1c7 
cells (Chapter 5). 
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The results of the present study are clearly time-dependent, with POR KO HepG2 cells 
displaying the greatest levels of BaP metabolite and dG-N2-BPDE adduct formation 
being 48 hours after treatment, whereas in WT HepG2 cells this was observed after 
just 24 hours. BaP-DNA adduct formation has previously been assessed in WT HepG2 
cells over a range of BaP concentrations (0.01-5 µM) and time points. Whilst 
concentration was found to affect levels of DNA adducts, there was no significant 
difference between the 6, 24 and 48 hour time points for each concentration (Hockley 
et al., 2006). The time-dependent differences in the POR KO HepG2 cells could be 
indicative of slower clearance of BaP compared to WT HepG2 cells. Loss of POR in 
HRN and HBRN mice resulted in steatotic livers that could have stored BaP. Lipid 
content of the POR KO HepG2 cells was not assessed; however if a similar effect on 
lipid metabolism was to occur in POR KO HepG2 cells it could alter BaP 
bioavailability, BaP metabolism and elimination. Levels of unmetabolised BaP in the 
cell culture media of POR KO HepG2 cells were significantly higher than with WT 
HepG2 cells regardless of concentration or time, however whether this is because of 
reduced cellular uptake of BaP due to slower metabolism is unknown. The levels of 
BaP sequestered in HepG2 cells were not assessed but a combination of slower 
metabolic clearance of BaP and higher levels of sequestered BaP could offer an 
explanation for the accumulation of dG-N2-BPDE adducts in POR KO HepG2 cells. 
The accumulation of dG-N2-BPDE adducts in HRN mice (Arlt et al., 2012) and POR 
KO Hepa-1c1c7 cells (Chapter 5) was associated with increased levels of Cyb5 protein 
expression, however no difference in Cyb5 expression was observed regardless of 
concentration or time between POR KO HepG2 and WT HepG2 cells despite the 
accumulation of dG-N2-BPDE adduct formation in the POR KO HepG2 cells. Still, it 
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is probable that Cyb5 compensates for the lack of POR and contributes to increased 
P450-mediated activation of BaP. 
Although HepG2 cells have inducible CYP1A1 (Hockley et al., 2006), they lack PXR 
expression, which is a low affinity nuclear receptor that transcriptionally regulates 
many genes associated with xenobiotic metabolism. It plays an important role in 
detoxication, so much so that PXR is considered to be a xenosensor due to the broad 
range of xenobiotic substrates including pharmaceuticals, dietary nutrients and 
environmental contaminants (Kliewer, 2003). In order to assess the role of PXR and 
the subsequent upregulation of XMEs that metabolise BaP, previous studies used a 
PXR-transfected HepG2 cell line (Naspinski et al., 2008). Formation of BaP-DNA 
adducts in PXT-overexpressing HepG2 cells was significantly decreased compared to 
WT HepG2 cells, suggesting that the presence of PXR reduces the formation of BPDE. 
These results correlate with findings from AHR(‒/‒) mice in which BaP-DNA adduct 
formation was greater than in WT mice (Kondraganti et al., 2003). BaP-DNA adduct 
formation was also significantly reduced in PXR-overexpressing HepG2 cells that had 
been pretreated with rifampicin, a CYP3A4 inducer, indicating the importance of 
P450s for detoxication in this model (Naspinski et al., 2008). After exposure to BaP, 
mRNA levels of CYP1A2 and GSTP1 (glutathione S-transferase P1) were notably 
higher in the PXR-overexpressing cells HepG2 compared to WT HepG2 cells. Levels 
of CYP1A1 mRNA was also increased in both cell lines after BaP treatment, however 
this effect was attenuated in PXR-transfected cells (Naspinski et al., 2008). This 
correlates with results observed in Cyp1a1(‒/‒) mice where absence of Cyp1a1 
activity led to increased levels of BaP-DNA adduct formation (Uno et al., 2001, Uno 
et al., 2004, Uno et al., 2006). The results from the present study also indicate that 
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P450 enzymes play a more important role in the detoxification of BaP as opposed to 
bioactivation.  
Other XMEs have been implicated in the activation of BaP. BPDE-DNA adduct 
formation was shown to have reduced levels in the hepatic S9 fractions from gpt, 
>80%, and HRN-gpt mice, >50%, in the presence of aldo-keto reductase (AKR), 
COX1/2 and 5-LOX inhibitors (Wang et al., 2017). HepG2 cells have been shown to 
have significantly increased levels of AKR gene expression after treatment with BaP 
(Hockley et al., 2006, Jennen et al., 2010). AKRs have been shown to catalyse the 
oxidation of BaP-7,8-dihydrodiol to form a ketol, which tautomerises to form the air-
sensitive BaP-7,8-catechol. This catechol undergoes one-electron oxidation in air to 
form an o-semiquinone anion radical and a subsequent one-electron oxidation in air to 
form the fully oxidised BaP-7,8-dione (o-quinone) that leads to DNA base oxidation 
(e.g. 8-oxo-dGuo) (Penning, 2014). Studies with AKR1A1-transfected human 
bronchoalveolar cells showed that AKRs and P450 enzymes compete in the activation 
of BaP-7,8-dihydrodiol (Jiang et al., 2005). A later study utilising AKR1A1-transfected 
cells found that the same major adduct, dG-N2-BPDE, was formed as in CYP1A1/1B1-
induced cells when treated with BaP-7,8-dihydrodiol. However, AKR1A1-transfected 
cells exhibited a 3-hour lag phase before significant BaP-DNA adduct formation (i.e. 
dG-N2-BPDE) was detected (Ruan et al., 2007). In POR KO HepG2 cells therefore, 
AKRs could potentially contribute to BaP-DNA-adduct formation. On the other hand, 
previous findings showed that control HepG2 cells exhibited the highest levels of 
DNA-adduct formation compared to AKR1A1-transfected or CYP1A1/1B1-induced 
HepG2 cells, raising further questions about the roles of P450 and AKR enzymes in 
BaP bioactivation (Ruan et al., 2007). Whilst COX1/2 has previously been implicated 
in the activation of BaP, no significant changes in gene expression were seen in HepG2 
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cells treated with BaP (Hockley et al., 2006, Jennen et al., 2010). Further investigation 
of these enzymes and the effect of BaP on their expression in the POR KO HepG2 
cells as opposed to WT HepG2 cells could offer further insight into enzymes involved 
in the bioactivation of BaP. This could then help identify potential P450-independent 
BaP activation pathways in the POR KO cells, this was however beyond the scope of 




7 General Discussion 
P450 enzymes have been implicated in the bioactivation of numerous procarcinogens, 
playing an important role in the process of chemical carcinogenesis (Guengerich, 
2008). Since the development of genetically-engineered P450 knockout mouse 
models, investigations into the role of P450s have shown how complex this process 
is. In Chapter 3 the results from studies using the pooled hepatic microsomal fractions 
incubated with NADPH showed that as electron donors were lost, the levels of BaP 
activation decreased from those seen in hepatic microsomal fractions isolated from 
WT mice, demonstrating that Cyb5 contributes to the activation of BaP in vitro. These 
results also clearly demonstrated the importance of P450s in the bioactivation of BaP 
in vitro. BaP-DNA adduct formation in vivo, however, contrasted with the findings in 
vitro. Hepatic BaP-DNA-adduct formation was significantly higher in HRN mice 
lacking POR expression in the hepatocytes compared to WT mice and formation in 
HBRN mice, whilst significantly lower than HRN mice, showed no significant 
difference compared to WT. These results suggest that P450 enzymes actually play a 
more important role in the detoxication of BaP in vivo.  
In Chapter 4 the in vitro studies using the pooled hepatic microsomal fractions 
incubated with NADPH showed that Cyb5 contributes to the activation of ellipticine 
in vitro. As electron donors were lost, the levels of ellipticine activation decreased 
from those seen in hepatic microsomal fractions isolated from WT mice. These results 
also clearly demonstrated the importance of P450s in the bioactivation of ellipticine 
in vitro. These results correlated with the in vitro studies with hepatic microsomal 
fractions and BaP from Chapter 3. The results on ellipticine-DNA adduct formation in 
vivo confirmed the importance role of P450 enzymes in the bioactivation of ellipticine. 
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Ellipticine-DNA adduct formation was significantly reduced in the livers of HRN and 
HBRN mice compared to WT mice. In contrast to in vitro results, however, there was 
no significant difference between ellipticine-DNA adduct levels in the livers of HRN 
and HBRN mice, demonstrating that whilst Cyb5 contributes to the activation of 
ellipticine in vitro, this role is not fulfilled in vivo. This contrasts with the role of Cyb5 
in BaP activation, whereby it was seen to play a role in the livers of HRN mice.  
The results from the POR KO Hepa-1c1c7 cells contrasted with the in vitro results 
from the hepatic microsomal fractions in Chapter 3, with BaP metabolite formation 
being significantly higher in the POR KO Hepa-1c1c7 cells compared to WT Hepa-
1c1c7 cells. Levels of BaP-DNA adducts also contrasted with that seen in hepatic 
microsomal fractions incubated with NADPH and BaP in vitro, instead correlating 
with hepatic microsomal fractions incubated with NADH and in vivo results from 
HRN mice. This suggests that Cyb5 contributes to the bioactivation of BaP in POR 
KO Hepa-1c1c7 cells. Levels of Cyb5 expression were induced in both the WT and 
POR KO Hepa-1c1c7 cells exposed to BaP, however the accumulation of BaP-DNA 
adducts was only observed in the POR KO Hepa-1c1c7 cells. As with the results from 
Chapter 3, these results are indicative that cytochrome P450s may play a more 
important role in the detoxication of BaP, as opposed to its bioactivation.  
The results from POR KO HepG2 cells showed that levels of BaP activation (i.e. BaP-
7,8-dihydrodiol formation) were higher in POR KO cells than WT HepG2 cells which 
also resulted in substantially higher BaP-DNA adduct formation in POR KO HepG2 
cells. These results correlate with those seen in HRN mice and POR KO Hepa-1c1c7 
cells, where an absence of POR expression results in higher levels of BaP activation, 
suggesting P450s play a more important role in the detoxication of BaP as opposed to 
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activation. Future studies should aim to additionally knockout Cyb5 in both POR KO 
HepG2 and POR KO Hepa-1c1c7 cells in order to have in vitro cell culture models 
that mimic the HBRN mouse model and to specifically assess the contribution of Cyb5 
in the BaP bioactivation in these cells. 
The paradoxical results discussed in Chapter 3, and the evidence that cytochrome 
P450s play a more important role in BaP detoxication as opposed to its activation 
discussed in Chapter 3, 5 and 6 are not isolated phenomena. Enzyme kinetic studies 
carried out with liver microsomes from Cyp1a2(‒/‒) and Cyp2e1(‒/‒) mice 
demonstrated the importance of cytochrome P450s in the N-hydroxylation of 4-ABP 
in vitro (Wang et al., 2015). Investigation of 4-ABP metabolism in vivo, however, in 
both Cyp1a2(‒/‒) and Ahr(‒/‒) mice showed that treatment of mice with 4-ABP 
induced hepatocellular adenoma and liver foci, however there were no differences 
found in incidence between Cyp1a2(‒/‒), Ahr(‒/‒) and WT mice (Kimura et al., 1999). 
Hepatic microsomal fractions isolated from Cyp1a2(‒/‒) and Ahr(‒/‒) mice exhibited 
half the microsomal arylamine N-hydroxylation activity of that seen with WT hepatic 
microsomal fractions during incubations with 4-ABP, indicating that only half of the 
enzymatic activity attributed to 4-ABP activation was due to Cyp1a2 (Kimura et al., 
1999). Another study using Cyp1a2(‒/‒) mice, with or without TCDD pretreatment, 
and measurement of methaemoglobin levels as a biomarker of 4-ABP exposure 
showed that the presence of Cyp1a2 actually decreased methaemoglobin formation 
and in fact TCDD pretreatment lowered it further (Shertzer et al., 2002). A third in-
vivo study using Cyp1a2(‒/‒) mice was carried out with or without TCDD 
pretreatment, this time focusing on DNA adduct formation (Tsuneoka et al., 2003). 
Cyp1a2(‒/‒) mice formed similar or higher levels 4-APB-DNA adducts than WT mice 
in both liver and bladder. When mice were pre-treated with TCDD, hepatic DNA 
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adduct levels were either lower or similar to the corresponding group of mice that did 
not receive TCDD, adding further weight to the argument that Cyp1a2 is more 
important for clearance of 4-ABP than for its activation (Tsuneoka et al., 2003). 
Evidence primarily from in vitro studies has demonstrated that P450s are the most 
important enzymes involved in the initial oxidation of PhIP to form the intermediate 
N-OH-PhIP with CYP1A2 as the predominant P450 enzyme in the activation of PhIP 
followed by CYP1A1 and 1B1 (Edwards et al., 1994, Shimada et al., 1996). Initial 
studies of PhIP activation in Cyp1a2(‒/‒) mice showed that exposure to PhIP led to 
significantly lower DNA adduct formation in Cyp1a2(‒/‒) mice compared to WT mice 
in the mammary gland and colon, and was not detectable in the liver and kidney of 
Cyp1a2(‒/‒) mice. These findings indicated the importance of the role of Cyp1a2 in 
the activation of PhIP in vivo (Snyderwine et al., 2002). In a later study in which PhIP 
was administered to Cyp1a2(‒/‒) mice, N-hydroxylation of PhIP was ~8-fold higher 
in microsomal fractions from WT mice than those from Cyp1a2(‒/‒) mice, however, 
the Cyp1a2(‒/‒) mice had a higher incidence of tumours than WT mice (Kimura et 
al., 2003). Hepatic microsomal fractions incubated with PhIP in vitro resulted in 8-
fold greater DNA adduct formation with hepatic microsomal fractions from RCN mice 
without 3MC pretreatment (i.e. mice with active POR) compared to RCN mice with 
3MC pretreatment (i.e. mice with inactive POR). These in-vitro results do not correlate 
with the in-vivo findings, however as DNA adduct formation in extrahepatic tissues 
was lower in POR-inactive mice than in POR-active mice and hepatic DNA adduct 
formation was not different between both mouse lines. These findings suggest that 
although Cyp1a2 plays a role in the bioactivation of PhIP in vitro, another P450-
independent mechanism may also contribute to its activation in vivo (Arlt et al., 2011).  
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To investigate the roles of hepatic and intestinal cytochrome P450s in the metabolic 
activation of AaC, two mouse models were employed (Turesky et al., 2015). The first, 
the liver-specific P450 reductase (Cpr)-null (LCN) mouse model (Gu et al., 2003), has 
POR deleted in the liver whereas the second mouse model, the intestinal epithelium-
specific Cpr-null (IECN) mouse, has POR deleted specifically in the intestinal 
epithelium (Zhang et al., 2009). IECN mice exposed to AaC did not show any 
significant differences to WT mice in the pharmacokinetic parameters for AaC or its 
metabolites, demonstrating a lack of contribution by intestinal P450s to first-pass 
clearance of AaC. The formation of DNA adducts in IECN mice was only significantly 
different from WT mice in the bladder where formation was 1.5-fold higher. On the 
other hand hepatic microsomal fractions from LCN mice were unable to oxidise AaC 
in vitro, whereas DNA adduct formation in vivo was found to be not lower in liver 
than in WT mice and significantly higher in lung (4-fold), bladder (1.2-fold) and colon 
(4-fold) (Turesky et al., 2015). These findings suggest that P450 enzymes do not 
contribute significantly to the activation of AaC but they may play a greater role in its 
detoxication (Turesky et al., 2015).  
P450-mediated α-hydroxylation of NNK has been demonstrated in vivo with the use 
of P450 inhibitors (Takeuchi et al., 2003, Hecht et al., 1996) and in vitro with lung 
microsomes (Hecht, 1998). Although activation of NNK is carried out in the lungs, 
hepatic microsomes have been shown to be at least as active as lung microsomes in 
activating NNK in vitro (Jalas et al., 2005). To further elucidate the role of hepatic and 
pulmonary P450s two mouse models were used, a lung-Cpr-null mouse (i.e. POR 
null). The lung-Cpr-null mice had fewer lung tumours than WT mice, implicating the 
role of pulmonary P450s in the activation of NNK. The liver-Cpr-null mice, however, 
had higher levels of lung tumour multiplicity than WT mice (Weng et al., 2007). These 
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findings were confirmed in a later study using HRN-gpt delta mice (Luan et al., 2012). 
NNK-induced mutation frequency was 3 times higher in the lung of HRN-gpt delta 
mice than in control gpt delta mice. Furthermore, pharmacokinetic studies showed 
significantly higher plasma levels of NNK and significantly lower rates of clearance 
in HRN-gpt delta mice compared to controls, suggesting that although pulmonary 
P450s play a role in NNK activation, hepatic P450s may in fact play a larger role in 
detoxification (Luan et al., 2012). However, in-vitro studies using recombinant 
CYP2A5 demonstrated the ability of this CYP enzyme to efficiently activate NNK 
(Felicia et al., 2000, Jalas et al., 2003) and NNK-induced lung tumorigenesis in mice 
was found to be reduced when Cyp2a enzymes were inhibited (Miyazaki et al., 2005). 
Cyp2a5-null mice treated with NNK showed there was no change in the systemic 
clearance of NNK or its major circulating metabolite 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL). Levels of pulmonary O6-mG adducts were significantly 
lower in Cyp2a5-null mice compared to WT mice. Levels of hepatic O6-mG adducts 
however showed no significant differences between Cyp2a5-null mice and WT mice 
at either dose despite previous studies showing that hepatic P450s were protective 
against NNK-induced lung tumorigenesis (Weng et al., 2007, Zhou et al., 2012). The 
P450 knockout was extended to Cyp2abfgs-null mice, in which all Cyp2a, 2b, 2g, 2f 
and 2s genes are deleted (Li et al., 2014). Levels of pulmonary O6-mG adducts were 
substantially reduced compared to both WT and Cyp2a5-null mice. The Cyp2abfgs-
null mice also demonstrated resistance to NNK-induced lung tumourigenesis, unlike 
the WT or Cyp2a5-null mice. In contrast to the POR knockout mice, these results 
suggest that there is in fact a contribution from mouse Cyp2a, 2b, 2g, 2f and 2s 
enzymes toward the bioactivation of NNK in vivo (Li et al., 2014).   
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The role of P450s in the metabolism of environmental carcinogens is complex. Whilst 
numerous in-vitro studies have demonstrated the role of P450s in the activation of 
carcinogens, the use of Cyp-knockout mice or Por-knockout mouse models lacking 
P450 enzyme activity have yielded paradoxical results demonstrating that P450s in 
vivo are in fact more important for detoxification. Although P450s are capable of 
activating carcinogens to their reactive intermediates, in an in vivo situation where 
myriad more biological factors are at play, this role appears to shift. These results are 
also not limited to a particular carcinogen or carcinogenic family, or to a particular 
knockout mouse model. Although the numerous mouse models utilised have been 
derived by a variety of methods for disrupting P450 expression or activity (Capecchi, 
1989, Le and Sauer, 2001), there is the possibility that by disrupting P450 expression 
or activity, the metabolic balance in tissues is disturbed and alternative contributing 
factors to activation or detoxication that may have been minor come to the fore. Many 
of the studies discussed have short exposure times (less than one month) and have 
focused on short-term markers, e.g. protein or DNA adduct and metabolite formation, 
which may not reflect the longer term carcinogenic consequences. Nevertheless two 
of the studies described here have investigated tumour formation with different 
carcinogens and have yielded the same overall paradoxical outcome as the short-term 
studies (Kimura et al., 2003, Weng et al., 2007). Whilst Por-knockout mouse models 
lacking P450 enzyme activity are powerful tools for investigations of xenobiotic 
metabolism, the paradoxical results they yield require further investigations to better 
understand mechanisms of activation. One possibility that arises from these studies 
and the work described within this project is the potential for P450-independent 
activation pathways that are as yet unidentified. 
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The results from this project, together with the studies of other carcinogens discussed 
previously, do raise questions about the wider implications of P450-mediated 
metabolism. If P450s are more important for detoxication than activation of 
carcinogens it would allow more accurate assessments to be made for risk factors such 
as CYP1A1 polymorphisms. If there is an unidentified P450-independent bioactivation 
pathway for procarcinogens such as BaP then there may be as yet unidentified risk 
groups for developing cancers associated with these compounds. This could ultimately 
also affect epidemiological predictions of disease development. Identifying any other 
P450-independent activation mechanisms would also be of importance in drug 
development as currently the main focus is on P450-mediated bioactivation pathways 
as the mechanism for reactive metabolite formation. Awareness of other potential 
pathways could help improve preclinical toxicity assessments and ensure that financial 
investments are not lost at later stages of drug development. This project has also 
added to the body of evidence regarding the in vitro and in vivo paradox that should 
be considered when using subcellular fractions to assess the potential of compounds 
being activated to reactive metabolites. By increasing understanding of the 
bioactivation mechanisms, both P450-dependent and P450-independent, the risk 
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